[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f0LiWFmuXnM3JOSKOUco9QPZo0FIo7Yjg1Il9KOQvvR0":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":38,"phaseBuckets":88,"rows":95},"University of Rochester",[4,6],"University of Rochester NCORP Research Base",730,false,152,29,319406,54,509,[15,18,21,24,27,30,33,35],{"name":16,"count":17},"Cancer",22,{"name":19,"count":20},"Depression",20,{"name":22,"count":23},"Asthma",18,{"name":25,"count":26},"Parkinson Disease",13,{"name":28,"count":29},"Loneliness",12,{"name":31,"count":32},"Insomnia",10,{"name":34,"count":32},"Heart Failure",{"name":36,"count":37},"Breast Cancer",9,[39,44,49,54,59,64,69,74,79,83],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT03781323","Neoadjuvant FOLFOX Therapy With Short Course Radiation and Active Surveillance in Locally Advanced Rectal Cancer","2022-06-01","FOLFOX",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT05597345","Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma","2024-10-29","Selinexor",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT01419730","Vitamin D and Physical Activity on Bone Health","2024-12-30","Vitamin D3",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT05653492","Safety, Feasibility, and Tolerability of Sulforaphane in Children with Chronic Kidney Disease","2025-04-30","Sulforaphane",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT05029960","Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas","2025-08-31","Brivaracetam",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT03996265","Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors","2026-05-30","Bupropion Hydrochloride Controlled-release",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT05197530","Imaging of Lymphatic Vessels in People With Rheumatoid Arthritis (RA)","2026-06","Indocyanine green",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT04477343","A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma","2026-06-01","SX-682",{"nctId":80,"briefTitle":81,"date":77,"intervention":82},"NCT03758989","A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma","Rituximab Prednisone",{"nctId":84,"briefTitle":85,"date":86,"intervention":87},"NCT04635189","Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma","2026-07-31","Daratumumab",[89,90,91,92,93,94],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[96,145,184,211,229,247,271,365,399,445,467,489,521,556,610,652,689,726,764,789,807,832,850,868,886,911,935,960,978,998,1019,1044,1062,1086,1111,1135,1153,1171,1189,1213,1231,1269,1297,1322,1344,1362,1386,1412,1438,1456,1476,1513,1535,1557,1575,1640,1670,1708,1740,1778,1805,1828,1846,1864,1882,1900,1928,1946,1964,1982,2005,2023,2047,2071,2089,2107,2125,2151,2177,2200,2224,2242,2260,2278,2302,2328,2346,2372,2390,2414,2432,2456,2480,2504,2529,2547,2574,2597,2621,2639,2657,2682,2700,2743,2780,2815,2851,2887,2905,2923,2949,2967,2985,3003,3021,3039,3057,3082,3105,3132,3150,3174,3192,3210,3228,3252,3270,3295,3322,3349,3374,3392,3418,3436,3484,3518,3563,3597,3630,3664,3699,3727,3759,3796,3823,3844,3867,3885,3911,3936,3959,3983,4008,4030,4048,4070,4093,4116,4134,4152,4170,4193,4211,4229,4247,4265,4283,4306,4324,4342,4360,4378,4402,4427,4450,4472,4496,4518,4536,4554,4578,4596,4618,4641,4663,4688,4713,4731,4749,4767,4785,4807,4830,4848,4872,4897,4925,4947,4971,4993,5017,5038,5056,5074,5092,5110,5128,5146,5164,5187,5209,5227,5252,5270,5293,5315,5340,5358,5381,5405,5423,5449,5471,5496,5514,5532,5550,5574,5599,5617,5635,5660,5685,5709,5734,5760,5778,5796,5814,5855,5881,5915,5937,5962,5984,6010,6045,6067,6085,6107,6130,6153,6176,6201,6225,6243,6264,6286,6309,6330,6352,6376,6394,6419,6443,6466,6488,6509,6531,6553,6571,6594,6623,6647,6672,6695,6717,6741,6759,6782,6800,6822],{"intervention":97,"totalTrials":98,"cells":99},"carvedilol",2,{"EARLY_PHASE1":100,"PHASE1":103,"PHASE2":105,"PHASE3":107,"PHASE4":109,"NA":143},{"trials":101,"activeCount":102},[],0,{"trials":104,"activeCount":102},[],{"trials":106,"activeCount":102},[],{"trials":108,"activeCount":102},[],{"trials":110,"activeCount":142,"soonestReadout":128},[111,123],{"nctId":112,"briefTitle":113,"status":114,"phases":115,"primaryCompletion":116,"completion":117,"start":118,"enrollment":119,"conditions":120,"interventions":122},"NCT02056626","Conditioned Pharmacotherapeutic Effects in Hypertension","COMPLETED",[93],"2018-11-30","2018-12-31","2011-03",44,[121],"Hypertension",[97],{"nctId":124,"briefTitle":125,"status":126,"phases":127,"primaryCompletion":128,"completion":129,"start":130,"enrollment":131,"conditions":132,"interventions":139},"NCT06964464","Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator","RECRUITING",[93],"2031-06-01","2031-07-01","2025-08-17",2000,[133,134,135,136,137,138],"Heart Failure With Reduced Ejection Fraction (HFrEF)","Sudden Cardiac Death","Ventricular Arrhythmia","Implantable Cardioverter Defibrillator (ICD)","Beta-blocker Therapy","Cardiomyopathy",[140,141],"Metoprolol Succinate","Carvedilol",1,{"trials":144,"activeCount":102},[],{"intervention":146,"totalTrials":98,"cells":147},"Diphenhydramine",{"EARLY_PHASE1":148,"PHASE1":150,"PHASE2":152,"PHASE3":154,"PHASE4":156,"NA":182},{"trials":149,"activeCount":102},[],{"trials":151,"activeCount":102},[],{"trials":153,"activeCount":102},[],{"trials":155,"activeCount":102},[],{"trials":157,"activeCount":142,"soonestReadout":174},[158,169],{"nctId":159,"briefTitle":160,"status":114,"phases":161,"primaryCompletion":162,"completion":163,"start":164,"enrollment":10,"conditions":165,"interventions":167},"NCT00638443","Lumbar Stenosis Outcomes Research (LUSTOR)",[93],"2010-03","2010-09","2008-03",[166],"Lumbar Spinal Stenosis",[168,146],"Pregabalin",{"nctId":170,"briefTitle":171,"status":172,"phases":173,"primaryCompletion":174,"completion":174,"start":175,"enrollment":176,"conditions":177,"interventions":181},"NCT07542730","Diphenhydramine as an Adjunct to Moderate Sedation for Procedural First Trimester Abortions","NOT_YET_RECRUITING",[93],"2027-02","2026-05",98,[178,179,180],"Pain","Abortion","Anxiety",[146],{"trials":183,"activeCount":102},[],{"intervention":185,"totalTrials":142,"cells":186},"Treatment with oral sucrosomial iron",{"EARLY_PHASE1":187,"PHASE1":189,"PHASE2":191,"PHASE3":193,"PHASE4":195,"NA":209},{"trials":188,"activeCount":102},[],{"trials":190,"activeCount":102},[],{"trials":192,"activeCount":102},[],{"trials":194,"activeCount":102},[],{"trials":196,"activeCount":142,"soonestReadout":201},[197],{"nctId":198,"briefTitle":199,"status":172,"phases":200,"primaryCompletion":201,"completion":201,"start":202,"enrollment":203,"conditions":204,"interventions":207},"NCT07287371","Sucrosomial Vs Intravenous Iron for Preoperative Anemia",[93],"2027-06-30","2025-12-31",75,[205,206],"Anemia","Iron Deficiency Anemia",[185,208],"Treatment with intravenous iron",{"trials":210,"activeCount":102},[],{"intervention":208,"totalTrials":142,"cells":212},{"EARLY_PHASE1":213,"PHASE1":215,"PHASE2":217,"PHASE3":219,"PHASE4":221,"NA":227},{"trials":214,"activeCount":102},[],{"trials":216,"activeCount":102},[],{"trials":218,"activeCount":102},[],{"trials":220,"activeCount":102},[],{"trials":222,"activeCount":142,"soonestReadout":201},[223],{"nctId":198,"briefTitle":199,"status":172,"phases":224,"primaryCompletion":201,"completion":201,"start":202,"enrollment":203,"conditions":225,"interventions":226},[93],[205,206],[185,208],{"trials":228,"activeCount":102},[],{"intervention":140,"totalTrials":142,"cells":230},{"EARLY_PHASE1":231,"PHASE1":233,"PHASE2":235,"PHASE3":237,"PHASE4":239,"NA":245},{"trials":232,"activeCount":102},[],{"trials":234,"activeCount":102},[],{"trials":236,"activeCount":102},[],{"trials":238,"activeCount":102},[],{"trials":240,"activeCount":142,"soonestReadout":128},[241],{"nctId":124,"briefTitle":125,"status":126,"phases":242,"primaryCompletion":128,"completion":129,"start":130,"enrollment":131,"conditions":243,"interventions":244},[93],[133,134,135,136,137,138],[140,141],{"trials":246,"activeCount":102},[],{"intervention":68,"totalTrials":142,"cells":248},{"EARLY_PHASE1":249,"PHASE1":251,"PHASE2":253,"PHASE3":255,"PHASE4":267,"NA":269},{"trials":250,"activeCount":102},[],{"trials":252,"activeCount":102},[],{"trials":254,"activeCount":102},[],{"trials":256,"activeCount":142,"soonestReadout":67},[257],{"nctId":65,"briefTitle":66,"status":258,"phases":259,"primaryCompletion":67,"completion":260,"start":261,"enrollment":262,"conditions":263,"interventions":266},"ACTIVE_NOT_RECRUITING",[92],"2026-08-05","2019-06-27",422,[264,265],"Hematopoietic and Lymphatic System Neoplasm","Malignant Solid Neoplasm",[68],{"trials":268,"activeCount":102},[],{"trials":270,"activeCount":102},[],{"intervention":272,"totalTrials":273,"cells":274},"Cyclophosphamide",5,{"EARLY_PHASE1":275,"PHASE1":277,"PHASE2":279,"PHASE3":320,"PHASE4":322,"NA":324},{"trials":276,"activeCount":102},[],{"trials":278,"activeCount":102},[],{"trials":280,"activeCount":98,"soonestReadout":77},[281,298,309],{"nctId":282,"briefTitle":283,"status":114,"phases":284,"primaryCompletion":285,"start":286,"enrollment":287,"conditions":288,"interventions":290},"NCT00262886","Donor Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Relapsed or Refractory Metastatic Kidney Cancer",[91],"2007-07","2001-08",35,[289],"Kidney Cancer",[291,292,293,294,295,296,297],"anti-thymocyte globulin","graft-versus-tumor induction therapy","therapeutic allogeneic lymphocytes","cyclophosphamide","fludarabine phosphate","mycophenolate mofetil","tacrolimus",{"nctId":80,"briefTitle":81,"status":126,"phases":299,"primaryCompletion":77,"completion":300,"start":301,"enrollment":302,"conditions":303,"interventions":305},[91],"2027-06-01","2019-05-08",40,[304],"DLBCL",[82,272,306,307,308],"Doxorubicin","Vincristine","Prednisone",{"nctId":310,"briefTitle":311,"status":258,"phases":312,"primaryCompletion":86,"completion":86,"start":313,"enrollment":314,"conditions":315,"interventions":317},"NCT04594798","A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL",[91],"2021-09-20",39,[304,316],"Lymphoma, B-Cell",[318,319,272,306,308],"Polatuzumab vedotin","Rituximab",{"trials":321,"activeCount":102},[],{"trials":323,"activeCount":102},[],{"trials":325,"activeCount":142,"soonestReadout":349},[326,345],{"nctId":327,"briefTitle":328,"status":329,"phases":330,"primaryCompletion":331,"completion":332,"start":333,"enrollment":334,"conditions":335,"interventions":343},"NCT00255684","Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer","TERMINATED",[94],"2013-03","2016-06","2003-12",16,[336,337,338,339,340,341,342],"Chronic Myeloproliferative Disorders","Graft Versus Host Disease","Leukemia","Lymphoma","Multiple Myeloma","Myelodysplastic Syndromes","Myelodysplastic\u002FMyeloproliferative Neoplasms",[292,294,344,295,296],"cyclosporine",{"nctId":346,"briefTitle":347,"status":126,"phases":348,"primaryCompletion":349,"completion":349,"start":350,"enrollment":351,"conditions":352,"interventions":360},"NCT03016806","Umbilical Cord Blood Transplantation From Unrelated Donors",[],"2027-06","2015-06",30,[353,354,355,356,357,341,358,339,340,359],"Acute Leukemia","Immune Deficiency Disorder","Congenital Hematological Disorder","Metabolism Disorder","Aplastic Anemia","Chronic Leukemia","Solid Tumor",[272,361,362,363,364],"Mesna","Busulfan","Fludarabine","Melphalan",{"intervention":308,"totalTrials":366,"cells":367},3,{"EARLY_PHASE1":368,"PHASE1":370,"PHASE2":372,"PHASE3":382,"PHASE4":395,"NA":397},{"trials":369,"activeCount":102},[],{"trials":371,"activeCount":102},[],{"trials":373,"activeCount":98,"soonestReadout":77},[374,378],{"nctId":80,"briefTitle":81,"status":126,"phases":375,"primaryCompletion":77,"completion":300,"start":301,"enrollment":302,"conditions":376,"interventions":377},[91],[304],[82,272,306,307,308],{"nctId":310,"briefTitle":311,"status":258,"phases":379,"primaryCompletion":86,"completion":86,"start":313,"enrollment":314,"conditions":380,"interventions":381},[91],[304,316],[318,319,272,306,308],{"trials":383,"activeCount":102},[384],{"nctId":385,"briefTitle":386,"status":114,"phases":387,"primaryCompletion":388,"completion":388,"start":389,"enrollment":390,"conditions":391,"interventions":393},"NCT01603407","Finding the Optimum Regimen for Duchenne Muscular Dystrophy",[92],"2019-11","2013-01",196,[392],"Duchenne Muscular Dystrophy",[308,308,394],"Deflazacort",{"trials":396,"activeCount":102},[],{"trials":398,"activeCount":102},[],{"intervention":400,"totalTrials":366,"cells":401},"Methylene Blue",{"EARLY_PHASE1":402,"PHASE1":404,"PHASE2":417,"PHASE3":439,"PHASE4":441,"NA":443},{"trials":403,"activeCount":102},[],{"trials":405,"activeCount":102},[406],{"nctId":407,"briefTitle":408,"status":114,"phases":409,"primaryCompletion":410,"completion":410,"start":411,"enrollment":412,"conditions":413,"interventions":415},"NCT02240498","Safety and Feasibility Study of Methylene Blue Photodynamic Therapy to Sterilize Deep Tissue Abscess Cavities",[90],"2023-09","2014-09",21,[414],"Abscess",[400,416],"20% I.V. Fat Emulsion",{"trials":418,"activeCount":98,"soonestReadout":433},[419,429],{"nctId":420,"briefTitle":421,"status":172,"phases":422,"primaryCompletion":423,"completion":423,"start":424,"enrollment":425,"conditions":426,"interventions":427},"NCT06052956","Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses",[91],"2031-06-30","2026-07-15",120,[414],[400,428],"Lipid Emulsion",{"nctId":430,"briefTitle":431,"status":172,"phases":432,"primaryCompletion":433,"completion":433,"start":434,"enrollment":435,"conditions":436,"interventions":438},"NCT07179003","A Phase 2 Study of Methylene Blue Photodynamic Therapy for Treatment of Breast Abscesses",[91],"2031-03","2026-04",50,[437],"Breast Abscess",[400,428],{"trials":440,"activeCount":102},[],{"trials":442,"activeCount":102},[],{"trials":444,"activeCount":102},[],{"intervention":428,"totalTrials":98,"cells":446},{"EARLY_PHASE1":447,"PHASE1":449,"PHASE2":451,"PHASE3":461,"PHASE4":463,"NA":465},{"trials":448,"activeCount":102},[],{"trials":450,"activeCount":102},[],{"trials":452,"activeCount":98,"soonestReadout":433},[453,457],{"nctId":420,"briefTitle":421,"status":172,"phases":454,"primaryCompletion":423,"completion":423,"start":424,"enrollment":425,"conditions":455,"interventions":456},[91],[414],[400,428],{"nctId":430,"briefTitle":431,"status":172,"phases":458,"primaryCompletion":433,"completion":433,"start":434,"enrollment":435,"conditions":459,"interventions":460},[91],[437],[400,428],{"trials":462,"activeCount":102},[],{"trials":464,"activeCount":102},[],{"trials":466,"activeCount":102},[],{"intervention":306,"totalTrials":98,"cells":468},{"EARLY_PHASE1":469,"PHASE1":471,"PHASE2":473,"PHASE3":483,"PHASE4":485,"NA":487},{"trials":470,"activeCount":102},[],{"trials":472,"activeCount":102},[],{"trials":474,"activeCount":98,"soonestReadout":77},[475,479],{"nctId":80,"briefTitle":81,"status":126,"phases":476,"primaryCompletion":77,"completion":300,"start":301,"enrollment":302,"conditions":477,"interventions":478},[91],[304],[82,272,306,307,308],{"nctId":310,"briefTitle":311,"status":258,"phases":480,"primaryCompletion":86,"completion":86,"start":313,"enrollment":314,"conditions":481,"interventions":482},[91],[304,316],[318,319,272,306,308],{"trials":484,"activeCount":102},[],{"trials":486,"activeCount":102},[],{"trials":488,"activeCount":102},[],{"intervention":168,"totalTrials":98,"cells":490},{"EARLY_PHASE1":491,"PHASE1":493,"PHASE2":495,"PHASE3":511,"PHASE4":513,"NA":519},{"trials":492,"activeCount":102},[],{"trials":494,"activeCount":102},[],{"trials":496,"activeCount":142,"soonestReadout":501},[497],{"nctId":498,"briefTitle":499,"status":126,"phases":500,"primaryCompletion":501,"completion":501,"start":502,"enrollment":503,"conditions":504,"interventions":509},"NCT06614322","SPENDD: Quantitative Sensory Testing and Analgesic Response for Painful Peripheral Neuropathy.",[91],"2028-06","2026-01-29",190,[505,506,507,508],"Painful Peripheral Neuropathy","Diabetic Peripheral Neuropathic Pain (DPN)","Chemotherapy Induced Peripheral Neuropathy (CIPN)","Idiopathic Peripheral Neuropathy",[168,510],"Duloxetine",{"trials":512,"activeCount":102},[],{"trials":514,"activeCount":102},[515],{"nctId":159,"briefTitle":160,"status":114,"phases":516,"primaryCompletion":162,"completion":163,"start":164,"enrollment":10,"conditions":517,"interventions":518},[93],[166],[168,146],{"trials":520,"activeCount":102},[],{"intervention":522,"totalTrials":98,"cells":523},"Dexamethasone",{"EARLY_PHASE1":524,"PHASE1":526,"PHASE2":528,"PHASE3":537,"PHASE4":552,"NA":554},{"trials":525,"activeCount":102},[],{"trials":527,"activeCount":102},[],{"trials":529,"activeCount":142,"soonestReadout":86},[530],{"nctId":84,"briefTitle":85,"status":258,"phases":531,"primaryCompletion":86,"completion":86,"start":532,"enrollment":533,"conditions":534,"interventions":535},[91],"2021-07-27",28,[340],[87,536,522],"Lenalidomide",{"trials":538,"activeCount":102},[539],{"nctId":540,"briefTitle":541,"status":114,"phases":542,"primaryCompletion":543,"completion":543,"start":544,"enrollment":545,"conditions":546,"interventions":548},"NCT03367572","Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer",[92],"2024-04-13","2018-04-19",1363,[547],"Breast Carcinoma",[522,549,550,551],"Netupitant\u002FPalonosetron Hydrochloride","Olanzapine","Prochlorperazine",{"trials":553,"activeCount":102},[],{"trials":555,"activeCount":102},[],{"intervention":557,"totalTrials":558,"cells":559},"rituximab",4,{"EARLY_PHASE1":560,"PHASE1":562,"PHASE2":564,"PHASE3":604,"PHASE4":606,"NA":608},{"trials":561,"activeCount":102},[],{"trials":563,"activeCount":102},[],{"trials":565,"activeCount":142,"soonestReadout":86},[566,579,590,600],{"nctId":567,"briefTitle":568,"status":114,"phases":569,"primaryCompletion":570,"completion":571,"start":572,"enrollment":573,"conditions":574,"interventions":576},"NCT00547534","Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma",[91],"2009-06","2009-10","2007-10",31,[575],"Non-Hodgkin's Lymphoma",[577,578,557],"bortezomib","bendamustine",{"nctId":580,"briefTitle":581,"status":114,"phases":582,"primaryCompletion":583,"completion":583,"start":584,"enrollment":314,"conditions":585,"interventions":588},"NCT03788291","Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia \u002F Small Lymphocytic Lymphoma",[91],"2023-05-19","2019-03-25",[586,587],"Chronic Lymphocytic Leukemia (CLL)","Small Lymphocytic Lymphoma (SLL)",[589,319],"Acalabrutinib",{"nctId":591,"briefTitle":592,"status":114,"phases":593,"primaryCompletion":594,"completion":594,"start":595,"enrollment":596,"conditions":597,"interventions":598},"NCT00003356","Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma",[90,91],"2002-05","1997-11",58,[339],[599,557],"aldesleukin",{"nctId":310,"briefTitle":311,"status":258,"phases":601,"primaryCompletion":86,"completion":86,"start":313,"enrollment":314,"conditions":602,"interventions":603},[91],[304,316],[318,319,272,306,308],{"trials":605,"activeCount":102},[],{"trials":607,"activeCount":102},[],{"trials":609,"activeCount":102},[],{"intervention":58,"totalTrials":366,"cells":611},{"EARLY_PHASE1":612,"PHASE1":614,"PHASE2":627,"PHASE3":646,"PHASE4":648,"NA":650},{"trials":613,"activeCount":102},[],{"trials":615,"activeCount":102},[616],{"nctId":617,"briefTitle":618,"status":114,"phases":619,"primaryCompletion":620,"completion":621,"start":622,"enrollment":23,"conditions":623,"interventions":626},"NCT05153174","Study of Sulphoraphane in Chronic Kidney Disease",[90],"2023-05-25","2023-06-08","2022-05-02",[624,625],"Chronic Kidney Disease stage3","Chronic Kidney Disease stage4",[58],{"trials":628,"activeCount":142,"soonestReadout":57},[629,640],{"nctId":630,"briefTitle":631,"status":114,"phases":632,"primaryCompletion":633,"completion":202,"start":634,"enrollment":635,"conditions":636,"interventions":639},"NCT05797506","Safety, Feasibility and Efficacy of Sulforaphane (Avmacol Extra Strength) in Chronic Kidney Disease",[91],"2025-04-25","2023-05-03",96,[637,638],"Chronic Kidney Disease Stage 3","Chronic Kidney Disease Stage 4",[58],{"nctId":55,"briefTitle":56,"status":258,"phases":641,"primaryCompletion":57,"completion":202,"start":642,"enrollment":29,"conditions":643,"interventions":645},[91],"2023-05-15",[644],"Pediatric Kidney Disease",[58],{"trials":647,"activeCount":102},[],{"trials":649,"activeCount":102},[],{"trials":651,"activeCount":102},[],{"intervention":653,"totalTrials":98,"cells":654},"Daridorexant 50 mg",{"EARLY_PHASE1":655,"PHASE1":657,"PHASE2":659,"PHASE3":683,"PHASE4":685,"NA":687},{"trials":656,"activeCount":102},[],{"trials":658,"activeCount":102},[],{"trials":660,"activeCount":142,"soonestReadout":665},[661,672],{"nctId":662,"briefTitle":663,"status":126,"phases":664,"primaryCompletion":665,"completion":665,"start":666,"enrollment":667,"conditions":668,"interventions":671},"NCT07217912","Daridorexant to Prevent Post-cardiotomy Delirium",[91],"2027-11-01","2025-10-14",80,[669,670],"Postoperative Cognitive Decline","Postoperative Delirium",[653],{"nctId":673,"briefTitle":674,"status":114,"phases":675,"primaryCompletion":676,"completion":676,"start":677,"enrollment":678,"conditions":679,"interventions":682},"NCT06630390","Daridorexant to Prevent Delirium After Heart Surgery",[91],"2025-02-16","2024-11-11",11,[680,681],"POSTOPERATIVE DELIRIUM","POSTOPERATIVE COGNITIVE DECLINE",[653],{"trials":684,"activeCount":102},[],{"trials":686,"activeCount":102},[],{"trials":688,"activeCount":102},[],{"intervention":690,"totalTrials":98,"cells":691},"Epigallocatechin-3-Gallate",{"EARLY_PHASE1":692,"PHASE1":694,"PHASE2":696,"PHASE3":720,"PHASE4":722,"NA":724},{"trials":693,"activeCount":102},[],{"trials":695,"activeCount":102},[],{"trials":697,"activeCount":142,"soonestReadout":702},[698,711],{"nctId":699,"briefTitle":700,"status":126,"phases":701,"primaryCompletion":702,"completion":703,"start":704,"enrollment":705,"conditions":706,"interventions":709},"NCT06068543","Reducing Frailty for Older Cancer Survivors Using Supplements II",[91],"2030-01-01","2030-12-31","2024-10-25",118,[707,708],"Frailty","Inflammation",[690,710],"Microcrystalline cellulose",{"nctId":712,"briefTitle":713,"status":114,"phases":714,"primaryCompletion":715,"completion":715,"start":716,"enrollment":717,"conditions":718,"interventions":719},"NCT04553666","Reducing Frailty for Older Cancer Survivors Using Supplements",[91],"2023-08-31","2021-04-28",24,[707,708],[690],{"trials":721,"activeCount":102},[],{"trials":723,"activeCount":102},[],{"trials":725,"activeCount":102},[],{"intervention":727,"totalTrials":98,"cells":728},"Hyperbaric oxygen",{"EARLY_PHASE1":729,"PHASE1":741,"PHASE2":743,"PHASE3":758,"PHASE4":760,"NA":762},{"trials":730,"activeCount":102},[731],{"nctId":732,"briefTitle":733,"status":114,"phases":734,"primaryCompletion":735,"completion":736,"start":737,"enrollment":10,"conditions":738,"interventions":740},"NCT04862676","Repeated HBO Therapy in Myeloma Patients Undergoing High-Dose Therapy and Auto-HCT",[89],"2025-04-04","2025-06-30","2022-04-22",[739],"Myeloma",[727],{"trials":742,"activeCount":102},[],{"trials":744,"activeCount":142,"soonestReadout":349},[745],{"nctId":746,"briefTitle":747,"status":126,"phases":748,"primaryCompletion":349,"completion":349,"start":749,"enrollment":750,"conditions":751,"interventions":757},"NCT03739502","A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant",[91],"2019-02-28",64,[752,753,754,755,756],"AML","NHL","Hodgkin Disease","All","Myelodysplastic Syndrome",[727],{"trials":759,"activeCount":102},[],{"trials":761,"activeCount":102},[],{"trials":763,"activeCount":102},[],{"intervention":765,"totalTrials":142,"cells":766},"Methylphenidate",{"EARLY_PHASE1":767,"PHASE1":769,"PHASE2":771,"PHASE3":783,"PHASE4":785,"NA":787},{"trials":768,"activeCount":102},[],{"trials":770,"activeCount":102},[],{"trials":772,"activeCount":142,"soonestReadout":777},[773],{"nctId":774,"briefTitle":775,"status":126,"phases":776,"primaryCompletion":777,"completion":777,"start":778,"enrollment":32,"conditions":779,"interventions":781},"NCT05285683","The Role of Brain Dopamine in Chronic Pain",[91],"2027-12-22","2024-01-31",[780],"Chronic Pain",[765,782],"carbidopa-levodopa",{"trials":784,"activeCount":102},[],{"trials":786,"activeCount":102},[],{"trials":788,"activeCount":102},[],{"intervention":782,"totalTrials":142,"cells":790},{"EARLY_PHASE1":791,"PHASE1":793,"PHASE2":795,"PHASE3":801,"PHASE4":803,"NA":805},{"trials":792,"activeCount":102},[],{"trials":794,"activeCount":102},[],{"trials":796,"activeCount":142,"soonestReadout":777},[797],{"nctId":774,"briefTitle":775,"status":126,"phases":798,"primaryCompletion":777,"completion":777,"start":778,"enrollment":32,"conditions":799,"interventions":800},[91],[780],[765,782],{"trials":802,"activeCount":102},[],{"trials":804,"activeCount":102},[],{"trials":806,"activeCount":102},[],{"intervention":808,"totalTrials":142,"cells":809},"Ketamine hydrochloride",{"EARLY_PHASE1":810,"PHASE1":812,"PHASE2":814,"PHASE3":826,"PHASE4":828,"NA":830},{"trials":811,"activeCount":102},[],{"trials":813,"activeCount":102},[],{"trials":815,"activeCount":142,"soonestReadout":820},[816],{"nctId":817,"briefTitle":818,"status":172,"phases":819,"primaryCompletion":820,"completion":821,"start":72,"enrollment":822,"conditions":823,"interventions":825},"NCT07247006","Ketamine-Assisted Psychotherapy for Treatment-Resistant Depression",[91],"2028-01","2028-03",25,[824,780],"Treatment Resistant Depression (TRD)",[808],{"trials":827,"activeCount":102},[],{"trials":829,"activeCount":102},[],{"trials":831,"activeCount":102},[],{"intervention":710,"totalTrials":142,"cells":833},{"EARLY_PHASE1":834,"PHASE1":836,"PHASE2":838,"PHASE3":844,"PHASE4":846,"NA":848},{"trials":835,"activeCount":102},[],{"trials":837,"activeCount":102},[],{"trials":839,"activeCount":142,"soonestReadout":702},[840],{"nctId":699,"briefTitle":700,"status":126,"phases":841,"primaryCompletion":702,"completion":703,"start":704,"enrollment":705,"conditions":842,"interventions":843},[91],[707,708],[690,710],{"trials":845,"activeCount":102},[],{"trials":847,"activeCount":102},[],{"trials":849,"activeCount":102},[],{"intervention":87,"totalTrials":142,"cells":851},{"EARLY_PHASE1":852,"PHASE1":854,"PHASE2":856,"PHASE3":862,"PHASE4":864,"NA":866},{"trials":853,"activeCount":102},[],{"trials":855,"activeCount":102},[],{"trials":857,"activeCount":142,"soonestReadout":86},[858],{"nctId":84,"briefTitle":85,"status":258,"phases":859,"primaryCompletion":86,"completion":86,"start":532,"enrollment":533,"conditions":860,"interventions":861},[91],[340],[87,536,522],{"trials":863,"activeCount":102},[],{"trials":865,"activeCount":102},[],{"trials":867,"activeCount":102},[],{"intervention":536,"totalTrials":142,"cells":869},{"EARLY_PHASE1":870,"PHASE1":872,"PHASE2":874,"PHASE3":880,"PHASE4":882,"NA":884},{"trials":871,"activeCount":102},[],{"trials":873,"activeCount":102},[],{"trials":875,"activeCount":142,"soonestReadout":86},[876],{"nctId":84,"briefTitle":85,"status":258,"phases":877,"primaryCompletion":86,"completion":86,"start":532,"enrollment":533,"conditions":878,"interventions":879},[91],[340],[87,536,522],{"trials":881,"activeCount":102},[],{"trials":883,"activeCount":102},[],{"trials":885,"activeCount":102},[],{"intervention":887,"totalTrials":142,"cells":888},"CAV",{"EARLY_PHASE1":889,"PHASE1":891,"PHASE2":893,"PHASE3":905,"PHASE4":907,"NA":909},{"trials":890,"activeCount":102},[],{"trials":892,"activeCount":102},[],{"trials":894,"activeCount":142,"soonestReadout":899},[895],{"nctId":896,"briefTitle":897,"status":172,"phases":898,"primaryCompletion":899,"completion":900,"start":901,"enrollment":717,"conditions":902,"interventions":904},"NCT07423104","A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed\u002FRefractory or Secondary Acute Myeloid Leukemia",[91],"2029-02-01","2030-02-01","2026-08-15",[903],"Acute Myeloid Leukemia (AML)",[887],{"trials":906,"activeCount":102},[],{"trials":908,"activeCount":102},[],{"trials":910,"activeCount":102},[],{"intervention":912,"totalTrials":142,"cells":913},"Medical Cannabis",{"EARLY_PHASE1":914,"PHASE1":916,"PHASE2":918,"PHASE3":929,"PHASE4":931,"NA":933},{"trials":915,"activeCount":102},[],{"trials":917,"activeCount":102},[],{"trials":919,"activeCount":142,"soonestReadout":924},[920],{"nctId":921,"briefTitle":922,"status":172,"phases":923,"primaryCompletion":924,"completion":924,"start":925,"enrollment":435,"conditions":926,"interventions":928},"NCT07374939","Medical Cannabis for Nausea in Patients Receiving Moderately or Highly Emetogenic Chemotherapy",[91],"2028-03-01","2026-03-01",[927],"Nausea and Vomiting Chemotherapy-Induced",[912],{"trials":930,"activeCount":102},[],{"trials":932,"activeCount":102},[],{"trials":934,"activeCount":102},[],{"intervention":936,"totalTrials":142,"cells":937},"mFOLFOX6",{"EARLY_PHASE1":938,"PHASE1":940,"PHASE2":942,"PHASE3":954,"PHASE4":956,"NA":958},{"trials":939,"activeCount":102},[],{"trials":941,"activeCount":102},[],{"trials":943,"activeCount":142,"soonestReadout":948},[944],{"nctId":945,"briefTitle":946,"status":258,"phases":947,"primaryCompletion":948,"completion":948,"start":949,"enrollment":302,"conditions":950,"interventions":952},"NCT03110926","Induction Chemotherapy for Locally Advanced Esophageal Cancer",[91],"2027-05-31","2017-06-19",[951],"Esophageal Carcinoma",[936,953],"Chemoradiation",{"trials":955,"activeCount":102},[],{"trials":957,"activeCount":102},[],{"trials":959,"activeCount":102},[],{"intervention":953,"totalTrials":142,"cells":961},{"EARLY_PHASE1":962,"PHASE1":964,"PHASE2":966,"PHASE3":972,"PHASE4":974,"NA":976},{"trials":963,"activeCount":102},[],{"trials":965,"activeCount":102},[],{"trials":967,"activeCount":142,"soonestReadout":948},[968],{"nctId":945,"briefTitle":946,"status":258,"phases":969,"primaryCompletion":948,"completion":948,"start":949,"enrollment":302,"conditions":970,"interventions":971},[91],[951],[936,953],{"trials":973,"activeCount":102},[],{"trials":975,"activeCount":102},[],{"trials":977,"activeCount":102},[],{"intervention":43,"totalTrials":142,"cells":979},{"EARLY_PHASE1":980,"PHASE1":982,"PHASE2":984,"PHASE3":992,"PHASE4":994,"NA":996},{"trials":981,"activeCount":102},[],{"trials":983,"activeCount":102},[],{"trials":985,"activeCount":142,"soonestReadout":42},[986],{"nctId":40,"briefTitle":41,"status":258,"phases":987,"primaryCompletion":42,"completion":300,"start":988,"enrollment":29,"conditions":989,"interventions":991},[91],"2019-05-03",[990],"Advanced Rectal Cancer",[43],{"trials":993,"activeCount":102},[],{"trials":995,"activeCount":102},[],{"trials":997,"activeCount":102},[],{"intervention":48,"totalTrials":142,"cells":999},{"EARLY_PHASE1":1000,"PHASE1":1002,"PHASE2":1004,"PHASE3":1013,"PHASE4":1015,"NA":1017},{"trials":1001,"activeCount":102},[],{"trials":1003,"activeCount":102},[],{"trials":1005,"activeCount":142,"soonestReadout":47},[1006],{"nctId":45,"briefTitle":46,"status":126,"phases":1007,"primaryCompletion":47,"completion":202,"start":1008,"enrollment":1009,"conditions":1010,"interventions":1012},[91],"2023-08-21",15,[1011],"Smoldering Multiple Myeloma",[48],{"trials":1014,"activeCount":102},[],{"trials":1016,"activeCount":102},[],{"trials":1018,"activeCount":102},[],{"intervention":1020,"totalTrials":142,"cells":1021},"Fucoidan extracted from F. Vesiculosus",{"EARLY_PHASE1":1022,"PHASE1":1024,"PHASE2":1026,"PHASE3":1038,"PHASE4":1040,"NA":1042},{"trials":1023,"activeCount":102},[],{"trials":1025,"activeCount":102},[],{"trials":1027,"activeCount":142,"soonestReadout":1032},[1028],{"nctId":1029,"briefTitle":1030,"status":126,"phases":1031,"primaryCompletion":1032,"completion":300,"start":1033,"enrollment":302,"conditions":1034,"interventions":1036},"NCT06295588","Clinical Trial of the Seaweed Supplement Fucoidan in Survivors of Cancer",[91],"2026-12-31","2025-07-26",[1035,708],"Fatigue",[1020,1037],"Fucoidan extracted from U. Pinnatifida",{"trials":1039,"activeCount":102},[],{"trials":1041,"activeCount":102},[],{"trials":1043,"activeCount":102},[],{"intervention":1037,"totalTrials":142,"cells":1045},{"EARLY_PHASE1":1046,"PHASE1":1048,"PHASE2":1050,"PHASE3":1056,"PHASE4":1058,"NA":1060},{"trials":1047,"activeCount":102},[],{"trials":1049,"activeCount":102},[],{"trials":1051,"activeCount":142,"soonestReadout":1032},[1052],{"nctId":1029,"briefTitle":1030,"status":126,"phases":1053,"primaryCompletion":1032,"completion":300,"start":1033,"enrollment":302,"conditions":1054,"interventions":1055},[91],[1035,708],[1020,1037],{"trials":1057,"activeCount":102},[],{"trials":1059,"activeCount":102},[],{"trials":1061,"activeCount":102},[],{"intervention":53,"totalTrials":142,"cells":1063},{"EARLY_PHASE1":1064,"PHASE1":1066,"PHASE2":1068,"PHASE3":1080,"PHASE4":1082,"NA":1084},{"trials":1065,"activeCount":102},[],{"trials":1067,"activeCount":102},[],{"trials":1069,"activeCount":142,"soonestReadout":52},[1070],{"nctId":50,"briefTitle":51,"status":258,"phases":1071,"primaryCompletion":52,"completion":1072,"start":1073,"enrollment":1074,"conditions":1075,"interventions":1079},[91],"2026-12-30","2011-08",191,[1076,1077,1078],"Bone Metabolism Biomarkers","Bone Mineral Density","Physical Fitness",[53],{"trials":1081,"activeCount":102},[],{"trials":1083,"activeCount":102},[],{"trials":1085,"activeCount":102},[],{"intervention":1087,"totalTrials":142,"cells":1088},"10% povidone iodine + FV",{"EARLY_PHASE1":1089,"PHASE1":1091,"PHASE2":1093,"PHASE3":1105,"PHASE4":1107,"NA":1109},{"trials":1090,"activeCount":102},[],{"trials":1092,"activeCount":102},[],{"trials":1094,"activeCount":142,"soonestReadout":1099},[1095],{"nctId":1096,"briefTitle":1097,"status":126,"phases":1098,"primaryCompletion":1099,"completion":1099,"start":1100,"enrollment":1101,"conditions":1102,"interventions":1104},"NCT05272254","Povidone Iodine Efficacy Study",[91],"2027-05","2022-09-15",202,[1103],"Early Childhood Caries",[1087],{"trials":1106,"activeCount":102},[],{"trials":1108,"activeCount":102},[],{"trials":1110,"activeCount":102},[],{"intervention":1112,"totalTrials":142,"cells":1113},"Capecitabine and Neratinib.",{"EARLY_PHASE1":1114,"PHASE1":1116,"PHASE2":1118,"PHASE3":1129,"PHASE4":1131,"NA":1133},{"trials":1115,"activeCount":102},[],{"trials":1117,"activeCount":102},[],{"trials":1119,"activeCount":142,"soonestReadout":1124},[1120],{"nctId":1121,"briefTitle":1122,"status":126,"phases":1123,"primaryCompletion":1124,"completion":1125,"start":1126,"enrollment":17,"conditions":1127,"interventions":1128},"NCT04965064","Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling",[91],"2026-09-01","2027-09-01","2022-09-23",[36],[1112],{"trials":1130,"activeCount":102},[],{"trials":1132,"activeCount":102},[],{"trials":1134,"activeCount":102},[],{"intervention":82,"totalTrials":142,"cells":1136},{"EARLY_PHASE1":1137,"PHASE1":1139,"PHASE2":1141,"PHASE3":1147,"PHASE4":1149,"NA":1151},{"trials":1138,"activeCount":102},[],{"trials":1140,"activeCount":102},[],{"trials":1142,"activeCount":142,"soonestReadout":77},[1143],{"nctId":80,"briefTitle":81,"status":126,"phases":1144,"primaryCompletion":77,"completion":300,"start":301,"enrollment":302,"conditions":1145,"interventions":1146},[91],[304],[82,272,306,307,308],{"trials":1148,"activeCount":102},[],{"trials":1150,"activeCount":102},[],{"trials":1152,"activeCount":102},[],{"intervention":307,"totalTrials":142,"cells":1154},{"EARLY_PHASE1":1155,"PHASE1":1157,"PHASE2":1159,"PHASE3":1165,"PHASE4":1167,"NA":1169},{"trials":1156,"activeCount":102},[],{"trials":1158,"activeCount":102},[],{"trials":1160,"activeCount":142,"soonestReadout":77},[1161],{"nctId":80,"briefTitle":81,"status":126,"phases":1162,"primaryCompletion":77,"completion":300,"start":301,"enrollment":302,"conditions":1163,"interventions":1164},[91],[304],[82,272,306,307,308],{"trials":1166,"activeCount":102},[],{"trials":1168,"activeCount":102},[],{"trials":1170,"activeCount":102},[],{"intervention":510,"totalTrials":142,"cells":1172},{"EARLY_PHASE1":1173,"PHASE1":1175,"PHASE2":1177,"PHASE3":1183,"PHASE4":1185,"NA":1187},{"trials":1174,"activeCount":102},[],{"trials":1176,"activeCount":102},[],{"trials":1178,"activeCount":142,"soonestReadout":501},[1179],{"nctId":498,"briefTitle":499,"status":126,"phases":1180,"primaryCompletion":501,"completion":501,"start":502,"enrollment":503,"conditions":1181,"interventions":1182},[91],[505,506,507,508],[168,510],{"trials":1184,"activeCount":102},[],{"trials":1186,"activeCount":102},[],{"trials":1188,"activeCount":102},[],{"intervention":1190,"totalTrials":142,"cells":1191},"Caffeine Citrate",{"EARLY_PHASE1":1192,"PHASE1":1194,"PHASE2":1196,"PHASE3":1207,"PHASE4":1209,"NA":1211},{"trials":1193,"activeCount":102},[],{"trials":1195,"activeCount":102},[],{"trials":1197,"activeCount":142,"soonestReadout":1125},[1198],{"nctId":1199,"briefTitle":1200,"status":172,"phases":1201,"primaryCompletion":1125,"completion":1202,"start":77,"enrollment":302,"conditions":1203,"interventions":1206},"NCT07216365","Caffeine Optimization for Oxygen Saturation Index in ELBW Infants",[91],"2028-09-01",[1204,1205],"Neonatal Apnea","Infants",[1190],{"trials":1208,"activeCount":102},[],{"trials":1210,"activeCount":102},[],{"trials":1212,"activeCount":102},[],{"intervention":318,"totalTrials":142,"cells":1214},{"EARLY_PHASE1":1215,"PHASE1":1217,"PHASE2":1219,"PHASE3":1225,"PHASE4":1227,"NA":1229},{"trials":1216,"activeCount":102},[],{"trials":1218,"activeCount":102},[],{"trials":1220,"activeCount":142,"soonestReadout":86},[1221],{"nctId":310,"briefTitle":311,"status":258,"phases":1222,"primaryCompletion":86,"completion":86,"start":313,"enrollment":314,"conditions":1223,"interventions":1224},[91],[304,316],[318,319,272,306,308],{"trials":1226,"activeCount":102},[],{"trials":1228,"activeCount":102},[],{"trials":1230,"activeCount":102},[],{"intervention":1232,"totalTrials":366,"cells":1233},"Indocyanine Green",{"EARLY_PHASE1":1234,"PHASE1":1236,"PHASE2":1261,"PHASE3":1263,"PHASE4":1265,"NA":1267},{"trials":1235,"activeCount":102},[],{"trials":1237,"activeCount":142,"soonestReadout":72},[1238,1247,1256],{"nctId":1239,"briefTitle":1240,"status":114,"phases":1241,"primaryCompletion":1242,"completion":1242,"start":1243,"enrollment":98,"conditions":1244,"interventions":1246},"NCT04046146","Near InfraRed Fluorescence Using Indocyanine Green and Magnetic Resonance Lymphography of Lymphatic Transport",[90],"2020-03-15","2019-12-15",[1245],"Rheumatoid Arthritis",[1232],{"nctId":1248,"briefTitle":1249,"status":114,"phases":1250,"primaryCompletion":1251,"completion":1251,"start":1252,"enrollment":1253,"conditions":1254,"interventions":1255},"NCT02680067","NIR Fluorescence Imaging of Lymphatic Transport Using ICG",[90],"2022-07","2015-12-08",23,[1245],[1232],{"nctId":70,"briefTitle":71,"status":126,"phases":1257,"primaryCompletion":72,"completion":72,"start":1258,"enrollment":302,"conditions":1259,"interventions":1260},[90],"2021-12-30",[1245],[73],{"trials":1262,"activeCount":102},[],{"trials":1264,"activeCount":102},[],{"trials":1266,"activeCount":102},[],{"trials":1268,"activeCount":102},[],{"intervention":1270,"totalTrials":142,"cells":1271},"Oral disulfiram",{"EARLY_PHASE1":1272,"PHASE1":1274,"PHASE2":1289,"PHASE3":1291,"PHASE4":1293,"NA":1295},{"trials":1273,"activeCount":102},[],{"trials":1275,"activeCount":142,"soonestReadout":1280},[1276],{"nctId":1277,"briefTitle":1278,"status":126,"phases":1279,"primaryCompletion":1280,"completion":1280,"start":1281,"enrollment":1009,"conditions":1282,"interventions":1288},"NCT06319872","The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration",[90],"2029-05-19","2025-05-19",[1283,1284,1285,1286,1287],"Alcohol Use Disorder","Retinal Dystrophies","Age-Related Macular Degeneration","Retinitis Pigmentosa","Stargardt Disease",[1270],{"trials":1290,"activeCount":102},[],{"trials":1292,"activeCount":102},[],{"trials":1294,"activeCount":102},[],{"trials":1296,"activeCount":102},[],{"intervention":1298,"totalTrials":142,"cells":1299},"Pembrolizumab",{"EARLY_PHASE1":1300,"PHASE1":1302,"PHASE2":1314,"PHASE3":1316,"PHASE4":1318,"NA":1320},{"trials":1301,"activeCount":102},[],{"trials":1303,"activeCount":142,"soonestReadout":1308},[1304],{"nctId":1305,"briefTitle":1306,"status":126,"phases":1307,"primaryCompletion":1308,"completion":1309,"start":1310,"enrollment":533,"conditions":1311,"interventions":1313},"NCT04297605","Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2",[90],"2027-11-30","2028-01-30","2020-05-15",[1312],"Non-small Cell Lung Cancer",[1298],{"trials":1315,"activeCount":102},[],{"trials":1317,"activeCount":102},[],{"trials":1319,"activeCount":102},[],{"trials":1321,"activeCount":102},[],{"intervention":78,"totalTrials":142,"cells":1323},{"EARLY_PHASE1":1324,"PHASE1":1326,"PHASE2":1336,"PHASE3":1338,"PHASE4":1340,"NA":1342},{"trials":1325,"activeCount":102},[],{"trials":1327,"activeCount":142,"soonestReadout":77},[1328],{"nctId":75,"briefTitle":76,"status":126,"phases":1329,"primaryCompletion":77,"completion":1032,"start":1330,"enrollment":20,"conditions":1331,"interventions":1334},[90],"2020-11-23",[1332,1333],"Pancreatic Ductal Adenocarcinoma","Pancreatic Cancer",[78,1335],"Nivolumab Injectable Product",{"trials":1337,"activeCount":102},[],{"trials":1339,"activeCount":102},[],{"trials":1341,"activeCount":102},[],{"trials":1343,"activeCount":102},[],{"intervention":1335,"totalTrials":142,"cells":1345},{"EARLY_PHASE1":1346,"PHASE1":1348,"PHASE2":1354,"PHASE3":1356,"PHASE4":1358,"NA":1360},{"trials":1347,"activeCount":102},[],{"trials":1349,"activeCount":142,"soonestReadout":77},[1350],{"nctId":75,"briefTitle":76,"status":126,"phases":1351,"primaryCompletion":77,"completion":1032,"start":1330,"enrollment":20,"conditions":1352,"interventions":1353},[90],[1332,1333],[78,1335],{"trials":1355,"activeCount":102},[],{"trials":1357,"activeCount":102},[],{"trials":1359,"activeCount":102},[],{"trials":1361,"activeCount":102},[],{"intervention":1363,"totalTrials":142,"cells":1364},"Amlodipine",{"EARLY_PHASE1":1365,"PHASE1":1367,"PHASE2":1378,"PHASE3":1380,"PHASE4":1382,"NA":1384},{"trials":1366,"activeCount":102},[],{"trials":1368,"activeCount":142,"soonestReadout":1373},[1369],{"nctId":1370,"briefTitle":1371,"status":172,"phases":1372,"primaryCompletion":1373,"completion":1373,"start":1374,"enrollment":20,"conditions":1375,"interventions":1377},"NCT07075965","Calcium Channel Blocker in Myotonic Dystrophy Type 1",[90],"2030-10-01","2026-12-07",[1376],"Myotonic Dystrophy 1",[1363],{"trials":1379,"activeCount":102},[],{"trials":1381,"activeCount":102},[],{"trials":1383,"activeCount":102},[],{"trials":1385,"activeCount":102},[],{"intervention":1387,"totalTrials":142,"cells":1388},"Lisinopril",{"EARLY_PHASE1":1389,"PHASE1":1402,"PHASE2":1404,"PHASE3":1406,"PHASE4":1408,"NA":1410},{"trials":1390,"activeCount":142,"soonestReadout":1395},[1391],{"nctId":1392,"briefTitle":1393,"status":126,"phases":1394,"primaryCompletion":1395,"completion":1395,"start":1396,"enrollment":351,"conditions":1397,"interventions":1401},"NCT05530655","A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer",[89],"2028-01-01","2024-02-20",[1398,1399,1400],"Prostate Cancer","Radiation Toxicity","Urinary Complication",[1387],{"trials":1403,"activeCount":102},[],{"trials":1405,"activeCount":102},[],{"trials":1407,"activeCount":102},[],{"trials":1409,"activeCount":102},[],{"trials":1411,"activeCount":102},[],{"intervention":1413,"totalTrials":142,"cells":1414},"nivolumab",{"EARLY_PHASE1":1415,"PHASE1":1428,"PHASE2":1430,"PHASE3":1432,"PHASE4":1434,"NA":1436},{"trials":1416,"activeCount":142,"soonestReadout":1421},[1417],{"nctId":1418,"briefTitle":1419,"status":258,"phases":1420,"primaryCompletion":1421,"completion":1421,"start":1422,"enrollment":1423,"conditions":1424,"interventions":1426},"NCT03463408","Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma",[89],"2026-08-01","2018-07-17",14,[1425],"Sarcoma",[1413,1427],"ipilimumab",{"trials":1429,"activeCount":102},[],{"trials":1431,"activeCount":102},[],{"trials":1433,"activeCount":102},[],{"trials":1435,"activeCount":102},[],{"trials":1437,"activeCount":102},[],{"intervention":1427,"totalTrials":142,"cells":1439},{"EARLY_PHASE1":1440,"PHASE1":1446,"PHASE2":1448,"PHASE3":1450,"PHASE4":1452,"NA":1454},{"trials":1441,"activeCount":142,"soonestReadout":1421},[1442],{"nctId":1418,"briefTitle":1419,"status":258,"phases":1443,"primaryCompletion":1421,"completion":1421,"start":1422,"enrollment":1423,"conditions":1444,"interventions":1445},[89],[1425],[1413,1427],{"trials":1447,"activeCount":102},[],{"trials":1449,"activeCount":102},[],{"trials":1451,"activeCount":102},[],{"trials":1453,"activeCount":102},[],{"trials":1455,"activeCount":102},[],{"intervention":63,"totalTrials":142,"cells":1457},{"EARLY_PHASE1":1458,"PHASE1":1466,"PHASE2":1468,"PHASE3":1470,"PHASE4":1472,"NA":1474},{"trials":1459,"activeCount":142,"soonestReadout":62},[1460],{"nctId":60,"briefTitle":61,"status":258,"phases":1461,"primaryCompletion":62,"completion":62,"start":1462,"enrollment":351,"conditions":1463,"interventions":1465},[89],"2022-05-17",[1464],"Brain Tumor",[63],{"trials":1467,"activeCount":102},[],{"trials":1469,"activeCount":102},[],{"trials":1471,"activeCount":102},[],{"trials":1473,"activeCount":102},[],{"trials":1475,"activeCount":102},[],{"intervention":362,"totalTrials":98,"cells":1477},{"EARLY_PHASE1":1478,"PHASE1":1480,"PHASE2":1501,"PHASE3":1503,"PHASE4":1505,"NA":1507},{"trials":1479,"activeCount":102},[],{"trials":1481,"activeCount":102},[1482],{"nctId":1483,"briefTitle":1484,"status":114,"phases":1485,"primaryCompletion":1486,"completion":1487,"start":1488,"enrollment":1489,"conditions":1490,"interventions":1495},"NCT02660281","URMC Related Haplo-identical Donor BMT",[90],"2019-10-28","2021-01-07","2015-10",74,[1491,1492,1493,1494,340,339],"Hematological Disease","Immune Deficiencies","Solid Tumors","Myelofibrosis",[363,1496,1497,362,364,1498,1499,1500],"Pre-Stem Cell Infusion Cyclophosphamide","Pre-Stem Cell Infusion Mesna","Post-Stem Cell Infusion Cyclophosphamide","Post-Stem Cell Infusion Mesna","Thiotepa",{"trials":1502,"activeCount":102},[],{"trials":1504,"activeCount":102},[],{"trials":1506,"activeCount":102},[],{"trials":1508,"activeCount":142,"soonestReadout":349},[1509],{"nctId":346,"briefTitle":347,"status":126,"phases":1510,"primaryCompletion":349,"completion":349,"start":350,"enrollment":351,"conditions":1511,"interventions":1512},[],[353,354,355,356,357,341,358,339,340,359],[272,361,362,363,364],{"intervention":363,"totalTrials":98,"cells":1514},{"EARLY_PHASE1":1515,"PHASE1":1517,"PHASE2":1523,"PHASE3":1525,"PHASE4":1527,"NA":1529},{"trials":1516,"activeCount":102},[],{"trials":1518,"activeCount":102},[1519],{"nctId":1483,"briefTitle":1484,"status":114,"phases":1520,"primaryCompletion":1486,"completion":1487,"start":1488,"enrollment":1489,"conditions":1521,"interventions":1522},[90],[1491,1492,1493,1494,340,339],[363,1496,1497,362,364,1498,1499,1500],{"trials":1524,"activeCount":102},[],{"trials":1526,"activeCount":102},[],{"trials":1528,"activeCount":102},[],{"trials":1530,"activeCount":142,"soonestReadout":349},[1531],{"nctId":346,"briefTitle":347,"status":126,"phases":1532,"primaryCompletion":349,"completion":349,"start":350,"enrollment":351,"conditions":1533,"interventions":1534},[],[353,354,355,356,357,341,358,339,340,359],[272,361,362,363,364],{"intervention":364,"totalTrials":98,"cells":1536},{"EARLY_PHASE1":1537,"PHASE1":1539,"PHASE2":1545,"PHASE3":1547,"PHASE4":1549,"NA":1551},{"trials":1538,"activeCount":102},[],{"trials":1540,"activeCount":102},[1541],{"nctId":1483,"briefTitle":1484,"status":114,"phases":1542,"primaryCompletion":1486,"completion":1487,"start":1488,"enrollment":1489,"conditions":1543,"interventions":1544},[90],[1491,1492,1493,1494,340,339],[363,1496,1497,362,364,1498,1499,1500],{"trials":1546,"activeCount":102},[],{"trials":1548,"activeCount":102},[],{"trials":1550,"activeCount":102},[],{"trials":1552,"activeCount":142,"soonestReadout":349},[1553],{"nctId":346,"briefTitle":347,"status":126,"phases":1554,"primaryCompletion":349,"completion":349,"start":350,"enrollment":351,"conditions":1555,"interventions":1556},[],[353,354,355,356,357,341,358,339,340,359],[272,361,362,363,364],{"intervention":361,"totalTrials":142,"cells":1558},{"EARLY_PHASE1":1559,"PHASE1":1561,"PHASE2":1563,"PHASE3":1565,"PHASE4":1567,"NA":1569},{"trials":1560,"activeCount":102},[],{"trials":1562,"activeCount":102},[],{"trials":1564,"activeCount":102},[],{"trials":1566,"activeCount":102},[],{"trials":1568,"activeCount":102},[],{"trials":1570,"activeCount":142,"soonestReadout":349},[1571],{"nctId":346,"briefTitle":347,"status":126,"phases":1572,"primaryCompletion":349,"completion":349,"start":350,"enrollment":351,"conditions":1573,"interventions":1574},[],[353,354,355,356,357,341,358,339,340,359],[272,361,362,363,364],{"intervention":1576,"totalTrials":558,"cells":1577},"Ibuprofen",{"EARLY_PHASE1":1578,"PHASE1":1580,"PHASE2":1582,"PHASE3":1622,"PHASE4":1624,"NA":1638},{"trials":1579,"activeCount":102},[],{"trials":1581,"activeCount":102},[],{"trials":1583,"activeCount":102},[1584,1595,1611],{"nctId":1585,"briefTitle":1586,"status":114,"phases":1587,"primaryCompletion":1588,"completion":42,"start":1589,"enrollment":1590,"conditions":1591,"interventions":1594},"NCT03186638","Low-Dose Ibuprofen in Improving Cognitive Impairment in Patients With Cancer",[91],"2022-03-30","2017-05-26",87,[1592,1593],"Cognitive Impairment","Malignant Neoplasm",[1576],{"nctId":1596,"briefTitle":1597,"status":114,"phases":1598,"primaryCompletion":1599,"completion":1599,"start":1600,"enrollment":1601,"conditions":1602,"interventions":1609},"NCT03399318","Aggressive Antipyretics for Fever Reduction in CNS Malaria",[91],"2022-12-02","2019-01-07",256,[1603,1604,1605,1606,1607,1608],"Malaria","Seizures","Coma","Parasitemia","Hyperpyrexia","Fever",[1610,1576],"Acetaminophen",{"nctId":1612,"briefTitle":1613,"status":114,"phases":1614,"primaryCompletion":1615,"completion":1616,"start":1617,"enrollment":1618,"conditions":1619,"interventions":1621},"NCT01238120","The Effects of Physical Activity and Low-Dose Ibuprofen on Cognitive Function in Cancer Patients",[91],"2019-12","2020-12","2010-11",110,[1620],"Cancer-related Cognitive Difficulties",[1576],{"trials":1623,"activeCount":102},[],{"trials":1625,"activeCount":102},[1626],{"nctId":1627,"briefTitle":1628,"status":329,"phases":1629,"primaryCompletion":1630,"completion":1630,"start":1631,"enrollment":1632,"conditions":1633,"interventions":1634},"NCT02932579","Utility of Pharmacogenomic Testing and Postoperative Dental Pain Outcomes",[93],"2021-01-13","2017-07-01",59,[178],[1576,1635,1636,1637],"hydroxycontin\u002Facetominophen","acetominophen","Oxycontin\u002Facetominophen",{"trials":1639,"activeCount":102},[],{"intervention":1641,"totalTrials":98,"cells":1642},"acetaminophen",{"EARLY_PHASE1":1643,"PHASE1":1645,"PHASE2":1647,"PHASE3":1653,"PHASE4":1655,"NA":1668},{"trials":1644,"activeCount":102},[],{"trials":1646,"activeCount":102},[],{"trials":1648,"activeCount":102},[1649],{"nctId":1596,"briefTitle":1597,"status":114,"phases":1650,"primaryCompletion":1599,"completion":1599,"start":1600,"enrollment":1601,"conditions":1651,"interventions":1652},[91],[1603,1604,1605,1606,1607,1608],[1610,1576],{"trials":1654,"activeCount":102},[],{"trials":1656,"activeCount":102},[1657],{"nctId":1658,"briefTitle":1659,"status":114,"phases":1660,"primaryCompletion":1661,"completion":1661,"start":1662,"enrollment":1663,"conditions":1664,"interventions":1666},"NCT03365622","Efficacy of IV Acetaminophen Versus Oral Acetaminophen",[93],"2024-04-10","2018-08-08",214,[1665],"Nephrectomy",[1641,1610,1667],"Placebos",{"trials":1669,"activeCount":102},[],{"intervention":1671,"totalTrials":98,"cells":1672},"Live attenuated Influenza vaccine",{"EARLY_PHASE1":1673,"PHASE1":1675,"PHASE2":1677,"PHASE3":1679,"PHASE4":1681,"NA":1706},{"trials":1674,"activeCount":102},[],{"trials":1676,"activeCount":102},[],{"trials":1678,"activeCount":102},[],{"trials":1680,"activeCount":102},[],{"trials":1682,"activeCount":102},[1683,1696],{"nctId":1684,"briefTitle":1685,"status":114,"phases":1686,"primaryCompletion":389,"completion":1687,"start":1688,"enrollment":1689,"conditions":1690,"interventions":1692},"NCT01246999","Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children",[93],"2013-06","2010-10",34,[1691],"Influenza",[1671,1693,1694,1695],"Trivalent Influenza Vaccine","TIV followed by LAIV","LAIV followed by TIV",{"nctId":1697,"briefTitle":1698,"status":329,"phases":1699,"primaryCompletion":1700,"completion":1700,"start":1701,"enrollment":366,"conditions":1702,"interventions":1703},"NCT01194297","Study of Live, Attenuated Influenza Vaccination in Preterm and Full-Term Infants",[93],"2012-05","2010-08",[1691],[1704,1705],"Live attenuated influenza vaccine","Inactivated influenza vaccine",{"trials":1707,"activeCount":102},[],{"intervention":1709,"totalTrials":98,"cells":1710},"memantine",{"EARLY_PHASE1":1711,"PHASE1":1713,"PHASE2":1715,"PHASE3":1725,"PHASE4":1727,"NA":1738},{"trials":1712,"activeCount":102},[],{"trials":1714,"activeCount":102},[],{"trials":1716,"activeCount":102},[1717],{"nctId":1718,"briefTitle":1719,"status":329,"phases":1720,"primaryCompletion":1721,"completion":1721,"start":1617,"enrollment":558,"conditions":1722,"interventions":1724},"NCT01260467","Memantine for Recurrent Glioblastoma",[91],"2014-04",[1723],"Glioblastoma",[1709],{"trials":1726,"activeCount":102},[],{"trials":1728,"activeCount":102},[1729],{"nctId":1730,"briefTitle":1731,"status":114,"phases":1732,"primaryCompletion":1733,"completion":1733,"start":1734,"enrollment":412,"conditions":1735,"interventions":1737},"NCT00638027","Memantine for Spasticity in MS Patients",[93],"2009-02","2006-07",[1736],"Multiple Sclerosis",[1709],{"trials":1739,"activeCount":102},[],{"intervention":1741,"totalTrials":98,"cells":1742},"Sugar Pill",{"EARLY_PHASE1":1743,"PHASE1":1745,"PHASE2":1747,"PHASE3":1761,"PHASE4":1763,"NA":1776},{"trials":1744,"activeCount":102},[],{"trials":1746,"activeCount":102},[],{"trials":1748,"activeCount":102},[1749],{"nctId":1750,"briefTitle":1751,"status":114,"phases":1752,"primaryCompletion":1753,"completion":1754,"start":1755,"enrollment":635,"conditions":1756,"interventions":1758},"NCT00178373","Modafinil to Reduce Persistent Fatigue in Patients Following Treatment for Cancer",[91],"2005-12","2006-03","2004-05",[16,1035,1757],"Chemotherapy",[1759,1760],"Modafinil","sugar pill",{"trials":1762,"activeCount":102},[],{"trials":1764,"activeCount":102},[1765],{"nctId":1766,"briefTitle":1767,"status":114,"phases":1768,"primaryCompletion":1769,"completion":1769,"start":1770,"enrollment":20,"conditions":1771,"interventions":1774},"NCT00156533","Long Term Treatment With Zolpidem: Nightly and Intermittent Dosing",[93],"2008-02","2005-03",[31,1772,1773],"Primary Insomnia","Psychophysiologic Insomnia",[1775,1741],"Zolpidem",{"trials":1777,"activeCount":102},[],{"intervention":1779,"totalTrials":98,"cells":1780},"modafinil",{"EARLY_PHASE1":1781,"PHASE1":1783,"PHASE2":1785,"PHASE3":1791,"PHASE4":1793,"NA":1803},{"trials":1782,"activeCount":102},[],{"trials":1784,"activeCount":102},[],{"trials":1786,"activeCount":102},[1787],{"nctId":1750,"briefTitle":1751,"status":114,"phases":1788,"primaryCompletion":1753,"completion":1754,"start":1755,"enrollment":635,"conditions":1789,"interventions":1790},[91],[16,1035,1757],[1759,1760],{"trials":1792,"activeCount":102},[],{"trials":1794,"activeCount":102},[1795],{"nctId":1796,"briefTitle":1797,"status":114,"phases":1798,"primaryCompletion":1799,"completion":1799,"start":1800,"enrollment":302,"conditions":1801,"interventions":1802},"NCT00124384","The Effects of Modafinil on Waking Function and on Sleep in Individuals With Primary Insomnia",[93],"2007-08","2005-01",[1772],[1779],{"trials":1804,"activeCount":102},[],{"intervention":1806,"totalTrials":142,"cells":1807},"phenobarbital",{"EARLY_PHASE1":1808,"PHASE1":1810,"PHASE2":1812,"PHASE3":1814,"PHASE4":1816,"NA":1826},{"trials":1809,"activeCount":102},[],{"trials":1811,"activeCount":102},[],{"trials":1813,"activeCount":102},[],{"trials":1815,"activeCount":102},[],{"trials":1817,"activeCount":102},[1818],{"nctId":1819,"briefTitle":1820,"status":329,"phases":1821,"primaryCompletion":1822,"completion":1822,"start":163,"enrollment":26,"conditions":1823,"interventions":1825},"NCT01089504","Prophylactic Phenobarbital After Neonatal Seizures",[93],"2014-11",[1824],"Neonatal Seizures",[1806],{"trials":1827,"activeCount":102},[],{"intervention":1667,"totalTrials":142,"cells":1829},{"EARLY_PHASE1":1830,"PHASE1":1832,"PHASE2":1834,"PHASE3":1836,"PHASE4":1838,"NA":1844},{"trials":1831,"activeCount":102},[],{"trials":1833,"activeCount":102},[],{"trials":1835,"activeCount":102},[],{"trials":1837,"activeCount":102},[],{"trials":1839,"activeCount":102},[1840],{"nctId":1658,"briefTitle":1659,"status":114,"phases":1841,"primaryCompletion":1661,"completion":1661,"start":1662,"enrollment":1663,"conditions":1842,"interventions":1843},[93],[1665],[1641,1610,1667],{"trials":1845,"activeCount":102},[],{"intervention":1693,"totalTrials":142,"cells":1847},{"EARLY_PHASE1":1848,"PHASE1":1850,"PHASE2":1852,"PHASE3":1854,"PHASE4":1856,"NA":1862},{"trials":1849,"activeCount":102},[],{"trials":1851,"activeCount":102},[],{"trials":1853,"activeCount":102},[],{"trials":1855,"activeCount":102},[],{"trials":1857,"activeCount":102},[1858],{"nctId":1684,"briefTitle":1685,"status":114,"phases":1859,"primaryCompletion":389,"completion":1687,"start":1688,"enrollment":1689,"conditions":1860,"interventions":1861},[93],[1691],[1671,1693,1694,1695],{"trials":1863,"activeCount":102},[],{"intervention":1694,"totalTrials":142,"cells":1865},{"EARLY_PHASE1":1866,"PHASE1":1868,"PHASE2":1870,"PHASE3":1872,"PHASE4":1874,"NA":1880},{"trials":1867,"activeCount":102},[],{"trials":1869,"activeCount":102},[],{"trials":1871,"activeCount":102},[],{"trials":1873,"activeCount":102},[],{"trials":1875,"activeCount":102},[1876],{"nctId":1684,"briefTitle":1685,"status":114,"phases":1877,"primaryCompletion":389,"completion":1687,"start":1688,"enrollment":1689,"conditions":1878,"interventions":1879},[93],[1691],[1671,1693,1694,1695],{"trials":1881,"activeCount":102},[],{"intervention":1695,"totalTrials":142,"cells":1883},{"EARLY_PHASE1":1884,"PHASE1":1886,"PHASE2":1888,"PHASE3":1890,"PHASE4":1892,"NA":1898},{"trials":1885,"activeCount":102},[],{"trials":1887,"activeCount":102},[],{"trials":1889,"activeCount":102},[],{"trials":1891,"activeCount":102},[],{"trials":1893,"activeCount":102},[1894],{"nctId":1684,"briefTitle":1685,"status":114,"phases":1895,"primaryCompletion":389,"completion":1687,"start":1688,"enrollment":1689,"conditions":1896,"interventions":1897},[93],[1691],[1671,1693,1694,1695],{"trials":1899,"activeCount":102},[],{"intervention":1901,"totalTrials":142,"cells":1902},"FluBlok",{"EARLY_PHASE1":1903,"PHASE1":1905,"PHASE2":1907,"PHASE3":1909,"PHASE4":1911,"NA":1926},{"trials":1904,"activeCount":102},[],{"trials":1906,"activeCount":102},[],{"trials":1908,"activeCount":102},[],{"trials":1910,"activeCount":102},[],{"trials":1912,"activeCount":102},[1913],{"nctId":1914,"briefTitle":1915,"status":114,"phases":1916,"primaryCompletion":1917,"completion":1918,"start":1919,"enrollment":1920,"conditions":1921,"interventions":1922},"NCT03068949","Comparison of Three Licensed Influenza Vaccines",[93],"2020-06-30","2021-06-30","2015-10-28",413,[1691],[1901,1923,1924,1925],"Fluzone","FluCelVax","Fluzone HD",{"trials":1927,"activeCount":102},[],{"intervention":1923,"totalTrials":142,"cells":1929},{"EARLY_PHASE1":1930,"PHASE1":1932,"PHASE2":1934,"PHASE3":1936,"PHASE4":1938,"NA":1944},{"trials":1931,"activeCount":102},[],{"trials":1933,"activeCount":102},[],{"trials":1935,"activeCount":102},[],{"trials":1937,"activeCount":102},[],{"trials":1939,"activeCount":102},[1940],{"nctId":1914,"briefTitle":1915,"status":114,"phases":1941,"primaryCompletion":1917,"completion":1918,"start":1919,"enrollment":1920,"conditions":1942,"interventions":1943},[93],[1691],[1901,1923,1924,1925],{"trials":1945,"activeCount":102},[],{"intervention":1924,"totalTrials":142,"cells":1947},{"EARLY_PHASE1":1948,"PHASE1":1950,"PHASE2":1952,"PHASE3":1954,"PHASE4":1956,"NA":1962},{"trials":1949,"activeCount":102},[],{"trials":1951,"activeCount":102},[],{"trials":1953,"activeCount":102},[],{"trials":1955,"activeCount":102},[],{"trials":1957,"activeCount":102},[1958],{"nctId":1914,"briefTitle":1915,"status":114,"phases":1959,"primaryCompletion":1917,"completion":1918,"start":1919,"enrollment":1920,"conditions":1960,"interventions":1961},[93],[1691],[1901,1923,1924,1925],{"trials":1963,"activeCount":102},[],{"intervention":1925,"totalTrials":142,"cells":1965},{"EARLY_PHASE1":1966,"PHASE1":1968,"PHASE2":1970,"PHASE3":1972,"PHASE4":1974,"NA":1980},{"trials":1967,"activeCount":102},[],{"trials":1969,"activeCount":102},[],{"trials":1971,"activeCount":102},[],{"trials":1973,"activeCount":102},[],{"trials":1975,"activeCount":102},[1976],{"nctId":1914,"briefTitle":1915,"status":114,"phases":1977,"primaryCompletion":1917,"completion":1918,"start":1919,"enrollment":1920,"conditions":1978,"interventions":1979},[93],[1691],[1901,1923,1924,1925],{"trials":1981,"activeCount":102},[],{"intervention":1983,"totalTrials":142,"cells":1984},"Extended Release Oxycodone",{"EARLY_PHASE1":1985,"PHASE1":1987,"PHASE2":1989,"PHASE3":1991,"PHASE4":1993,"NA":2003},{"trials":1986,"activeCount":102},[],{"trials":1988,"activeCount":102},[],{"trials":1990,"activeCount":102},[],{"trials":1992,"activeCount":102},[],{"trials":1994,"activeCount":102},[1995],{"nctId":1996,"briefTitle":1997,"status":329,"phases":1998,"primaryCompletion":1999,"completion":1999,"start":162,"enrollment":23,"conditions":2000,"interventions":2001},"NCT01162304","Open-Label Trial Comparing Oxycodone Medications",[93],"2013-12",[780],[1983,2002],"Immediate Release Oxycodone",{"trials":2004,"activeCount":102},[],{"intervention":2002,"totalTrials":142,"cells":2006},{"EARLY_PHASE1":2007,"PHASE1":2009,"PHASE2":2011,"PHASE3":2013,"PHASE4":2015,"NA":2021},{"trials":2008,"activeCount":102},[],{"trials":2010,"activeCount":102},[],{"trials":2012,"activeCount":102},[],{"trials":2014,"activeCount":102},[],{"trials":2016,"activeCount":102},[2017],{"nctId":1996,"briefTitle":1997,"status":329,"phases":2018,"primaryCompletion":1999,"completion":1999,"start":162,"enrollment":23,"conditions":2019,"interventions":2020},[93],[780],[1983,2002],{"trials":2022,"activeCount":102},[],{"intervention":2024,"totalTrials":142,"cells":2025},"Morphine",{"EARLY_PHASE1":2026,"PHASE1":2028,"PHASE2":2030,"PHASE3":2032,"PHASE4":2034,"NA":2045},{"trials":2027,"activeCount":102},[],{"trials":2029,"activeCount":102},[],{"trials":2031,"activeCount":102},[],{"trials":2033,"activeCount":102},[],{"trials":2035,"activeCount":102},[2036],{"nctId":2037,"briefTitle":2038,"status":114,"phases":2039,"primaryCompletion":2040,"completion":2040,"start":2041,"enrollment":32,"conditions":2042,"interventions":2044},"NCT04342130","Brain Effects of Opiate Agonist and Antagonist",[93],"2019-04-16","2018-04-27",[2043],"Chronic Low-back Pain",[2024],{"trials":2046,"activeCount":102},[],{"intervention":2048,"totalTrials":142,"cells":2049},"opana then darvocet then placebo",{"EARLY_PHASE1":2050,"PHASE1":2052,"PHASE2":2054,"PHASE3":2056,"PHASE4":2058,"NA":2069},{"trials":2051,"activeCount":102},[],{"trials":2053,"activeCount":102},[],{"trials":2055,"activeCount":102},[],{"trials":2057,"activeCount":102},[],{"trials":2059,"activeCount":102},[2060],{"nctId":2061,"briefTitle":2062,"status":329,"phases":2063,"primaryCompletion":1617,"completion":1073,"start":164,"enrollment":717,"conditions":2064,"interventions":2065},"NCT00652093","Lumbar Stenosis Outcomes Research II",[93],[166],[2048,2066,2067,2068],"opana then placebo then darvocet","Darvocet then opana then placebo","Darvocet then placebo then opana",{"trials":2070,"activeCount":102},[],{"intervention":2066,"totalTrials":142,"cells":2072},{"EARLY_PHASE1":2073,"PHASE1":2075,"PHASE2":2077,"PHASE3":2079,"PHASE4":2081,"NA":2087},{"trials":2074,"activeCount":102},[],{"trials":2076,"activeCount":102},[],{"trials":2078,"activeCount":102},[],{"trials":2080,"activeCount":102},[],{"trials":2082,"activeCount":102},[2083],{"nctId":2061,"briefTitle":2062,"status":329,"phases":2084,"primaryCompletion":1617,"completion":1073,"start":164,"enrollment":717,"conditions":2085,"interventions":2086},[93],[166],[2048,2066,2067,2068],{"trials":2088,"activeCount":102},[],{"intervention":2067,"totalTrials":142,"cells":2090},{"EARLY_PHASE1":2091,"PHASE1":2093,"PHASE2":2095,"PHASE3":2097,"PHASE4":2099,"NA":2105},{"trials":2092,"activeCount":102},[],{"trials":2094,"activeCount":102},[],{"trials":2096,"activeCount":102},[],{"trials":2098,"activeCount":102},[],{"trials":2100,"activeCount":102},[2101],{"nctId":2061,"briefTitle":2062,"status":329,"phases":2102,"primaryCompletion":1617,"completion":1073,"start":164,"enrollment":717,"conditions":2103,"interventions":2104},[93],[166],[2048,2066,2067,2068],{"trials":2106,"activeCount":102},[],{"intervention":2068,"totalTrials":142,"cells":2108},{"EARLY_PHASE1":2109,"PHASE1":2111,"PHASE2":2113,"PHASE3":2115,"PHASE4":2117,"NA":2123},{"trials":2110,"activeCount":102},[],{"trials":2112,"activeCount":102},[],{"trials":2114,"activeCount":102},[],{"trials":2116,"activeCount":102},[],{"trials":2118,"activeCount":102},[2119],{"nctId":2061,"briefTitle":2062,"status":329,"phases":2120,"primaryCompletion":1617,"completion":1073,"start":164,"enrollment":717,"conditions":2121,"interventions":2122},[93],[166],[2048,2066,2067,2068],{"trials":2124,"activeCount":102},[],{"intervention":2126,"totalTrials":142,"cells":2127},"Infliximab",{"EARLY_PHASE1":2128,"PHASE1":2130,"PHASE2":2132,"PHASE3":2134,"PHASE4":2136,"NA":2149},{"trials":2129,"activeCount":102},[],{"trials":2131,"activeCount":102},[],{"trials":2133,"activeCount":102},[],{"trials":2135,"activeCount":102},[],{"trials":2137,"activeCount":102},[2138],{"nctId":2139,"briefTitle":2140,"status":114,"phases":2141,"primaryCompletion":2142,"completion":1701,"start":2143,"enrollment":573,"conditions":2144,"interventions":2148},"NCT00462072","Centocor Microarray Study of Patients",[93],"2010-06","2007-03",[1245,2145,2146,2147],"Psoriatic Arthritis","Psoriasis","Crohn's Disease",[2126],{"trials":2150,"activeCount":102},[],{"intervention":2152,"totalTrials":142,"cells":2153},"Gralise®",{"EARLY_PHASE1":2154,"PHASE1":2156,"PHASE2":2158,"PHASE3":2160,"PHASE4":2162,"NA":2175},{"trials":2155,"activeCount":102},[],{"trials":2157,"activeCount":102},[],{"trials":2159,"activeCount":102},[],{"trials":2161,"activeCount":102},[],{"trials":2163,"activeCount":102},[2164],{"nctId":2165,"briefTitle":2166,"status":114,"phases":2167,"primaryCompletion":2168,"completion":2169,"start":2170,"enrollment":2171,"conditions":2172,"interventions":2174},"NCT01764464","GRASSP: Gralise® for Spine Surgery Pain",[93],"2016-03","2016-04","2012-12",53,[2173],"Post-laminectomy Pain Syndrome",[2152],{"trials":2176,"activeCount":102},[],{"intervention":2178,"totalTrials":142,"cells":2179},"aprotonin; epsilon aminocaproic acid",{"EARLY_PHASE1":2180,"PHASE1":2182,"PHASE2":2184,"PHASE3":2186,"PHASE4":2188,"NA":2198},{"trials":2181,"activeCount":102},[],{"trials":2183,"activeCount":102},[],{"trials":2185,"activeCount":102},[],{"trials":2187,"activeCount":102},[],{"trials":2189,"activeCount":102},[2190],{"nctId":2191,"briefTitle":2192,"status":114,"phases":2193,"completion":2194,"start":1770,"enrollment":302,"conditions":2195,"interventions":2197},"NCT00156520","Platelet Function And Aggregometry In Patients With Aortic Valve Stenosis",[93],"2005-09",[2196],"Hemorrhage",[2178],{"trials":2199,"activeCount":102},[],{"intervention":2201,"totalTrials":142,"cells":2202},"Namenda",{"EARLY_PHASE1":2203,"PHASE1":2205,"PHASE2":2207,"PHASE3":2209,"PHASE4":2211,"NA":2222},{"trials":2204,"activeCount":102},[],{"trials":2206,"activeCount":102},[],{"trials":2208,"activeCount":102},[],{"trials":2210,"activeCount":102},[],{"trials":2212,"activeCount":102},[2213],{"nctId":2214,"briefTitle":2215,"status":329,"phases":2216,"completion":2217,"start":1754,"enrollment":351,"conditions":2218,"interventions":2221},"NCT00303433","Namenda to Prevent Post-Operative Delirium",[93],"2006-09",[2219,2220],"Delirium","Post-Operative States",[2201],{"trials":2223,"activeCount":102},[],{"intervention":1635,"totalTrials":142,"cells":2225},{"EARLY_PHASE1":2226,"PHASE1":2228,"PHASE2":2230,"PHASE3":2232,"PHASE4":2234,"NA":2240},{"trials":2227,"activeCount":102},[],{"trials":2229,"activeCount":102},[],{"trials":2231,"activeCount":102},[],{"trials":2233,"activeCount":102},[],{"trials":2235,"activeCount":102},[2236],{"nctId":1627,"briefTitle":1628,"status":329,"phases":2237,"primaryCompletion":1630,"completion":1630,"start":1631,"enrollment":1632,"conditions":2238,"interventions":2239},[93],[178],[1576,1635,1636,1637],{"trials":2241,"activeCount":102},[],{"intervention":1636,"totalTrials":142,"cells":2243},{"EARLY_PHASE1":2244,"PHASE1":2246,"PHASE2":2248,"PHASE3":2250,"PHASE4":2252,"NA":2258},{"trials":2245,"activeCount":102},[],{"trials":2247,"activeCount":102},[],{"trials":2249,"activeCount":102},[],{"trials":2251,"activeCount":102},[],{"trials":2253,"activeCount":102},[2254],{"nctId":1627,"briefTitle":1628,"status":329,"phases":2255,"primaryCompletion":1630,"completion":1630,"start":1631,"enrollment":1632,"conditions":2256,"interventions":2257},[93],[178],[1576,1635,1636,1637],{"trials":2259,"activeCount":102},[],{"intervention":1637,"totalTrials":142,"cells":2261},{"EARLY_PHASE1":2262,"PHASE1":2264,"PHASE2":2266,"PHASE3":2268,"PHASE4":2270,"NA":2276},{"trials":2263,"activeCount":102},[],{"trials":2265,"activeCount":102},[],{"trials":2267,"activeCount":102},[],{"trials":2269,"activeCount":102},[],{"trials":2271,"activeCount":102},[2272],{"nctId":1627,"briefTitle":1628,"status":329,"phases":2273,"primaryCompletion":1630,"completion":1630,"start":1631,"enrollment":1632,"conditions":2274,"interventions":2275},[93],[178],[1576,1635,1636,1637],{"trials":2277,"activeCount":102},[],{"intervention":2279,"totalTrials":142,"cells":2280},"dapagliflozin",{"EARLY_PHASE1":2281,"PHASE1":2283,"PHASE2":2285,"PHASE3":2287,"PHASE4":2289,"NA":2300},{"trials":2282,"activeCount":102},[],{"trials":2284,"activeCount":102},[],{"trials":2286,"activeCount":102},[],{"trials":2288,"activeCount":102},[],{"trials":2290,"activeCount":102},[2291],{"nctId":2292,"briefTitle":2293,"status":114,"phases":2294,"primaryCompletion":2295,"completion":2296,"start":532,"enrollment":822,"conditions":2297,"interventions":2299},"NCT04792190","Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation",[93],"2023-03-31","2023-06-30",[2298],"Atrial Fibrillation",[2279],{"trials":2301,"activeCount":102},[],{"intervention":2303,"totalTrials":142,"cells":2304},"moxifloxacin",{"EARLY_PHASE1":2305,"PHASE1":2307,"PHASE2":2309,"PHASE3":2311,"PHASE4":2313,"NA":2326},{"trials":2306,"activeCount":102},[],{"trials":2308,"activeCount":102},[],{"trials":2310,"activeCount":102},[],{"trials":2312,"activeCount":102},[],{"trials":2314,"activeCount":102},[2315],{"nctId":2316,"briefTitle":2317,"status":114,"phases":2318,"primaryCompletion":2319,"completion":2320,"start":2143,"enrollment":2321,"conditions":2322,"interventions":2324},"NCT00581542","Moxifloxacin vs. Polytrim for Conjunctivitis",[93],"2009-03","2012-03",124,[2323],"Conjunctivitis",[2303,2325],"polytrim",{"trials":2327,"activeCount":102},[],{"intervention":2325,"totalTrials":142,"cells":2329},{"EARLY_PHASE1":2330,"PHASE1":2332,"PHASE2":2334,"PHASE3":2336,"PHASE4":2338,"NA":2344},{"trials":2331,"activeCount":102},[],{"trials":2333,"activeCount":102},[],{"trials":2335,"activeCount":102},[],{"trials":2337,"activeCount":102},[],{"trials":2339,"activeCount":102},[2340],{"nctId":2316,"briefTitle":2317,"status":114,"phases":2341,"primaryCompletion":2319,"completion":2320,"start":2143,"enrollment":2321,"conditions":2342,"interventions":2343},[93],[2323],[2303,2325],{"trials":2345,"activeCount":102},[],{"intervention":2347,"totalTrials":142,"cells":2348},"Aflibercept",{"EARLY_PHASE1":2349,"PHASE1":2351,"PHASE2":2353,"PHASE3":2355,"PHASE4":2357,"NA":2370},{"trials":2350,"activeCount":102},[],{"trials":2352,"activeCount":102},[],{"trials":2354,"activeCount":102},[],{"trials":2356,"activeCount":102},[],{"trials":2358,"activeCount":102},[2359],{"nctId":2360,"briefTitle":2361,"status":2362,"phases":2363,"primaryCompletion":2364,"completion":2364,"start":2365,"enrollment":102,"conditions":2366,"interventions":2368},"NCT04702048","Evaluation of the Retina in Patients With Non-proliferative Diabetic Retinopathy After Aflibercept Injection in the Eye","WITHDRAWN",[93],"2024-02-01","2021-02-01",[2367],"Retinopathy, Diabetic",[2347,2369],"Sham",{"trials":2371,"activeCount":102},[],{"intervention":2369,"totalTrials":142,"cells":2373},{"EARLY_PHASE1":2374,"PHASE1":2376,"PHASE2":2378,"PHASE3":2380,"PHASE4":2382,"NA":2388},{"trials":2375,"activeCount":102},[],{"trials":2377,"activeCount":102},[],{"trials":2379,"activeCount":102},[],{"trials":2381,"activeCount":102},[],{"trials":2383,"activeCount":102},[2384],{"nctId":2360,"briefTitle":2361,"status":2362,"phases":2385,"primaryCompletion":2364,"completion":2364,"start":2365,"enrollment":102,"conditions":2386,"interventions":2387},[93],[2367],[2347,2369],{"trials":2389,"activeCount":102},[],{"intervention":2391,"totalTrials":142,"cells":2392},"RSV vaccine",{"EARLY_PHASE1":2393,"PHASE1":2395,"PHASE2":2397,"PHASE3":2399,"PHASE4":2401,"NA":2412},{"trials":2394,"activeCount":102},[],{"trials":2396,"activeCount":102},[],{"trials":2398,"activeCount":102},[],{"trials":2400,"activeCount":102},[],{"trials":2402,"activeCount":102},[2403],{"nctId":2404,"briefTitle":2405,"status":114,"phases":2406,"primaryCompletion":2407,"completion":2407,"start":2408,"enrollment":9,"conditions":2409,"interventions":2411},"NCT06077149","Immunogenicity of RSV Vaccines in Residents of Long-Term Care Facilities (LTCF)",[93],"2024-11-01","2023-11-07",[2410],"Respiratory Syncytial Virus (RSV)",[2391],{"trials":2413,"activeCount":102},[],{"intervention":1775,"totalTrials":142,"cells":2415},{"EARLY_PHASE1":2416,"PHASE1":2418,"PHASE2":2420,"PHASE3":2422,"PHASE4":2424,"NA":2430},{"trials":2417,"activeCount":102},[],{"trials":2419,"activeCount":102},[],{"trials":2421,"activeCount":102},[],{"trials":2423,"activeCount":102},[],{"trials":2425,"activeCount":102},[2426],{"nctId":1766,"briefTitle":1767,"status":114,"phases":2427,"primaryCompletion":1769,"completion":1769,"start":1770,"enrollment":20,"conditions":2428,"interventions":2429},[93],[31,1772,1773],[1775,1741],{"trials":2431,"activeCount":102},[],{"intervention":2433,"totalTrials":142,"cells":2434},"A\u002FCalifornia\u002F07\u002F09 live monovalent H1N1 vaccine",{"EARLY_PHASE1":2435,"PHASE1":2437,"PHASE2":2439,"PHASE3":2441,"PHASE4":2443,"NA":2454},{"trials":2436,"activeCount":102},[],{"trials":2438,"activeCount":102},[],{"trials":2440,"activeCount":102},[],{"trials":2442,"activeCount":102},[],{"trials":2444,"activeCount":102},[2445],{"nctId":2446,"briefTitle":2447,"status":114,"phases":2448,"primaryCompletion":2449,"completion":2450,"start":2451,"enrollment":20,"conditions":2452,"interventions":2453},"NCT01023776","Infectivity, Replication & Immunogenicity of Live nH1N1 Vaccine",[93],"2010-04","2010-07","2009-11",[1691],[2433],{"trials":2455,"activeCount":102},[],{"intervention":2457,"totalTrials":142,"cells":2458},"Gabapentin, Estrogen and placebo administration",{"EARLY_PHASE1":2459,"PHASE1":2461,"PHASE2":2463,"PHASE3":2465,"PHASE4":2467,"NA":2478},{"trials":2460,"activeCount":102},[],{"trials":2462,"activeCount":102},[],{"trials":2464,"activeCount":102},[],{"trials":2466,"activeCount":102},[],{"trials":2468,"activeCount":102},[2469],{"nctId":2470,"briefTitle":2471,"status":114,"phases":2472,"completion":2473,"start":594,"enrollment":2474,"conditions":2475,"interventions":2477},"NCT00276081","Gabapentin Versus Estrogen for the Treatment of Hot Flashes",[93],"2004-09",60,[2476],"Hot Flashes",[2457],{"trials":2479,"activeCount":102},[],{"intervention":2481,"totalTrials":142,"cells":2482},"Lubiprostone",{"EARLY_PHASE1":2483,"PHASE1":2485,"PHASE2":2487,"PHASE3":2489,"PHASE4":2491,"NA":2502},{"trials":2484,"activeCount":102},[],{"trials":2486,"activeCount":102},[],{"trials":2488,"activeCount":102},[],{"trials":2490,"activeCount":102},[],{"trials":2492,"activeCount":102},[2493],{"nctId":2494,"briefTitle":2495,"status":114,"phases":2496,"primaryCompletion":2497,"completion":2498,"start":1617,"enrollment":412,"conditions":2499,"interventions":2501},"NCT01236534","Lubiprostone in Patients With Multiple Sclerosis Associated Constipation",[93],"2012-01","2012-04",[1736,2500],"Constipation",[2481],{"trials":2503,"activeCount":102},[],{"intervention":2505,"totalTrials":142,"cells":2506},"Lidocaine patch 5%",{"EARLY_PHASE1":2507,"PHASE1":2509,"PHASE2":2511,"PHASE3":2513,"PHASE4":2515,"NA":2527},{"trials":2508,"activeCount":102},[],{"trials":2510,"activeCount":102},[],{"trials":2512,"activeCount":102},[],{"trials":2514,"activeCount":102},[],{"trials":2516,"activeCount":102},[2517],{"nctId":2518,"briefTitle":2519,"status":329,"phases":2520,"primaryCompletion":1073,"completion":1073,"start":2521,"enrollment":2522,"conditions":2523,"interventions":2525},"NCT00414453","Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple Sclerosis",[93],"2007-01",19,[2524,780,1736],"Neuropathic Pain",[2505,2526],"Extended-release oxycodone",{"trials":2528,"activeCount":102},[],{"intervention":2526,"totalTrials":142,"cells":2530},{"EARLY_PHASE1":2531,"PHASE1":2533,"PHASE2":2535,"PHASE3":2537,"PHASE4":2539,"NA":2545},{"trials":2532,"activeCount":102},[],{"trials":2534,"activeCount":102},[],{"trials":2536,"activeCount":102},[],{"trials":2538,"activeCount":102},[],{"trials":2540,"activeCount":102},[2541],{"nctId":2518,"briefTitle":2519,"status":329,"phases":2542,"primaryCompletion":1073,"completion":1073,"start":2521,"enrollment":2522,"conditions":2543,"interventions":2544},[93],[2524,780,1736],[2505,2526],{"trials":2546,"activeCount":102},[],{"intervention":2548,"totalTrials":142,"cells":2549},"atomoxetine",{"EARLY_PHASE1":2550,"PHASE1":2552,"PHASE2":2554,"PHASE3":2556,"PHASE4":2558,"NA":2572},{"trials":2551,"activeCount":102},[],{"trials":2553,"activeCount":102},[],{"trials":2555,"activeCount":102},[],{"trials":2557,"activeCount":102},[],{"trials":2559,"activeCount":102},[2560],{"nctId":2561,"briefTitle":2562,"status":114,"phases":2563,"primaryCompletion":1721,"completion":1721,"start":2564,"enrollment":2565,"conditions":2566,"interventions":2571},"NCT00844753","Atomoxetine, Placebo and Parent Management Training in Autism",[93],"2008-10",128,[2567,2568,2569,2570],"Autism","Pervasive Development Disorder","Asperger's Disorder","Attention Deficit Hyperactivity Disorder",[2548],{"trials":2573,"activeCount":102},[],{"intervention":2575,"totalTrials":142,"cells":2576},"Dupilumab",{"EARLY_PHASE1":2577,"PHASE1":2579,"PHASE2":2581,"PHASE3":2583,"PHASE4":2585,"NA":2595},{"trials":2578,"activeCount":102},[],{"trials":2580,"activeCount":102},[],{"trials":2582,"activeCount":102},[],{"trials":2584,"activeCount":102},[],{"trials":2586,"activeCount":102},[2587],{"nctId":2588,"briefTitle":2589,"status":2362,"phases":2590,"primaryCompletion":77,"completion":300,"start":2591,"enrollment":102,"conditions":2592,"interventions":2594},"NCT06188871","Early-onset Dupilumab Effects in CRSwNP",[93],"2024-06-01",[2593],"Chronic Rhinosinusitis With Nasal Polyps",[2575],{"trials":2596,"activeCount":102},[],{"intervention":2598,"totalTrials":142,"cells":2599},"Live Attenuated H1N1 Influenza Vaccine",{"EARLY_PHASE1":2600,"PHASE1":2602,"PHASE2":2604,"PHASE3":2606,"PHASE4":2608,"NA":2619},{"trials":2601,"activeCount":102},[],{"trials":2603,"activeCount":102},[],{"trials":2605,"activeCount":102},[],{"trials":2607,"activeCount":102},[],{"trials":2609,"activeCount":102},[2610],{"nctId":2611,"briefTitle":2612,"status":2362,"phases":2613,"primaryCompletion":163,"completion":163,"start":162,"enrollment":102,"conditions":2614,"interventions":2616},"NCT01097941","Effect of Age and Prior Immunity on Response to H1N1 Vaccines in Children",[93],[2615],"2009 H1N1 Influenza",[2598,2617,2618],"Influenza A (H1N1) 2009 Monovalent Vaccine","Influenza A (H1N1) 2009 Monovalent Vaccine\u002F Influenza A (H1N1) Monovalent Vaccine Live",{"trials":2620,"activeCount":102},[],{"intervention":2617,"totalTrials":142,"cells":2622},{"EARLY_PHASE1":2623,"PHASE1":2625,"PHASE2":2627,"PHASE3":2629,"PHASE4":2631,"NA":2637},{"trials":2624,"activeCount":102},[],{"trials":2626,"activeCount":102},[],{"trials":2628,"activeCount":102},[],{"trials":2630,"activeCount":102},[],{"trials":2632,"activeCount":102},[2633],{"nctId":2611,"briefTitle":2612,"status":2362,"phases":2634,"primaryCompletion":163,"completion":163,"start":162,"enrollment":102,"conditions":2635,"interventions":2636},[93],[2615],[2598,2617,2618],{"trials":2638,"activeCount":102},[],{"intervention":2618,"totalTrials":142,"cells":2640},{"EARLY_PHASE1":2641,"PHASE1":2643,"PHASE2":2645,"PHASE3":2647,"PHASE4":2649,"NA":2655},{"trials":2642,"activeCount":102},[],{"trials":2644,"activeCount":102},[],{"trials":2646,"activeCount":102},[],{"trials":2648,"activeCount":102},[],{"trials":2650,"activeCount":102},[2651],{"nctId":2611,"briefTitle":2612,"status":2362,"phases":2652,"primaryCompletion":163,"completion":163,"start":162,"enrollment":102,"conditions":2653,"interventions":2654},[93],[2615],[2598,2617,2618],{"trials":2656,"activeCount":102},[],{"intervention":2658,"totalTrials":142,"cells":2659},"Normal Saline",{"EARLY_PHASE1":2660,"PHASE1":2662,"PHASE2":2664,"PHASE3":2666,"PHASE4":2668,"NA":2680},{"trials":2661,"activeCount":102},[],{"trials":2663,"activeCount":102},[],{"trials":2665,"activeCount":102},[],{"trials":2667,"activeCount":102},[],{"trials":2669,"activeCount":102},[2670],{"nctId":2671,"briefTitle":2672,"status":114,"phases":2673,"primaryCompletion":2498,"completion":2498,"start":2674,"enrollment":2675,"conditions":2676,"interventions":2678},"NCT01195116","Usefulness of Dexmedetomidine on Post-operative Pain Management in Patients With Interstitial Cystitis",[93],"2010-05",41,[2677],"Interstitial Cystitis",[2679,2658],"Dexmedetomidine",{"trials":2681,"activeCount":102},[],{"intervention":1705,"totalTrials":142,"cells":2683},{"EARLY_PHASE1":2684,"PHASE1":2686,"PHASE2":2688,"PHASE3":2690,"PHASE4":2692,"NA":2698},{"trials":2685,"activeCount":102},[],{"trials":2687,"activeCount":102},[],{"trials":2689,"activeCount":102},[],{"trials":2691,"activeCount":102},[],{"trials":2693,"activeCount":102},[2694],{"nctId":1697,"briefTitle":1698,"status":329,"phases":2695,"primaryCompletion":1700,"completion":1700,"start":1701,"enrollment":366,"conditions":2696,"interventions":2697},[93],[1691],[1704,1705],{"trials":2699,"activeCount":102},[],{"intervention":2701,"totalTrials":98,"cells":2702},"Doxycycline",{"EARLY_PHASE1":2703,"PHASE1":2705,"PHASE2":2707,"PHASE3":2727,"PHASE4":2739,"NA":2741},{"trials":2704,"activeCount":102},[],{"trials":2706,"activeCount":102},[],{"trials":2708,"activeCount":102},[2709],{"nctId":2710,"briefTitle":2711,"status":329,"phases":2712,"primaryCompletion":2713,"completion":2714,"start":2715,"enrollment":2716,"conditions":2717,"interventions":2726},"NCT02086591","A Phase II Study of Doxycycline in Relapsed NHL",[91],"2015-07","2015-11","2014-03",7,[2718,2719,2720,2721,2722,2723,2724,586,2725],"Adult Diffuse Large B-Cell Lymphoma","Mantle Cell Lymphoma Recurrent","Lymphoma, Follicular","Marginal Zone B-Cell Lymphoma","Malignant Lymphoma - Lymphoplasmacytic","Waldenstrom Macroglobulinemia","Small Lymphocytic Lymphoma","T-Cell Lymphoma",[2701],{"trials":2728,"activeCount":102},[2729],{"nctId":2730,"briefTitle":2731,"status":114,"phases":2732,"primaryCompletion":411,"completion":411,"start":1617,"enrollment":32,"conditions":2733,"interventions":2737},"NCT01788215","Effect of a Commonly Used Antibiotic, Doxycycline, in Women With Polycystic Ovarian Syndrome",[92],[2734,2735,2736],"Polycystic Ovarian Syndrome (PCOS)","Irregular Menstrual Cycles","Androgen Excess",[2738],"doxycycline",{"trials":2740,"activeCount":102},[],{"trials":2742,"activeCount":102},[],{"intervention":2744,"totalTrials":98,"cells":2745},"Metformin",{"EARLY_PHASE1":2746,"PHASE1":2748,"PHASE2":2750,"PHASE3":2752,"PHASE4":2776,"NA":2778},{"trials":2747,"activeCount":102},[],{"trials":2749,"activeCount":102},[],{"trials":2751,"activeCount":102},[],{"trials":2753,"activeCount":102},[2754,2765],{"nctId":2755,"briefTitle":2756,"status":114,"phases":2757,"primaryCompletion":2758,"completion":2758,"start":2759,"enrollment":2760,"conditions":2761,"interventions":2763},"NCT00283816","Impact of Metformin in Teens With Polycystic Ovary Syndrome (PCOS) on Oral Contraceptive Therapy",[92],"2008-01","2006-01",36,[2762],"Polycystic Ovary Syndrome",[2744,2764],"Oral Contraceptive Pill",{"nctId":2766,"briefTitle":2767,"status":114,"phases":2768,"primaryCompletion":2769,"completion":2770,"start":2771,"enrollment":2772,"conditions":2773,"interventions":2774},"NCT00714233","Treatment of Adolescent Polycystic Ovary Syndrome (PCOS)",[92],"2004-04","2007-12","2002-08",43,[2762],[2744,2775],"Oral Contraceptive Pills",{"trials":2777,"activeCount":102},[],{"trials":2779,"activeCount":102},[],{"intervention":2781,"totalTrials":98,"cells":2782},"Ranolazine",{"EARLY_PHASE1":2783,"PHASE1":2785,"PHASE2":2787,"PHASE3":2798,"PHASE4":2811,"NA":2813},{"trials":2784,"activeCount":102},[],{"trials":2786,"activeCount":102},[],{"trials":2788,"activeCount":102},[2789],{"nctId":2790,"briefTitle":2791,"status":114,"phases":2792,"primaryCompletion":2793,"completion":2793,"start":2794,"enrollment":822,"conditions":2795,"interventions":2797},"NCT01648205","Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients",[91],"2018-07-20","2012-09",[2796],"Long QT Syndrome",[2781],{"trials":2799,"activeCount":102},[2800],{"nctId":2801,"briefTitle":2802,"status":114,"phases":2803,"primaryCompletion":2804,"completion":2804,"start":2805,"enrollment":2806,"conditions":2807,"interventions":2810},"NCT01215253","Ranolazine Implantable Cardioverter-Defibrillator Trial",[92],"2017-02-28","2011-09",1012,[2808,2809,34],"Ischemic Cardiomyopathy","Nonischemic Cardiomyopathy",[2781],{"trials":2812,"activeCount":102},[],{"trials":2814,"activeCount":102},[],{"intervention":2816,"totalTrials":98,"cells":2817},"Ketamine",{"EARLY_PHASE1":2818,"PHASE1":2820,"PHASE2":2830,"PHASE3":2832,"PHASE4":2847,"NA":2849},{"trials":2819,"activeCount":102},[],{"trials":2821,"activeCount":102},[2822],{"nctId":2823,"briefTitle":2824,"status":114,"phases":2825,"primaryCompletion":2826,"completion":2826,"start":2827,"enrollment":29,"conditions":2828,"interventions":2829},"NCT01369680","Oral Ketamine for Control of Chronic Pain in Children",[90],"2012-10","2011-05",[780],[2816],{"trials":2831,"activeCount":102},[],{"trials":2833,"activeCount":102},[2834],{"nctId":2835,"briefTitle":2836,"status":114,"phases":2837,"primaryCompletion":350,"completion":350,"start":2838,"enrollment":37,"conditions":2839,"interventions":2841},"NCT02099006","Novel Topical Therapies for the Treatment of Genital Pain",[91,92],"2013-11",[2840],"Female Genital Diseases",[2842,2843,2844,2816,2845,2846],"Amitriptyline","Baclofen","Ketoprofen","Loperamide","Gabapentin",{"trials":2848,"activeCount":102},[],{"trials":2850,"activeCount":102},[],{"intervention":2852,"totalTrials":98,"cells":2853},"creatine",{"EARLY_PHASE1":2854,"PHASE1":2856,"PHASE2":2858,"PHASE3":2872,"PHASE4":2883,"NA":2885},{"trials":2855,"activeCount":102},[],{"trials":2857,"activeCount":102},[],{"trials":2859,"activeCount":102},[2860],{"nctId":2861,"briefTitle":2862,"status":114,"phases":2863,"primaryCompletion":2864,"completion":2865,"start":2866,"enrollment":2867,"conditions":2868,"interventions":2870},"NCT00063193","National Institute of Neurological Disorders and Stroke (NINDS) Parkinson's Disease Neuroprotection Trial",[91],"2005-05","2005-07","2003-05",195,[2869],"Parkinson's Disease",[2871,2852],"minocycline",{"trials":2873,"activeCount":102},[2874],{"nctId":2875,"briefTitle":2876,"status":329,"phases":2877,"primaryCompletion":2878,"completion":2879,"start":2143,"enrollment":2880,"conditions":2881,"interventions":2882},"NCT00449865","NET-PD LS-1 Creatine in Parkinson's Disease",[92],"2013-09","2014-05",1741,[2869],[2852],{"trials":2884,"activeCount":102},[],{"trials":2886,"activeCount":102},[],{"intervention":2764,"totalTrials":142,"cells":2888},{"EARLY_PHASE1":2889,"PHASE1":2891,"PHASE2":2893,"PHASE3":2895,"PHASE4":2901,"NA":2903},{"trials":2890,"activeCount":102},[],{"trials":2892,"activeCount":102},[],{"trials":2894,"activeCount":102},[],{"trials":2896,"activeCount":102},[2897],{"nctId":2755,"briefTitle":2756,"status":114,"phases":2898,"primaryCompletion":2758,"completion":2758,"start":2759,"enrollment":2760,"conditions":2899,"interventions":2900},[92],[2762],[2744,2764],{"trials":2902,"activeCount":102},[],{"trials":2904,"activeCount":102},[],{"intervention":2775,"totalTrials":142,"cells":2906},{"EARLY_PHASE1":2907,"PHASE1":2909,"PHASE2":2911,"PHASE3":2913,"PHASE4":2919,"NA":2921},{"trials":2908,"activeCount":102},[],{"trials":2910,"activeCount":102},[],{"trials":2912,"activeCount":102},[],{"trials":2914,"activeCount":102},[2915],{"nctId":2766,"briefTitle":2767,"status":114,"phases":2916,"primaryCompletion":2769,"completion":2770,"start":2771,"enrollment":2772,"conditions":2917,"interventions":2918},[92],[2762],[2744,2775],{"trials":2920,"activeCount":102},[],{"trials":2922,"activeCount":102},[],{"intervention":2924,"totalTrials":142,"cells":2925},"Crisaborole",{"EARLY_PHASE1":2926,"PHASE1":2928,"PHASE2":2930,"PHASE3":2932,"PHASE4":2945,"NA":2947},{"trials":2927,"activeCount":102},[],{"trials":2929,"activeCount":102},[],{"trials":2931,"activeCount":102},[],{"trials":2933,"activeCount":102},[2934],{"nctId":2935,"briefTitle":2936,"status":114,"phases":2937,"primaryCompletion":2938,"completion":2938,"start":2939,"enrollment":2940,"conditions":2941,"interventions":2943},"NCT03645057","ASPIRE: PROs & Caregiver Burden in Children With Atopic Dermatitis",[92],"2021-08-01","2019-02-20",92,[2942],"Atopic Dermatitis",[2924,2944],"Tacrolimus 0.03% Ointment",{"trials":2946,"activeCount":102},[],{"trials":2948,"activeCount":102},[],{"intervention":2944,"totalTrials":142,"cells":2950},{"EARLY_PHASE1":2951,"PHASE1":2953,"PHASE2":2955,"PHASE3":2957,"PHASE4":2963,"NA":2965},{"trials":2952,"activeCount":102},[],{"trials":2954,"activeCount":102},[],{"trials":2956,"activeCount":102},[],{"trials":2958,"activeCount":102},[2959],{"nctId":2935,"briefTitle":2936,"status":114,"phases":2960,"primaryCompletion":2938,"completion":2938,"start":2939,"enrollment":2940,"conditions":2961,"interventions":2962},[92],[2942],[2924,2944],{"trials":2964,"activeCount":102},[],{"trials":2966,"activeCount":102},[],{"intervention":2842,"totalTrials":142,"cells":2968},{"EARLY_PHASE1":2969,"PHASE1":2971,"PHASE2":2973,"PHASE3":2975,"PHASE4":2981,"NA":2983},{"trials":2970,"activeCount":102},[],{"trials":2972,"activeCount":102},[],{"trials":2974,"activeCount":102},[],{"trials":2976,"activeCount":102},[2977],{"nctId":2835,"briefTitle":2836,"status":114,"phases":2978,"primaryCompletion":350,"completion":350,"start":2838,"enrollment":37,"conditions":2979,"interventions":2980},[91,92],[2840],[2842,2843,2844,2816,2845,2846],{"trials":2982,"activeCount":102},[],{"trials":2984,"activeCount":102},[],{"intervention":2843,"totalTrials":142,"cells":2986},{"EARLY_PHASE1":2987,"PHASE1":2989,"PHASE2":2991,"PHASE3":2993,"PHASE4":2999,"NA":3001},{"trials":2988,"activeCount":102},[],{"trials":2990,"activeCount":102},[],{"trials":2992,"activeCount":102},[],{"trials":2994,"activeCount":102},[2995],{"nctId":2835,"briefTitle":2836,"status":114,"phases":2996,"primaryCompletion":350,"completion":350,"start":2838,"enrollment":37,"conditions":2997,"interventions":2998},[91,92],[2840],[2842,2843,2844,2816,2845,2846],{"trials":3000,"activeCount":102},[],{"trials":3002,"activeCount":102},[],{"intervention":2844,"totalTrials":142,"cells":3004},{"EARLY_PHASE1":3005,"PHASE1":3007,"PHASE2":3009,"PHASE3":3011,"PHASE4":3017,"NA":3019},{"trials":3006,"activeCount":102},[],{"trials":3008,"activeCount":102},[],{"trials":3010,"activeCount":102},[],{"trials":3012,"activeCount":102},[3013],{"nctId":2835,"briefTitle":2836,"status":114,"phases":3014,"primaryCompletion":350,"completion":350,"start":2838,"enrollment":37,"conditions":3015,"interventions":3016},[91,92],[2840],[2842,2843,2844,2816,2845,2846],{"trials":3018,"activeCount":102},[],{"trials":3020,"activeCount":102},[],{"intervention":2845,"totalTrials":142,"cells":3022},{"EARLY_PHASE1":3023,"PHASE1":3025,"PHASE2":3027,"PHASE3":3029,"PHASE4":3035,"NA":3037},{"trials":3024,"activeCount":102},[],{"trials":3026,"activeCount":102},[],{"trials":3028,"activeCount":102},[],{"trials":3030,"activeCount":102},[3031],{"nctId":2835,"briefTitle":2836,"status":114,"phases":3032,"primaryCompletion":350,"completion":350,"start":2838,"enrollment":37,"conditions":3033,"interventions":3034},[91,92],[2840],[2842,2843,2844,2816,2845,2846],{"trials":3036,"activeCount":102},[],{"trials":3038,"activeCount":102},[],{"intervention":2846,"totalTrials":142,"cells":3040},{"EARLY_PHASE1":3041,"PHASE1":3043,"PHASE2":3045,"PHASE3":3047,"PHASE4":3053,"NA":3055},{"trials":3042,"activeCount":102},[],{"trials":3044,"activeCount":102},[],{"trials":3046,"activeCount":102},[],{"trials":3048,"activeCount":102},[3049],{"nctId":2835,"briefTitle":2836,"status":114,"phases":3050,"primaryCompletion":350,"completion":350,"start":2838,"enrollment":37,"conditions":3051,"interventions":3052},[91,92],[2840],[2842,2843,2844,2816,2845,2846],{"trials":3054,"activeCount":102},[],{"trials":3056,"activeCount":102},[],{"intervention":3058,"totalTrials":142,"cells":3059},"Curcumin",{"EARLY_PHASE1":3060,"PHASE1":3062,"PHASE2":3064,"PHASE3":3066,"PHASE4":3078,"NA":3080},{"trials":3061,"activeCount":102},[],{"trials":3063,"activeCount":102},[],{"trials":3065,"activeCount":102},[],{"trials":3067,"activeCount":102},[3068],{"nctId":3069,"briefTitle":3070,"status":114,"phases":3071,"primaryCompletion":1822,"completion":3072,"start":3073,"enrollment":3074,"conditions":3075,"interventions":3077},"NCT01246973","Oral Curcumin for Radiation Dermatitis",[91,92],"2015-01","2011-02",686,[3076],"Radiation-induced Dermatitis",[3058],{"trials":3079,"activeCount":102},[],{"trials":3081,"activeCount":102},[],{"intervention":3083,"totalTrials":142,"cells":3084},"Isradipine",{"EARLY_PHASE1":3085,"PHASE1":3087,"PHASE2":3089,"PHASE3":3091,"PHASE4":3101,"NA":3103},{"trials":3086,"activeCount":102},[],{"trials":3088,"activeCount":102},[],{"trials":3090,"activeCount":102},[],{"trials":3092,"activeCount":102},[3093],{"nctId":3094,"briefTitle":3095,"status":114,"phases":3096,"primaryCompletion":3097,"completion":3097,"start":1822,"enrollment":3098,"conditions":3099,"interventions":3100},"NCT02168842","Efficacy of Isradipine in Early Parkinson Disease",[92],"2018-11",336,[25],[3083],{"trials":3102,"activeCount":102},[],{"trials":3104,"activeCount":102},[],{"intervention":3106,"totalTrials":142,"cells":3107},"oral levofloxacin",{"EARLY_PHASE1":3108,"PHASE1":3110,"PHASE2":3112,"PHASE3":3114,"PHASE4":3128,"NA":3130},{"trials":3109,"activeCount":102},[],{"trials":3111,"activeCount":102},[],{"trials":3113,"activeCount":102},[],{"trials":3115,"activeCount":102},[3116],{"nctId":3117,"briefTitle":3118,"status":114,"phases":3119,"primaryCompletion":3120,"completion":3121,"start":3122,"enrollment":3123,"conditions":3124,"interventions":3126},"NCT01988779","Oral Versus Topical Antibiotics for Chronic Rhinosinusitis Exacerbations",[92],"2017-09-11","2020-12-31","2013-10",33,[3125],"Chronic Rhinosinusitis",[3106,3127],"nebulized levofloxacin",{"trials":3129,"activeCount":102},[],{"trials":3131,"activeCount":102},[],{"intervention":3127,"totalTrials":142,"cells":3133},{"EARLY_PHASE1":3134,"PHASE1":3136,"PHASE2":3138,"PHASE3":3140,"PHASE4":3146,"NA":3148},{"trials":3135,"activeCount":102},[],{"trials":3137,"activeCount":102},[],{"trials":3139,"activeCount":102},[],{"trials":3141,"activeCount":102},[3142],{"nctId":3117,"briefTitle":3118,"status":114,"phases":3143,"primaryCompletion":3120,"completion":3121,"start":3122,"enrollment":3123,"conditions":3144,"interventions":3145},[92],[3125],[3106,3127],{"trials":3147,"activeCount":102},[],{"trials":3149,"activeCount":102},[],{"intervention":3151,"totalTrials":142,"cells":3152},"Daptomycin",{"EARLY_PHASE1":3153,"PHASE1":3155,"PHASE2":3157,"PHASE3":3159,"PHASE4":3170,"NA":3172},{"trials":3154,"activeCount":102},[],{"trials":3156,"activeCount":102},[],{"trials":3158,"activeCount":102},[],{"trials":3160,"activeCount":102},[3161],{"nctId":3162,"briefTitle":3163,"status":329,"phases":3164,"primaryCompletion":3165,"completion":3165,"start":3166,"enrollment":2760,"conditions":3167,"interventions":3169},"NCT01216241","Daptomycin Versus Placebo in Patients With Neutropenia and Fever",[92],"2013-04","2011-04",[3168],"Febrile Neutropenia",[3151,3151],{"trials":3171,"activeCount":102},[],{"trials":3173,"activeCount":102},[],{"intervention":549,"totalTrials":142,"cells":3175},{"EARLY_PHASE1":3176,"PHASE1":3178,"PHASE2":3180,"PHASE3":3182,"PHASE4":3188,"NA":3190},{"trials":3177,"activeCount":102},[],{"trials":3179,"activeCount":102},[],{"trials":3181,"activeCount":102},[],{"trials":3183,"activeCount":102},[3184],{"nctId":540,"briefTitle":541,"status":114,"phases":3185,"primaryCompletion":543,"completion":543,"start":544,"enrollment":545,"conditions":3186,"interventions":3187},[92],[547],[522,549,550,551],{"trials":3189,"activeCount":102},[],{"trials":3191,"activeCount":102},[],{"intervention":550,"totalTrials":142,"cells":3193},{"EARLY_PHASE1":3194,"PHASE1":3196,"PHASE2":3198,"PHASE3":3200,"PHASE4":3206,"NA":3208},{"trials":3195,"activeCount":102},[],{"trials":3197,"activeCount":102},[],{"trials":3199,"activeCount":102},[],{"trials":3201,"activeCount":102},[3202],{"nctId":540,"briefTitle":541,"status":114,"phases":3203,"primaryCompletion":543,"completion":543,"start":544,"enrollment":545,"conditions":3204,"interventions":3205},[92],[547],[522,549,550,551],{"trials":3207,"activeCount":102},[],{"trials":3209,"activeCount":102},[],{"intervention":551,"totalTrials":142,"cells":3211},{"EARLY_PHASE1":3212,"PHASE1":3214,"PHASE2":3216,"PHASE3":3218,"PHASE4":3224,"NA":3226},{"trials":3213,"activeCount":102},[],{"trials":3215,"activeCount":102},[],{"trials":3217,"activeCount":102},[],{"trials":3219,"activeCount":102},[3220],{"nctId":540,"briefTitle":541,"status":114,"phases":3221,"primaryCompletion":543,"completion":543,"start":544,"enrollment":545,"conditions":3222,"interventions":3223},[92],[547],[522,549,550,551],{"trials":3225,"activeCount":102},[],{"trials":3227,"activeCount":102},[],{"intervention":3229,"totalTrials":142,"cells":3230},"paroxetine",{"EARLY_PHASE1":3231,"PHASE1":3233,"PHASE2":3235,"PHASE3":3237,"PHASE4":3248,"NA":3250},{"trials":3232,"activeCount":102},[],{"trials":3234,"activeCount":102},[],{"trials":3236,"activeCount":102},[],{"trials":3238,"activeCount":102},[3239],{"nctId":3240,"briefTitle":3241,"status":114,"phases":3242,"primaryCompletion":2451,"completion":2451,"start":3243,"enrollment":3244,"conditions":3245,"interventions":3246},"NCT00086190","Study of Antidepressants in Parkinson's Disease",[92],"2005-06",115,[25,19],[3229,3247],"venlafaxine",{"trials":3249,"activeCount":102},[],{"trials":3251,"activeCount":102},[],{"intervention":3247,"totalTrials":142,"cells":3253},{"EARLY_PHASE1":3254,"PHASE1":3256,"PHASE2":3258,"PHASE3":3260,"PHASE4":3266,"NA":3268},{"trials":3255,"activeCount":102},[],{"trials":3257,"activeCount":102},[],{"trials":3259,"activeCount":102},[],{"trials":3261,"activeCount":102},[3262],{"nctId":3240,"briefTitle":3241,"status":114,"phases":3263,"primaryCompletion":2451,"completion":2451,"start":3243,"enrollment":3244,"conditions":3264,"interventions":3265},[92],[25,19],[3229,3247],{"trials":3267,"activeCount":102},[],{"trials":3269,"activeCount":102},[],{"intervention":3271,"totalTrials":142,"cells":3272},"intravenous lipid",{"EARLY_PHASE1":3273,"PHASE1":3275,"PHASE2":3277,"PHASE3":3279,"PHASE4":3291,"NA":3293},{"trials":3274,"activeCount":102},[],{"trials":3276,"activeCount":102},[],{"trials":3278,"activeCount":102},[],{"trials":3280,"activeCount":102},[3281],{"nctId":3282,"briefTitle":3283,"status":114,"phases":3284,"primaryCompletion":3285,"completion":3286,"start":3287,"enrollment":302,"conditions":3288,"interventions":3290},"NCT01555957","Prospective Randomized Clinical Trial of Intravenous Lipids and Cholestasis",[92],"2018-10-30","2019-01-31","2012-02",[3289],"Parenteral Nutrition Associated Cholestasis",[3271],{"trials":3292,"activeCount":102},[],{"trials":3294,"activeCount":102},[],{"intervention":3296,"totalTrials":142,"cells":3297},"buspirone hydrochloride",{"EARLY_PHASE1":3298,"PHASE1":3300,"PHASE2":3302,"PHASE3":3304,"PHASE4":3318,"NA":3320},{"trials":3299,"activeCount":102},[],{"trials":3301,"activeCount":102},[],{"trials":3303,"activeCount":102},[],{"trials":3305,"activeCount":102},[3306],{"nctId":3307,"briefTitle":3308,"status":114,"phases":3309,"primaryCompletion":1617,"completion":3310,"start":3311,"enrollment":3312,"conditions":3313,"interventions":3317},"NCT00053846","Buspirone in Reducing Shortness of Breath in Patients With Cancer",[91,92],"2011-01","2002-11",432,[3314,3315,3316],"Dyspnea","Pulmonary Complications","Unspecified Adult Solid Tumor, Protocol Specific",[3296],{"trials":3319,"activeCount":102},[],{"trials":3321,"activeCount":102},[],{"intervention":3323,"totalTrials":142,"cells":3324},"dalteparin",{"EARLY_PHASE1":3325,"PHASE1":3327,"PHASE2":3329,"PHASE3":3331,"PHASE4":3345,"NA":3347},{"trials":3326,"activeCount":102},[],{"trials":3328,"activeCount":102},[],{"trials":3330,"activeCount":102},[],{"trials":3332,"activeCount":102},[3333],{"nctId":3334,"briefTitle":3335,"status":329,"phases":3336,"primaryCompletion":3337,"completion":3338,"start":3339,"enrollment":3340,"conditions":3341,"interventions":3344},"NCT00876915","A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients",[92],"2014-07","2014-12","2009-07",218,[3342,3343],"Venous Thromboembolism","Pulmonary Embolism",[3323],{"trials":3346,"activeCount":102},[],{"trials":3348,"activeCount":102},[],{"intervention":3350,"totalTrials":142,"cells":3351},"Mifepristone",{"EARLY_PHASE1":3352,"PHASE1":3354,"PHASE2":3356,"PHASE3":3358,"PHASE4":3370,"NA":3372},{"trials":3353,"activeCount":102},[],{"trials":3355,"activeCount":102},[],{"trials":3357,"activeCount":102},[],{"trials":3359,"activeCount":102},[3360],{"nctId":3361,"briefTitle":3362,"status":114,"phases":3363,"primaryCompletion":2142,"completion":2142,"start":3364,"enrollment":3365,"conditions":3366,"interventions":3368},"NCT00133705","Trial of Mifepristone for Fibroids",[92],"2003-07",70,[3367],"Leiomyoma",[3350,3369],"Inert",{"trials":3371,"activeCount":102},[],{"trials":3373,"activeCount":102},[],{"intervention":3369,"totalTrials":142,"cells":3375},{"EARLY_PHASE1":3376,"PHASE1":3378,"PHASE2":3380,"PHASE3":3382,"PHASE4":3388,"NA":3390},{"trials":3377,"activeCount":102},[],{"trials":3379,"activeCount":102},[],{"trials":3381,"activeCount":102},[],{"trials":3383,"activeCount":102},[3384],{"nctId":3361,"briefTitle":3362,"status":114,"phases":3385,"primaryCompletion":2142,"completion":2142,"start":3364,"enrollment":3365,"conditions":3386,"interventions":3387},[92],[3367],[3350,3369],{"trials":3389,"activeCount":102},[],{"trials":3391,"activeCount":102},[],{"intervention":3393,"totalTrials":142,"cells":3394},"Dichlorphenamide",{"EARLY_PHASE1":3395,"PHASE1":3397,"PHASE2":3399,"PHASE3":3401,"PHASE4":3414,"NA":3416},{"trials":3396,"activeCount":102},[],{"trials":3398,"activeCount":102},[],{"trials":3400,"activeCount":102},[],{"trials":3402,"activeCount":102},[3403],{"nctId":3404,"briefTitle":3405,"status":114,"phases":3406,"primaryCompletion":3165,"completion":3407,"start":3408,"enrollment":3409,"conditions":3410,"interventions":3413},"NCT00494507","Hyper- and Hypokalemic Periodic Paralysis Study",[92],"2013-05","2007-06",71,[3411,3412],"Hyperkalemic Periodic Paralysis","Hypokalemic Periodic Paralysis",[3393,3393],{"trials":3415,"activeCount":102},[],{"trials":3417,"activeCount":102},[],{"intervention":394,"totalTrials":142,"cells":3419},{"EARLY_PHASE1":3420,"PHASE1":3422,"PHASE2":3424,"PHASE3":3426,"PHASE4":3432,"NA":3434},{"trials":3421,"activeCount":102},[],{"trials":3423,"activeCount":102},[],{"trials":3425,"activeCount":102},[],{"trials":3427,"activeCount":102},[3428],{"nctId":385,"briefTitle":386,"status":114,"phases":3429,"primaryCompletion":388,"completion":388,"start":389,"enrollment":390,"conditions":3430,"interventions":3431},[92],[392],[308,308,394],{"trials":3433,"activeCount":102},[],{"trials":3435,"activeCount":102},[],{"intervention":3437,"totalTrials":366,"cells":3438},"Aspirin",{"EARLY_PHASE1":3439,"PHASE1":3441,"PHASE2":3452,"PHASE3":3478,"PHASE4":3480,"NA":3482},{"trials":3440,"activeCount":102},[],{"trials":3442,"activeCount":102},[3443],{"nctId":3444,"briefTitle":3445,"status":114,"phases":3446,"primaryCompletion":3447,"completion":2451,"start":1770,"enrollment":678,"conditions":3448,"interventions":3450},"NCT00178464","Aspirin Prophylaxis in Sickle Cell Disease",[90],"2009-04",[3449],"Sickle Cell Disease",[3451],"aspirin",{"trials":3453,"activeCount":102},[3454,3466],{"nctId":3455,"briefTitle":3456,"status":114,"phases":3457,"primaryCompletion":2142,"completion":3458,"start":3459,"enrollment":302,"conditions":3460,"interventions":3464},"NCT00861341","Effects of Pioglitazone on Platelet Function",[91],"2011-06","2008-12",[3461,3462,3463],"Diabetes","Platelet Function","Healthy",[3437,3465],"Pioglitazone",{"nctId":3467,"briefTitle":3468,"status":114,"phases":3469,"primaryCompletion":3470,"completion":3470,"start":3471,"enrollment":3472,"conditions":3473,"interventions":3475},"NCT00771914","The Effects of Omega-3 Fatty Acids on Aspirin Resistance",[90,91],"2009-01","2008-11",27,[3474],"Increased Drug Resistance",[3437,3476,3477],"Lovaza","Both Aspirin and Lovaza",{"trials":3479,"activeCount":102},[],{"trials":3481,"activeCount":102},[],{"trials":3483,"activeCount":102},[],{"intervention":577,"totalTrials":366,"cells":3485},{"EARLY_PHASE1":3486,"PHASE1":3488,"PHASE2":3490,"PHASE3":3512,"PHASE4":3514,"NA":3516},{"trials":3487,"activeCount":102},[],{"trials":3489,"activeCount":102},[],{"trials":3491,"activeCount":102},[3492,3496,3505],{"nctId":567,"briefTitle":568,"status":114,"phases":3493,"primaryCompletion":570,"completion":571,"start":572,"enrollment":573,"conditions":3494,"interventions":3495},[91],[575],[577,578,557],{"nctId":3497,"briefTitle":3498,"status":114,"phases":3499,"primaryCompletion":3500,"start":3501,"enrollment":23,"conditions":3502,"interventions":3503},"NCT00262860","Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma",[91],"2008-05","2005-04",[339],[577,3504],"gemcitabine hydrochloride",{"nctId":3506,"briefTitle":3507,"status":114,"phases":3508,"primaryCompletion":1688,"completion":1688,"start":2864,"enrollment":3509,"conditions":3510,"interventions":3511},"NCT00262873","Bortezomib in Treating Patients With Myelodysplastic Syndromes",[91],8,[341],[577],{"trials":3513,"activeCount":102},[],{"trials":3515,"activeCount":102},[],{"trials":3517,"activeCount":102},[],{"intervention":3519,"totalTrials":366,"cells":3520},"docetaxel",{"EARLY_PHASE1":3521,"PHASE1":3523,"PHASE2":3525,"PHASE3":3557,"PHASE4":3559,"NA":3561},{"trials":3522,"activeCount":102},[],{"trials":3524,"activeCount":102},[],{"trials":3526,"activeCount":102},[3527,3535,3548],{"nctId":3528,"briefTitle":3529,"status":114,"phases":3530,"primaryCompletion":3531,"start":1800,"conditions":3532,"interventions":3534},"NCT00178269","Low-Dose Taxotere® (Docetaxel) With Concurrent Radiotherapy For Localized, Inoperable Carcinoma Of The Uterine Cervix",[91],"2006-06",[3533],"Cervix Neoplasm",[3519],{"nctId":3536,"briefTitle":3537,"status":2362,"phases":3538,"primaryCompletion":77,"completion":300,"start":3539,"enrollment":102,"conditions":3540,"interventions":3542},"NCT04419181","Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer",[91],"2025-08-11",[3541],"HER2-positive Breast Cancer",[3543,3544,3545,3546,3547],"Docetaxel","Carboplatin","Trastuzumab","Pertuzumab","Trastuzumab emtansine",{"nctId":3549,"briefTitle":3550,"status":114,"phases":3551,"primaryCompletion":3408,"start":3552,"conditions":3553,"interventions":3555},"NCT00167401","Trial of Chemotherapy Followed by Pulsed Docetaxel and Concurrent Radiation for Non-Small Cell Lung Cancer",[91],"2002-02",[3554],"Carcinoma, Non-Small-Cell Lung",[3519,3556],"cisplatin",{"trials":3558,"activeCount":102},[],{"trials":3560,"activeCount":102},[],{"trials":3562,"activeCount":102},[],{"intervention":3564,"totalTrials":98,"cells":3565},"Mexiletine",{"EARLY_PHASE1":3566,"PHASE1":3568,"PHASE2":3570,"PHASE3":3591,"PHASE4":3593,"NA":3595},{"trials":3567,"activeCount":102},[],{"trials":3569,"activeCount":102},[],{"trials":3571,"activeCount":102},[3572,3582],{"nctId":3573,"briefTitle":3574,"status":114,"phases":3575,"primaryCompletion":3576,"completion":3577,"start":3458,"enrollment":3578,"conditions":3579,"interventions":3581},"NCT01406873","Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1",[91],"2017-02","2017-03",42,[3580],"Myotonic Dystrophy",[3564],{"nctId":3583,"briefTitle":3584,"status":114,"phases":3585,"primaryCompletion":3586,"completion":3586,"start":3587,"enrollment":558,"conditions":3588,"interventions":3590},"NCT02561702","Mexiletine for Muscle Cramps in Charcot Marie Tooth Disease",[91],"2016-12-31","2015-09",[3589],"Charcot Marie Tooth Disease",[3564],{"trials":3592,"activeCount":102},[],{"trials":3594,"activeCount":102},[],{"trials":3596,"activeCount":102},[],{"intervention":3598,"totalTrials":98,"cells":3599},"Calcitriol",{"EARLY_PHASE1":3600,"PHASE1":3602,"PHASE2":3604,"PHASE3":3624,"PHASE4":3626,"NA":3628},{"trials":3601,"activeCount":102},[],{"trials":3603,"activeCount":102},[],{"trials":3605,"activeCount":102},[3606,3616],{"nctId":3607,"briefTitle":3608,"status":114,"phases":3609,"primaryCompletion":3610,"completion":3610,"start":3611,"enrollment":2675,"conditions":3612,"interventions":3615},"NCT00904033","Calcitriol, Physical Activity, and Bone Health in Cancer Survivors",[91],"2018-01-01","2008-12-01",[3613,3614],"Breast Neoplasms","Bone and Bones",[3598],{"nctId":3617,"briefTitle":3618,"status":114,"phases":3619,"primaryCompletion":3620,"completion":3621,"start":1617,"enrollment":29,"conditions":3622,"interventions":3623},"NCT01293682","Effects of High Dose Calcitriol in Breast Cancer Patients",[91],"2018-08","2021-12",[36],[3598],{"trials":3625,"activeCount":102},[],{"trials":3627,"activeCount":102},[],{"trials":3629,"activeCount":102},[],{"intervention":3631,"totalTrials":98,"cells":3632},"Ruxolitinib",{"EARLY_PHASE1":3633,"PHASE1":3635,"PHASE2":3637,"PHASE3":3658,"PHASE4":3660,"NA":3662},{"trials":3634,"activeCount":102},[],{"trials":3636,"activeCount":102},[],{"trials":3638,"activeCount":102},[3639,3648],{"nctId":3640,"briefTitle":3641,"status":114,"phases":3642,"primaryCompletion":3643,"completion":3643,"start":3644,"enrollment":32,"conditions":3645,"interventions":3647},"NCT04908280","Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus",[91],"2024-03-04","2022-05-04",[3646],"Discoid Lupus Erythematosus",[3631],{"nctId":3649,"briefTitle":3650,"status":114,"phases":3651,"primaryCompletion":3652,"completion":3653,"start":3654,"enrollment":334,"conditions":3655,"interventions":3657},"NCT05293717","Topical Ruxolitinib in Chronic Hand Dermatitis",[90,91],"2023-06-21","2024-12-31","2022-07-11",[3656],"Chronic Hand Dermatitis",[3631],{"trials":3659,"activeCount":102},[],{"trials":3661,"activeCount":102},[],{"trials":3663,"activeCount":102},[],{"intervention":3665,"totalTrials":98,"cells":3666},"bevacizumab",{"EARLY_PHASE1":3667,"PHASE1":3669,"PHASE2":3682,"PHASE3":3693,"PHASE4":3695,"NA":3697},{"trials":3668,"activeCount":102},[],{"trials":3670,"activeCount":102},[3671],{"nctId":3672,"briefTitle":3673,"status":114,"phases":3674,"primaryCompletion":3675,"completion":3676,"start":3677,"enrollment":20,"conditions":3678,"interventions":3680},"NCT03746041","A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes",[90],"2022-04-01","2022-06-06","2019-02-14",[341,3679],"Chronic Myelomonocytic Leukemia",[3681,3665],"abaloparatide",{"trials":3683,"activeCount":102},[3684],{"nctId":3685,"briefTitle":3686,"status":114,"phases":3687,"primaryCompletion":3688,"start":2194,"enrollment":435,"conditions":3689,"interventions":3691},"NCT00309998","Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer",[91],"2007-05",[3690],"Lung Cancer",[3665,3692],"vinorelbine tartrate",{"trials":3694,"activeCount":102},[],{"trials":3696,"activeCount":102},[],{"trials":3698,"activeCount":102},[],{"intervention":291,"totalTrials":98,"cells":3700},{"EARLY_PHASE1":3701,"PHASE1":3703,"PHASE2":3715,"PHASE3":3721,"PHASE4":3723,"NA":3725},{"trials":3702,"activeCount":102},[],{"trials":3704,"activeCount":102},[3705],{"nctId":3706,"briefTitle":3707,"status":114,"phases":3708,"primaryCompletion":3166,"completion":3166,"start":3709,"enrollment":23,"conditions":3710,"interventions":3713},"NCT00317798","Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma",[90],"2006-04",[3711,3712],"Drug\u002FAgent Toxicity by Tissue\u002FOrgan","Multiple Myeloma and Plasma Cell Neoplasm",[291,3714],"sirolimus",{"trials":3716,"activeCount":102},[3717],{"nctId":282,"briefTitle":283,"status":114,"phases":3718,"primaryCompletion":285,"start":286,"enrollment":287,"conditions":3719,"interventions":3720},[91],[289],[291,292,293,294,295,296,297],{"trials":3722,"activeCount":102},[],{"trials":3724,"activeCount":102},[],{"trials":3726,"activeCount":102},[],{"intervention":3728,"totalTrials":98,"cells":3729},"Decitabine",{"EARLY_PHASE1":3730,"PHASE1":3732,"PHASE2":3743,"PHASE3":3753,"PHASE4":3755,"NA":3757},{"trials":3731,"activeCount":102},[],{"trials":3733,"activeCount":102},[3734],{"nctId":3735,"briefTitle":3736,"status":114,"phases":3737,"primaryCompletion":2794,"start":3738,"enrollment":26,"conditions":3739,"interventions":3741},"NCT00861874","A Study of Decitabine in Combination With Escalating Doses of Rapamycin in Patients With Relapsed or Refractory Acute Myeloid Leukemia",[90],"2010-01",[3740],"Acute Myeloid Leukemia",[3728,3742],"Rapamycin",{"trials":3744,"activeCount":102},[3745],{"nctId":3746,"briefTitle":3747,"status":114,"phases":3748,"primaryCompletion":3749,"completion":3749,"start":2715,"enrollment":3472,"conditions":3750,"interventions":3752},"NCT02109744","Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients",[90,91],"2022-01-01",[3751],"Acute Myelogenous Leukemia",[3728],{"trials":3754,"activeCount":102},[],{"trials":3756,"activeCount":102},[],{"trials":3758,"activeCount":102},[],{"intervention":3760,"totalTrials":98,"cells":3761},"oxaliplatin",{"EARLY_PHASE1":3762,"PHASE1":3764,"PHASE2":3766,"PHASE3":3790,"PHASE4":3792,"NA":3794},{"trials":3763,"activeCount":102},[],{"trials":3765,"activeCount":102},[],{"trials":3767,"activeCount":102},[3768,3779],{"nctId":3769,"briefTitle":3770,"status":114,"phases":3771,"primaryCompletion":389,"completion":389,"start":3772,"enrollment":573,"conditions":3773,"interventions":3776},"NCT01308840","Gemcitabine, Oxaliplatin and Panitumumab in Kras\u002FB-raf Wild-Type Biliary Track and Gallbladder Cancer",[91],"2010-12",[3774,3775],"Biliary Tract Cancer","Gallbladder Cancer",[3777,3760,3778],"Panitumumab","gemcitabine",{"nctId":3780,"briefTitle":3781,"status":114,"phases":3782,"primaryCompletion":2217,"completion":2217,"start":3783,"enrollment":435,"conditions":3784,"interventions":3786},"NCT00262808","GM-CSF and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Colon Cancer",[91],"2004-03",[3785],"Colorectal Cancer",[3787,3788,3789,3760],"sargramostim","fluorouracil","leucovorin calcium",{"trials":3791,"activeCount":102},[],{"trials":3793,"activeCount":102},[],{"trials":3795,"activeCount":102},[],{"intervention":3797,"totalTrials":98,"cells":3798},"Cisplatin",{"EARLY_PHASE1":3799,"PHASE1":3809,"PHASE2":3811,"PHASE3":3817,"PHASE4":3819,"NA":3821},{"trials":3800,"activeCount":102},[3801],{"nctId":3802,"briefTitle":3803,"status":114,"phases":3804,"primaryCompletion":3805,"completion":3805,"start":3806,"enrollment":29,"conditions":3807,"interventions":3808},"NCT03275857","Cisplatin in Castration Resistant Prostate Cancer",[89],"2023-07-31","2018-09-21",[1398],[3797],{"trials":3810,"activeCount":102},[],{"trials":3812,"activeCount":102},[3813],{"nctId":3549,"briefTitle":3550,"status":114,"phases":3814,"primaryCompletion":3408,"start":3552,"conditions":3815,"interventions":3816},[91],[3554],[3519,3556],{"trials":3818,"activeCount":102},[],{"trials":3820,"activeCount":102},[],{"trials":3822,"activeCount":102},[],{"intervention":3824,"totalTrials":142,"cells":3825},"Curcumin C3 Complex",{"EARLY_PHASE1":3826,"PHASE1":3828,"PHASE2":3830,"PHASE3":3838,"PHASE4":3840,"NA":3842},{"trials":3827,"activeCount":102},[],{"trials":3829,"activeCount":102},[],{"trials":3831,"activeCount":102},[3832],{"nctId":3833,"briefTitle":3834,"status":114,"phases":3835,"primaryCompletion":163,"completion":3166,"start":2758,"enrollment":287,"conditions":3836,"interventions":3837},"NCT01042938","Curcumin for the Prevention of Radiation-induced Dermatitis in Breast Cancer Patients",[91],[36],[3824],{"trials":3839,"activeCount":102},[],{"trials":3841,"activeCount":102},[],{"trials":3843,"activeCount":102},[],{"intervention":3845,"totalTrials":142,"cells":3846},"CoQ10",{"EARLY_PHASE1":3847,"PHASE1":3849,"PHASE2":3851,"PHASE3":3861,"PHASE4":3863,"NA":3865},{"trials":3848,"activeCount":102},[],{"trials":3850,"activeCount":102},[],{"trials":3852,"activeCount":102},[3853],{"nctId":3854,"briefTitle":3855,"status":114,"phases":3856,"primaryCompletion":2194,"completion":2194,"start":3857,"enrollment":2867,"conditions":3858,"interventions":3859},"NCT00076492","NINDS Parkinson's Disease Neuroprotection Trial of CoQ10 and GPI 1485",[91],"2004-01",[25],[3845,3860],"GPI 1485",{"trials":3862,"activeCount":102},[],{"trials":3864,"activeCount":102},[],{"trials":3866,"activeCount":102},[],{"intervention":3860,"totalTrials":142,"cells":3868},{"EARLY_PHASE1":3869,"PHASE1":3871,"PHASE2":3873,"PHASE3":3879,"PHASE4":3881,"NA":3883},{"trials":3870,"activeCount":102},[],{"trials":3872,"activeCount":102},[],{"trials":3874,"activeCount":102},[3875],{"nctId":3854,"briefTitle":3855,"status":114,"phases":3876,"primaryCompletion":2194,"completion":2194,"start":3857,"enrollment":2867,"conditions":3877,"interventions":3878},[91],[25],[3845,3860],{"trials":3880,"activeCount":102},[],{"trials":3882,"activeCount":102},[],{"trials":3884,"activeCount":102},[],{"intervention":3886,"totalTrials":142,"cells":3887},"Risperidone",{"EARLY_PHASE1":3888,"PHASE1":3890,"PHASE2":3892,"PHASE3":3905,"PHASE4":3907,"NA":3909},{"trials":3889,"activeCount":102},[],{"trials":3891,"activeCount":102},[],{"trials":3893,"activeCount":102},[3894],{"nctId":3895,"briefTitle":3896,"status":114,"phases":3897,"primaryCompletion":3898,"completion":3898,"start":3899,"enrollment":3900,"conditions":3901,"interventions":3904},"NCT04201834","Risperidone for the Treatment of Huntington's Disease Involuntary Movements",[91],"2023-12-30","2020-08-13",6,[3902,3903],"Huntington Disease","Chorea",[3886],{"trials":3906,"activeCount":102},[],{"trials":3908,"activeCount":102},[],{"trials":3910,"activeCount":102},[],{"intervention":3912,"totalTrials":142,"cells":3913},"PXS-5505 and Atezolizumab and Bevacizumab",{"EARLY_PHASE1":3914,"PHASE1":3916,"PHASE2":3918,"PHASE3":3930,"PHASE4":3932,"NA":3934},{"trials":3915,"activeCount":102},[],{"trials":3917,"activeCount":102},[],{"trials":3919,"activeCount":102},[3920],{"nctId":3921,"briefTitle":3922,"status":2362,"phases":3923,"primaryCompletion":3924,"completion":3924,"start":3925,"enrollment":102,"conditions":3926,"interventions":3929},"NCT05109052","Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma",[90,91],"2028-12-31","2022-09-20",[3927,3928],"Hepatocellular Carcinoma","Cancer of Liver",[3912],{"trials":3931,"activeCount":102},[],{"trials":3933,"activeCount":102},[],{"trials":3935,"activeCount":102},[],{"intervention":3937,"totalTrials":142,"cells":3938},"gefitinib",{"EARLY_PHASE1":3939,"PHASE1":3941,"PHASE2":3943,"PHASE3":3953,"PHASE4":3955,"NA":3957},{"trials":3940,"activeCount":102},[],{"trials":3942,"activeCount":102},[],{"trials":3944,"activeCount":102},[3945],{"nctId":3946,"briefTitle":3947,"status":329,"phases":3948,"primaryCompletion":3949,"completion":3949,"start":2769,"enrollment":351,"conditions":3950,"interventions":3952},"NCT00258297","Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery",[91],"2006-11",[3951],"Esophageal Cancer",[3937],{"trials":3954,"activeCount":102},[],{"trials":3956,"activeCount":102},[],{"trials":3958,"activeCount":102},[],{"intervention":3960,"totalTrials":142,"cells":3961},"Enzalutamide",{"EARLY_PHASE1":3962,"PHASE1":3964,"PHASE2":3966,"PHASE3":3977,"PHASE4":3979,"NA":3981},{"trials":3963,"activeCount":102},[],{"trials":3965,"activeCount":102},[],{"trials":3967,"activeCount":102},[3968],{"nctId":3969,"briefTitle":3970,"status":329,"phases":3971,"primaryCompletion":3972,"completion":3972,"start":3973,"enrollment":142,"conditions":3974,"interventions":3976},"NCT02605863","Enzalutamide for Bladder Cancer Chemoprevention",[91],"2018-02","2016-01",[3975],"Bladder Cancer",[3960],{"trials":3978,"activeCount":102},[],{"trials":3980,"activeCount":102},[],{"trials":3982,"activeCount":102},[],{"intervention":3984,"totalTrials":142,"cells":3985},"Atorvastatin",{"EARLY_PHASE1":3986,"PHASE1":3988,"PHASE2":3990,"PHASE3":4002,"PHASE4":4004,"NA":4006},{"trials":3987,"activeCount":102},[],{"trials":3989,"activeCount":102},[],{"trials":3991,"activeCount":102},[3992],{"nctId":3993,"briefTitle":3994,"status":114,"phases":3995,"primaryCompletion":3996,"completion":3407,"start":3997,"enrollment":3998,"conditions":3999,"interventions":4001},"NCT01785615","Prothrombotic Inflammatory Markers in Women With Metabolic Syndrome - Effect of Atorvastatin",[90,91],"2011-12","2004-11",116,[4000],"Metabolic Syndrome",[3984],{"trials":4003,"activeCount":102},[],{"trials":4005,"activeCount":102},[],{"trials":4007,"activeCount":102},[],{"intervention":4009,"totalTrials":142,"cells":4010},"Abciximab",{"EARLY_PHASE1":4011,"PHASE1":4013,"PHASE2":4015,"PHASE3":4024,"PHASE4":4026,"NA":4028},{"trials":4012,"activeCount":102},[],{"trials":4014,"activeCount":102},[],{"trials":4016,"activeCount":102},[4017],{"nctId":4018,"briefTitle":4019,"status":2362,"phases":4020,"enrollment":102,"conditions":4021,"interventions":4023},"NCT00178451","Stroke Prevention With Abciximab in Carotid Endarterectomy",[90,91],[4022],"Carotid Stenosis",[4009],{"trials":4025,"activeCount":102},[],{"trials":4027,"activeCount":102},[],{"trials":4029,"activeCount":102},[],{"intervention":3692,"totalTrials":142,"cells":4031},{"EARLY_PHASE1":4032,"PHASE1":4034,"PHASE2":4036,"PHASE3":4042,"PHASE4":4044,"NA":4046},{"trials":4033,"activeCount":102},[],{"trials":4035,"activeCount":102},[],{"trials":4037,"activeCount":102},[4038],{"nctId":3685,"briefTitle":3686,"status":114,"phases":4039,"primaryCompletion":3688,"start":2194,"enrollment":435,"conditions":4040,"interventions":4041},[91],[3690],[3665,3692],{"trials":4043,"activeCount":102},[],{"trials":4045,"activeCount":102},[],{"trials":4047,"activeCount":102},[],{"intervention":4049,"totalTrials":142,"cells":4050},"Enzalutamide and Dutasteride or finasteride",{"EARLY_PHASE1":4051,"PHASE1":4053,"PHASE2":4055,"PHASE3":4064,"PHASE4":4066,"NA":4068},{"trials":4052,"activeCount":102},[],{"trials":4054,"activeCount":102},[],{"trials":4056,"activeCount":102},[4057],{"nctId":4058,"briefTitle":4059,"status":114,"phases":4060,"primaryCompletion":4061,"completion":4061,"start":411,"enrollment":2772,"conditions":4062,"interventions":4063},"NCT02213107","Enzalutamide & Dutasteride\u002FFinasteride as 1st Line Treatment for Patients =\u002F> 65 Years Old With Prostate Cancer.",[91],"2023-10-31",[1398],[4049],{"trials":4065,"activeCount":102},[],{"trials":4067,"activeCount":102},[],{"trials":4069,"activeCount":102},[],{"intervention":4071,"totalTrials":142,"cells":4072},"Activated Protein C",{"EARLY_PHASE1":4073,"PHASE1":4075,"PHASE2":4077,"PHASE3":4087,"PHASE4":4089,"NA":4091},{"trials":4074,"activeCount":102},[],{"trials":4076,"activeCount":102},[],{"trials":4078,"activeCount":102},[4079],{"nctId":4080,"briefTitle":4081,"status":329,"phases":4082,"primaryCompletion":1688,"completion":1688,"start":4083,"enrollment":29,"conditions":4084,"interventions":4086},"NCT00533546","Activated Protein C in Acute Stroke Trial",[91],"2007-09",[4085],"Stroke",[4071],{"trials":4088,"activeCount":102},[],{"trials":4090,"activeCount":102},[],{"trials":4092,"activeCount":102},[],{"intervention":4094,"totalTrials":142,"cells":4095},"Lovaza®",{"EARLY_PHASE1":4096,"PHASE1":4098,"PHASE2":4100,"PHASE3":4110,"PHASE4":4112,"NA":4114},{"trials":4097,"activeCount":102},[],{"trials":4099,"activeCount":102},[],{"trials":4101,"activeCount":102},[4102],{"nctId":4103,"briefTitle":4104,"status":329,"phases":4105,"primaryCompletion":2827,"completion":2827,"start":2142,"enrollment":558,"conditions":4106,"interventions":4108},"NCT01155336","The Effects of Lovaza® in Acute Myocardial Infarction",[90,91],[4107],"Myocardial Infarction",[4094,4109],"The placebo contained 1 gram of corn oil in each capsule.",{"trials":4111,"activeCount":102},[],{"trials":4113,"activeCount":102},[],{"trials":4115,"activeCount":102},[],{"intervention":4109,"totalTrials":142,"cells":4117},{"EARLY_PHASE1":4118,"PHASE1":4120,"PHASE2":4122,"PHASE3":4128,"PHASE4":4130,"NA":4132},{"trials":4119,"activeCount":102},[],{"trials":4121,"activeCount":102},[],{"trials":4123,"activeCount":102},[4124],{"nctId":4103,"briefTitle":4104,"status":329,"phases":4125,"primaryCompletion":2827,"completion":2827,"start":2142,"enrollment":558,"conditions":4126,"interventions":4127},[90,91],[4107],[4094,4109],{"trials":4129,"activeCount":102},[],{"trials":4131,"activeCount":102},[],{"trials":4133,"activeCount":102},[],{"intervention":578,"totalTrials":142,"cells":4135},{"EARLY_PHASE1":4136,"PHASE1":4138,"PHASE2":4140,"PHASE3":4146,"PHASE4":4148,"NA":4150},{"trials":4137,"activeCount":102},[],{"trials":4139,"activeCount":102},[],{"trials":4141,"activeCount":102},[4142],{"nctId":567,"briefTitle":568,"status":114,"phases":4143,"primaryCompletion":570,"completion":571,"start":572,"enrollment":573,"conditions":4144,"interventions":4145},[91],[575],[577,578,557],{"trials":4147,"activeCount":102},[],{"trials":4149,"activeCount":102},[],{"trials":4151,"activeCount":102},[],{"intervention":589,"totalTrials":142,"cells":4153},{"EARLY_PHASE1":4154,"PHASE1":4156,"PHASE2":4158,"PHASE3":4164,"PHASE4":4166,"NA":4168},{"trials":4155,"activeCount":102},[],{"trials":4157,"activeCount":102},[],{"trials":4159,"activeCount":102},[4160],{"nctId":580,"briefTitle":581,"status":114,"phases":4161,"primaryCompletion":583,"completion":583,"start":584,"enrollment":314,"conditions":4162,"interventions":4163},[91],[586,587],[589,319],{"trials":4165,"activeCount":102},[],{"trials":4167,"activeCount":102},[],{"trials":4169,"activeCount":102},[],{"intervention":4171,"totalTrials":142,"cells":4172},"sodium phenylbutyrate",{"EARLY_PHASE1":4173,"PHASE1":4175,"PHASE2":4177,"PHASE3":4187,"PHASE4":4189,"NA":4191},{"trials":4174,"activeCount":102},[],{"trials":4176,"activeCount":102},[],{"trials":4178,"activeCount":102},[4179],{"nctId":4180,"briefTitle":4181,"status":114,"phases":4182,"completion":3531,"start":4183,"enrollment":2474,"conditions":4184,"interventions":4186},"NCT00212316","Safety and Tolerability Study of Phenylbutyrate in Huntington's Disease (PHEND-HD)",[91],"2005-08",[4185],"Huntington's Disease",[4171],{"trials":4188,"activeCount":102},[],{"trials":4190,"activeCount":102},[],{"trials":4192,"activeCount":102},[],{"intervention":293,"totalTrials":142,"cells":4194},{"EARLY_PHASE1":4195,"PHASE1":4197,"PHASE2":4199,"PHASE3":4205,"PHASE4":4207,"NA":4209},{"trials":4196,"activeCount":102},[],{"trials":4198,"activeCount":102},[],{"trials":4200,"activeCount":102},[4201],{"nctId":282,"briefTitle":283,"status":114,"phases":4202,"primaryCompletion":285,"start":286,"enrollment":287,"conditions":4203,"interventions":4204},[91],[289],[291,292,293,294,295,296,297],{"trials":4206,"activeCount":102},[],{"trials":4208,"activeCount":102},[],{"trials":4210,"activeCount":102},[],{"intervention":297,"totalTrials":142,"cells":4212},{"EARLY_PHASE1":4213,"PHASE1":4215,"PHASE2":4217,"PHASE3":4223,"PHASE4":4225,"NA":4227},{"trials":4214,"activeCount":102},[],{"trials":4216,"activeCount":102},[],{"trials":4218,"activeCount":102},[4219],{"nctId":282,"briefTitle":283,"status":114,"phases":4220,"primaryCompletion":285,"start":286,"enrollment":287,"conditions":4221,"interventions":4222},[91],[289],[291,292,293,294,295,296,297],{"trials":4224,"activeCount":102},[],{"trials":4226,"activeCount":102},[],{"trials":4228,"activeCount":102},[],{"intervention":3777,"totalTrials":142,"cells":4230},{"EARLY_PHASE1":4231,"PHASE1":4233,"PHASE2":4235,"PHASE3":4241,"PHASE4":4243,"NA":4245},{"trials":4232,"activeCount":102},[],{"trials":4234,"activeCount":102},[],{"trials":4236,"activeCount":102},[4237],{"nctId":3769,"briefTitle":3770,"status":114,"phases":4238,"primaryCompletion":389,"completion":389,"start":3772,"enrollment":573,"conditions":4239,"interventions":4240},[91],[3774,3775],[3777,3760,3778],{"trials":4242,"activeCount":102},[],{"trials":4244,"activeCount":102},[],{"trials":4246,"activeCount":102},[],{"intervention":3778,"totalTrials":142,"cells":4248},{"EARLY_PHASE1":4249,"PHASE1":4251,"PHASE2":4253,"PHASE3":4259,"PHASE4":4261,"NA":4263},{"trials":4250,"activeCount":102},[],{"trials":4252,"activeCount":102},[],{"trials":4254,"activeCount":102},[4255],{"nctId":3769,"briefTitle":3770,"status":114,"phases":4256,"primaryCompletion":389,"completion":389,"start":3772,"enrollment":573,"conditions":4257,"interventions":4258},[91],[3774,3775],[3777,3760,3778],{"trials":4260,"activeCount":102},[],{"trials":4262,"activeCount":102},[],{"trials":4264,"activeCount":102},[],{"intervention":3504,"totalTrials":142,"cells":4266},{"EARLY_PHASE1":4267,"PHASE1":4269,"PHASE2":4271,"PHASE3":4277,"PHASE4":4279,"NA":4281},{"trials":4268,"activeCount":102},[],{"trials":4270,"activeCount":102},[],{"trials":4272,"activeCount":102},[4273],{"nctId":3497,"briefTitle":3498,"status":114,"phases":4274,"primaryCompletion":3500,"start":3501,"enrollment":23,"conditions":4275,"interventions":4276},[91],[339],[577,3504],{"trials":4278,"activeCount":102},[],{"trials":4280,"activeCount":102},[],{"trials":4282,"activeCount":102},[],{"intervention":4284,"totalTrials":142,"cells":4285},"Qutenza",{"EARLY_PHASE1":4286,"PHASE1":4288,"PHASE2":4290,"PHASE3":4300,"PHASE4":4302,"NA":4304},{"trials":4287,"activeCount":102},[],{"trials":4289,"activeCount":102},[],{"trials":4291,"activeCount":102},[4292],{"nctId":4293,"briefTitle":4294,"status":114,"phases":4295,"primaryCompletion":3996,"completion":2498,"start":1617,"enrollment":3900,"conditions":4296,"interventions":4299},"NCT01260454","The Qutenza Patch as Treatment for Disabling Treprostinil (Remodulin) Infusion Site Pain",[91],[4297,4298],"Pulmonary Hypertension","Pulmonary Arterial Hypertension",[4284],{"trials":4301,"activeCount":102},[],{"trials":4303,"activeCount":102},[],{"trials":4305,"activeCount":102},[],{"intervention":3544,"totalTrials":142,"cells":4307},{"EARLY_PHASE1":4308,"PHASE1":4310,"PHASE2":4312,"PHASE3":4318,"PHASE4":4320,"NA":4322},{"trials":4309,"activeCount":102},[],{"trials":4311,"activeCount":102},[],{"trials":4313,"activeCount":102},[4314],{"nctId":3536,"briefTitle":3537,"status":2362,"phases":4315,"primaryCompletion":77,"completion":300,"start":3539,"enrollment":102,"conditions":4316,"interventions":4317},[91],[3541],[3543,3544,3545,3546,3547],{"trials":4319,"activeCount":102},[],{"trials":4321,"activeCount":102},[],{"trials":4323,"activeCount":102},[],{"intervention":3545,"totalTrials":142,"cells":4325},{"EARLY_PHASE1":4326,"PHASE1":4328,"PHASE2":4330,"PHASE3":4336,"PHASE4":4338,"NA":4340},{"trials":4327,"activeCount":102},[],{"trials":4329,"activeCount":102},[],{"trials":4331,"activeCount":102},[4332],{"nctId":3536,"briefTitle":3537,"status":2362,"phases":4333,"primaryCompletion":77,"completion":300,"start":3539,"enrollment":102,"conditions":4334,"interventions":4335},[91],[3541],[3543,3544,3545,3546,3547],{"trials":4337,"activeCount":102},[],{"trials":4339,"activeCount":102},[],{"trials":4341,"activeCount":102},[],{"intervention":3546,"totalTrials":142,"cells":4343},{"EARLY_PHASE1":4344,"PHASE1":4346,"PHASE2":4348,"PHASE3":4354,"PHASE4":4356,"NA":4358},{"trials":4345,"activeCount":102},[],{"trials":4347,"activeCount":102},[],{"trials":4349,"activeCount":102},[4350],{"nctId":3536,"briefTitle":3537,"status":2362,"phases":4351,"primaryCompletion":77,"completion":300,"start":3539,"enrollment":102,"conditions":4352,"interventions":4353},[91],[3541],[3543,3544,3545,3546,3547],{"trials":4355,"activeCount":102},[],{"trials":4357,"activeCount":102},[],{"trials":4359,"activeCount":102},[],{"intervention":3547,"totalTrials":142,"cells":4361},{"EARLY_PHASE1":4362,"PHASE1":4364,"PHASE2":4366,"PHASE3":4372,"PHASE4":4374,"NA":4376},{"trials":4363,"activeCount":102},[],{"trials":4365,"activeCount":102},[],{"trials":4367,"activeCount":102},[4368],{"nctId":3536,"briefTitle":3537,"status":2362,"phases":4369,"primaryCompletion":77,"completion":300,"start":3539,"enrollment":102,"conditions":4370,"interventions":4371},[91],[3541],[3543,3544,3545,3546,3547],{"trials":4373,"activeCount":102},[],{"trials":4375,"activeCount":102},[],{"trials":4377,"activeCount":102},[],{"intervention":4379,"totalTrials":142,"cells":4380},"Flecainide Pill",{"EARLY_PHASE1":4381,"PHASE1":4383,"PHASE2":4385,"PHASE3":4396,"PHASE4":4398,"NA":4400},{"trials":4382,"activeCount":102},[],{"trials":4384,"activeCount":102},[],{"trials":4386,"activeCount":102},[4387],{"nctId":4388,"briefTitle":4389,"status":114,"phases":4390,"primaryCompletion":4391,"completion":4391,"start":4392,"enrollment":17,"conditions":4393,"interventions":4395},"NCT03685149","Pilot Randomized Trial With Flecainide in ARVC Patients",[91],"2022-07-31","2019-07-23",[4394],"Arrhythmogenic Right Ventricular Cardiomyopathy",[4379],{"trials":4397,"activeCount":102},[],{"trials":4399,"activeCount":102},[],{"trials":4401,"activeCount":102},[],{"intervention":4403,"totalTrials":142,"cells":4404},"Regorafenib",{"EARLY_PHASE1":4405,"PHASE1":4407,"PHASE2":4409,"PHASE3":4421,"PHASE4":4423,"NA":4425},{"trials":4406,"activeCount":102},[],{"trials":4408,"activeCount":102},[],{"trials":4410,"activeCount":102},[4411],{"nctId":4412,"briefTitle":4413,"status":114,"phases":4414,"primaryCompletion":4415,"completion":4416,"start":4417,"enrollment":3472,"conditions":4418,"interventions":4420},"NCT02466009","Regorafenib in Metastatic Colorectal Cancer",[91],"2019-07","2022-03-09","2015-03",[4419],"Metastatic Colorectal Cancer",[4403],{"trials":4422,"activeCount":102},[],{"trials":4424,"activeCount":102},[],{"trials":4426,"activeCount":102},[],{"intervention":4428,"totalTrials":142,"cells":4429},"4-aminopyridine",{"EARLY_PHASE1":4430,"PHASE1":4432,"PHASE2":4434,"PHASE3":4444,"PHASE4":4446,"NA":4448},{"trials":4431,"activeCount":102},[],{"trials":4433,"activeCount":102},[],{"trials":4435,"activeCount":102},[4436],{"nctId":4437,"briefTitle":4438,"status":2362,"phases":4439,"primaryCompletion":3285,"completion":3285,"start":4440,"enrollment":102,"conditions":4441,"interventions":4443},"NCT03658408","4-aminopyridine Treatment for Nerve Injury From Radical Retro-Pubic Prostatectomy",[91],"2018-10-03",[4442],"Prostate Disease",[4428],{"trials":4445,"activeCount":102},[],{"trials":4447,"activeCount":102},[],{"trials":4449,"activeCount":102},[],{"intervention":4451,"totalTrials":142,"cells":4452},"Paclitaxel",{"EARLY_PHASE1":4453,"PHASE1":4455,"PHASE2":4457,"PHASE3":4466,"PHASE4":4468,"NA":4470},{"trials":4454,"activeCount":102},[],{"trials":4456,"activeCount":102},[],{"trials":4458,"activeCount":102},[4459],{"nctId":4460,"briefTitle":4461,"status":114,"phases":4462,"primaryCompletion":2170,"completion":2170,"start":4463,"enrollment":2675,"conditions":4464,"interventions":4465},"NCT00178256","Pulsed Paclitaxel And Daily Thoracic Radiotherapy For Inoperable (Stage I\u002FII) Or Unresectable Lung Cancer",[90,91],"1998-06",[3554],[4451],{"trials":4467,"activeCount":102},[],{"trials":4469,"activeCount":102},[],{"trials":4471,"activeCount":102},[],{"intervention":4473,"totalTrials":142,"cells":4474},"Buspirone",{"EARLY_PHASE1":4475,"PHASE1":4477,"PHASE2":4479,"PHASE3":4490,"PHASE4":4492,"NA":4494},{"trials":4476,"activeCount":102},[],{"trials":4478,"activeCount":102},[],{"trials":4480,"activeCount":102},[4481],{"nctId":4482,"briefTitle":4483,"status":114,"phases":4484,"primaryCompletion":4485,"completion":4486,"start":4487,"enrollment":412,"conditions":4488,"interventions":4489},"NCT02803749","Buspirone in Parkinson's Disease",[91],"2019-01","2019-01-25","2016-10",[25,180],[4473],{"trials":4491,"activeCount":102},[],{"trials":4493,"activeCount":102},[],{"trials":4495,"activeCount":102},[],{"intervention":4497,"totalTrials":142,"cells":4498},"armodafinil",{"EARLY_PHASE1":4499,"PHASE1":4501,"PHASE2":4503,"PHASE3":4512,"PHASE4":4514,"NA":4516},{"trials":4500,"activeCount":102},[],{"trials":4502,"activeCount":102},[],{"trials":4504,"activeCount":102},[4505],{"nctId":4506,"briefTitle":4507,"status":114,"phases":4508,"primaryCompletion":3165,"completion":3165,"start":1769,"enrollment":4509,"conditions":4510,"interventions":4511},"NCT01091974","Cognitive Behavioral Therapy +\u002F- Armodafinil for Insomnia and Fatigue Following Chemotherapy",[91],138,[31,1035,36],[4497],{"trials":4513,"activeCount":102},[],{"trials":4515,"activeCount":102},[],{"trials":4517,"activeCount":102},[],{"intervention":3476,"totalTrials":142,"cells":4519},{"EARLY_PHASE1":4520,"PHASE1":4522,"PHASE2":4524,"PHASE3":4530,"PHASE4":4532,"NA":4534},{"trials":4521,"activeCount":102},[],{"trials":4523,"activeCount":102},[],{"trials":4525,"activeCount":102},[4526],{"nctId":3467,"briefTitle":3468,"status":114,"phases":4527,"primaryCompletion":3470,"completion":3470,"start":3471,"enrollment":3472,"conditions":4528,"interventions":4529},[90,91],[3474],[3437,3476,3477],{"trials":4531,"activeCount":102},[],{"trials":4533,"activeCount":102},[],{"trials":4535,"activeCount":102},[],{"intervention":3477,"totalTrials":142,"cells":4537},{"EARLY_PHASE1":4538,"PHASE1":4540,"PHASE2":4542,"PHASE3":4548,"PHASE4":4550,"NA":4552},{"trials":4539,"activeCount":102},[],{"trials":4541,"activeCount":102},[],{"trials":4543,"activeCount":102},[4544],{"nctId":3467,"briefTitle":3468,"status":114,"phases":4545,"primaryCompletion":3470,"completion":3470,"start":3471,"enrollment":3472,"conditions":4546,"interventions":4547},[90,91],[3474],[3437,3476,3477],{"trials":4549,"activeCount":102},[],{"trials":4551,"activeCount":102},[],{"trials":4553,"activeCount":102},[],{"intervention":4555,"totalTrials":142,"cells":4556},"Denosumab",{"EARLY_PHASE1":4557,"PHASE1":4559,"PHASE2":4561,"PHASE3":4572,"PHASE4":4574,"NA":4576},{"trials":4558,"activeCount":102},[],{"trials":4560,"activeCount":102},[],{"trials":4562,"activeCount":102},[4563],{"nctId":4564,"briefTitle":4565,"status":114,"phases":4566,"primaryCompletion":4567,"completion":4568,"start":4569,"enrollment":20,"conditions":4570,"interventions":4571},"NCT03839459","Denosumab for Smoldering Multiple Myeloma",[91],"2022-09-16","2025-01-30","2019-04-19",[1011],[4555],{"trials":4573,"activeCount":102},[],{"trials":4575,"activeCount":102},[],{"trials":4577,"activeCount":102},[],{"intervention":2871,"totalTrials":142,"cells":4579},{"EARLY_PHASE1":4580,"PHASE1":4582,"PHASE2":4584,"PHASE3":4590,"PHASE4":4592,"NA":4594},{"trials":4581,"activeCount":102},[],{"trials":4583,"activeCount":102},[],{"trials":4585,"activeCount":102},[4586],{"nctId":2861,"briefTitle":2862,"status":114,"phases":4587,"primaryCompletion":2864,"completion":2865,"start":2866,"enrollment":2867,"conditions":4588,"interventions":4589},[91],[2869],[2871,2852],{"trials":4591,"activeCount":102},[],{"trials":4593,"activeCount":102},[],{"trials":4595,"activeCount":102},[],{"intervention":4597,"totalTrials":142,"cells":4598},"2009 H1N1 Virus Vaccine",{"EARLY_PHASE1":4599,"PHASE1":4601,"PHASE2":4603,"PHASE3":4612,"PHASE4":4614,"NA":4616},{"trials":4600,"activeCount":102},[],{"trials":4602,"activeCount":102},[],{"trials":4604,"activeCount":102},[4605],{"nctId":4606,"briefTitle":4607,"status":114,"phases":4608,"primaryCompletion":3166,"start":162,"enrollment":1689,"conditions":4609,"interventions":4611},"NCT01055184","Effects of Age on Response to the 2009 H1N1 Virus Vaccine",[90,91],[4610],"2009 H1N1 Influenza Virus",[4597],{"trials":4613,"activeCount":102},[],{"trials":4615,"activeCount":102},[],{"trials":4617,"activeCount":102},[],{"intervention":4619,"totalTrials":142,"cells":4620},"Pentostatin; Cyclophosphamide; Rituximab",{"EARLY_PHASE1":4621,"PHASE1":4623,"PHASE2":4625,"PHASE3":4635,"PHASE4":4637,"NA":4639},{"trials":4622,"activeCount":102},[],{"trials":4624,"activeCount":102},[],{"trials":4626,"activeCount":102},[4627],{"nctId":4628,"briefTitle":4629,"status":2362,"phases":4630,"primaryCompletion":3310,"completion":3310,"start":4631,"enrollment":102,"conditions":4632,"interventions":4634},"NCT01001780","Pentostatin, Cyclophosphamide Plus Rituximab (PCR) for the Therapy of Poor-Prognosis Chronic Graft-Versus-Host Disease",[91],"2009-08",[4633],"Active Chronic Graft Versus Host Disease",[4619],{"trials":4636,"activeCount":102},[],{"trials":4638,"activeCount":102},[],{"trials":4640,"activeCount":102},[],{"intervention":4642,"totalTrials":142,"cells":4643},"nesiritide",{"EARLY_PHASE1":4644,"PHASE1":4646,"PHASE2":4648,"PHASE3":4657,"PHASE4":4659,"NA":4661},{"trials":4645,"activeCount":102},[],{"trials":4647,"activeCount":102},[],{"trials":4649,"activeCount":102},[4650],{"nctId":4651,"briefTitle":4652,"status":114,"phases":4653,"primaryCompletion":4654,"completion":4654,"start":3364,"enrollment":20,"conditions":4655,"interventions":4656},"NCT00240084","Nesiritide and Vo2 Max in Heart Failure Patients",[91],"2005-11",[34],[4642],{"trials":4658,"activeCount":102},[],{"trials":4660,"activeCount":102},[],{"trials":4662,"activeCount":102},[],{"intervention":4664,"totalTrials":142,"cells":4665},"LEVETIRACETAM",{"EARLY_PHASE1":4666,"PHASE1":4668,"PHASE2":4670,"PHASE3":4682,"PHASE4":4684,"NA":4686},{"trials":4667,"activeCount":102},[],{"trials":4669,"activeCount":102},[],{"trials":4671,"activeCount":102},[4672],{"nctId":4673,"briefTitle":4674,"status":114,"phases":4675,"primaryCompletion":4676,"completion":4676,"start":389,"enrollment":2716,"conditions":4677,"interventions":4681},"NCT01660672","Enteral Levetiracetam For Seizure Control In Pediatric Cerebral Malaria",[90,91],"2013-07",[4678,4679,4680],"Seizure","Epilepsy","Cerebral Malaria",[4664],{"trials":4683,"activeCount":102},[],{"trials":4685,"activeCount":102},[],{"trials":4687,"activeCount":102},[],{"intervention":4689,"totalTrials":142,"cells":4690},"Chlorthalidone",{"EARLY_PHASE1":4691,"PHASE1":4693,"PHASE2":4695,"PHASE3":4707,"PHASE4":4709,"NA":4711},{"trials":4692,"activeCount":102},[],{"trials":4694,"activeCount":102},[],{"trials":4696,"activeCount":102},[4697],{"nctId":4698,"briefTitle":4699,"status":329,"phases":4700,"primaryCompletion":4701,"completion":4701,"start":4702,"enrollment":142,"conditions":4703,"interventions":4706},"NCT03325114","Safety and Efficacy of Chlorthalidone in Type 1 Diabetes",[91],"2020-06-01","2019-06-28",[4704,4705],"Type 1 Diabetes Mellitus","Hypercalciuria",[4689],{"trials":4708,"activeCount":102},[],{"trials":4710,"activeCount":102},[],{"trials":4712,"activeCount":102},[],{"intervention":599,"totalTrials":142,"cells":4714},{"EARLY_PHASE1":4715,"PHASE1":4717,"PHASE2":4719,"PHASE3":4725,"PHASE4":4727,"NA":4729},{"trials":4716,"activeCount":102},[],{"trials":4718,"activeCount":102},[],{"trials":4720,"activeCount":102},[4721],{"nctId":591,"briefTitle":592,"status":114,"phases":4722,"primaryCompletion":594,"completion":594,"start":595,"enrollment":596,"conditions":4723,"interventions":4724},[90,91],[339],[599,557],{"trials":4726,"activeCount":102},[],{"trials":4728,"activeCount":102},[],{"trials":4730,"activeCount":102},[],{"intervention":3787,"totalTrials":142,"cells":4732},{"EARLY_PHASE1":4733,"PHASE1":4735,"PHASE2":4737,"PHASE3":4743,"PHASE4":4745,"NA":4747},{"trials":4734,"activeCount":102},[],{"trials":4736,"activeCount":102},[],{"trials":4738,"activeCount":102},[4739],{"nctId":3780,"briefTitle":3781,"status":114,"phases":4740,"primaryCompletion":2217,"completion":2217,"start":3783,"enrollment":435,"conditions":4741,"interventions":4742},[91],[3785],[3787,3788,3789,3760],{"trials":4744,"activeCount":102},[],{"trials":4746,"activeCount":102},[],{"trials":4748,"activeCount":102},[],{"intervention":3788,"totalTrials":142,"cells":4750},{"EARLY_PHASE1":4751,"PHASE1":4753,"PHASE2":4755,"PHASE3":4761,"PHASE4":4763,"NA":4765},{"trials":4752,"activeCount":102},[],{"trials":4754,"activeCount":102},[],{"trials":4756,"activeCount":102},[4757],{"nctId":3780,"briefTitle":3781,"status":114,"phases":4758,"primaryCompletion":2217,"completion":2217,"start":3783,"enrollment":435,"conditions":4759,"interventions":4760},[91],[3785],[3787,3788,3789,3760],{"trials":4762,"activeCount":102},[],{"trials":4764,"activeCount":102},[],{"trials":4766,"activeCount":102},[],{"intervention":3789,"totalTrials":142,"cells":4768},{"EARLY_PHASE1":4769,"PHASE1":4771,"PHASE2":4773,"PHASE3":4779,"PHASE4":4781,"NA":4783},{"trials":4770,"activeCount":102},[],{"trials":4772,"activeCount":102},[],{"trials":4774,"activeCount":102},[4775],{"nctId":3780,"briefTitle":3781,"status":114,"phases":4776,"primaryCompletion":2217,"completion":2217,"start":3783,"enrollment":435,"conditions":4777,"interventions":4778},[91],[3785],[3787,3788,3789,3760],{"trials":4780,"activeCount":102},[],{"trials":4782,"activeCount":102},[],{"trials":4784,"activeCount":102},[],{"intervention":4786,"totalTrials":142,"cells":4787},"SomatoKine\u002FIPLEX",{"EARLY_PHASE1":4788,"PHASE1":4790,"PHASE2":4792,"PHASE3":4801,"PHASE4":4803,"NA":4805},{"trials":4789,"activeCount":102},[],{"trials":4791,"activeCount":102},[],{"trials":4793,"activeCount":102},[4794],{"nctId":4795,"briefTitle":4796,"status":114,"phases":4797,"primaryCompletion":3500,"completion":3500,"start":4654,"enrollment":4798,"conditions":4799,"interventions":4800},"NCT00233519","Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1\u002FRecombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I\u002FrhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1)",[90,91],17,[3580],[4786],{"trials":4802,"activeCount":102},[],{"trials":4804,"activeCount":102},[],{"trials":4806,"activeCount":102},[],{"intervention":4808,"totalTrials":142,"cells":4809},"Oral Levetiracetam",{"EARLY_PHASE1":4810,"PHASE1":4812,"PHASE2":4814,"PHASE3":4824,"PHASE4":4826,"NA":4828},{"trials":4811,"activeCount":102},[],{"trials":4813,"activeCount":102},[],{"trials":4815,"activeCount":102},[4816],{"nctId":4817,"briefTitle":4818,"status":114,"phases":4819,"primaryCompletion":350,"completion":350,"start":4820,"enrollment":119,"conditions":4821,"interventions":4822},"NCT01982812","A Safety and Feasibility Study of Enteral LVT vs. Standard of Care for Seizure Control in Pediatric CM",[91],"2014-01",[4678,4679,4680],[4808,4823],"Standard AED",{"trials":4825,"activeCount":102},[],{"trials":4827,"activeCount":102},[],{"trials":4829,"activeCount":102},[],{"intervention":4823,"totalTrials":142,"cells":4831},{"EARLY_PHASE1":4832,"PHASE1":4834,"PHASE2":4836,"PHASE3":4842,"PHASE4":4844,"NA":4846},{"trials":4833,"activeCount":102},[],{"trials":4835,"activeCount":102},[],{"trials":4837,"activeCount":102},[4838],{"nctId":4817,"briefTitle":4818,"status":114,"phases":4839,"primaryCompletion":350,"completion":350,"start":4820,"enrollment":119,"conditions":4840,"interventions":4841},[91],[4678,4679,4680],[4808,4823],{"trials":4843,"activeCount":102},[],{"trials":4845,"activeCount":102},[],{"trials":4847,"activeCount":102},[],{"intervention":4849,"totalTrials":142,"cells":4850},"Liquid Placebo",{"EARLY_PHASE1":4851,"PHASE1":4853,"PHASE2":4855,"PHASE3":4866,"PHASE4":4868,"NA":4870},{"trials":4852,"activeCount":102},[],{"trials":4854,"activeCount":102},[],{"trials":4856,"activeCount":102},[4857],{"nctId":4858,"briefTitle":4859,"status":114,"phases":4860,"primaryCompletion":2714,"completion":2714,"start":4861,"enrollment":2522,"conditions":4862,"interventions":4864},"NCT01399047","Cellcept for Treatment of Juvenile Neuronal Ceroid Lipofuscinosis",[91],"2011-07",[4863],"Juvenile Neuronal Ceroid Lipofuscinosis",[4865,4849],"Mycophenolate mofetil",{"trials":4867,"activeCount":102},[],{"trials":4869,"activeCount":102},[],{"trials":4871,"activeCount":102},[],{"intervention":4873,"totalTrials":142,"cells":4874},"Curcumin plus Piperine",{"EARLY_PHASE1":4875,"PHASE1":4877,"PHASE2":4879,"PHASE3":4891,"PHASE4":4893,"NA":4895},{"trials":4876,"activeCount":102},[],{"trials":4878,"activeCount":102},[],{"trials":4880,"activeCount":102},[4881],{"nctId":4882,"briefTitle":4883,"status":114,"phases":4884,"primaryCompletion":4885,"completion":4885,"start":4886,"enrollment":351,"conditions":4887,"interventions":4890},"NCT04731844","Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer",[91],"2024-09-19","2021-12-14",[1398,340,4888,4889],"Smoldering Multiple Myeloma (SMM)","Monoclonal Gammopathy of Undetermined Significance",[4873],{"trials":4892,"activeCount":102},[],{"trials":4894,"activeCount":102},[],{"trials":4896,"activeCount":102},[],{"intervention":4898,"totalTrials":142,"cells":4899},"Imexon",{"EARLY_PHASE1":4900,"PHASE1":4902,"PHASE2":4904,"PHASE3":4919,"PHASE4":4921,"NA":4923},{"trials":4901,"activeCount":102},[],{"trials":4903,"activeCount":102},[],{"trials":4905,"activeCount":102},[4906],{"nctId":4907,"briefTitle":4908,"status":114,"phases":4909,"primaryCompletion":331,"completion":4910,"start":2827,"enrollment":17,"conditions":4911,"interventions":4918},"NCT01314014","Imexon for Relapsed Follicular and Aggressive Lymphomas",[91],"2014-08",[4912,2724,4913,4914,4915,4916,4917],"Follicular Lymphoma","Marginal Zone Lymphoma","Lymphoplasmacytic Lymphoma","Diffuse Large B Cell Lymphoma","Mantle Cell Lymphoma","Burkitt's Lymphoma",[4898],{"trials":4920,"activeCount":102},[],{"trials":4922,"activeCount":102},[],{"trials":4924,"activeCount":102},[],{"intervention":4926,"totalTrials":142,"cells":4927},"Paclitaxel Protein-Bound, and CARBOPLATIN",{"EARLY_PHASE1":4928,"PHASE1":4930,"PHASE2":4932,"PHASE3":4941,"PHASE4":4943,"NA":4945},{"trials":4929,"activeCount":102},[],{"trials":4931,"activeCount":102},[],{"trials":4933,"activeCount":102},[4934],{"nctId":4935,"briefTitle":4936,"status":2362,"phases":4937,"primaryCompletion":2320,"start":164,"enrollment":102,"conditions":4938,"interventions":4940},"NCT00903942","Abraxane and RT for Non-Small Cell Lung Cancer (NSCLC)",[91],[4939],"Non-small Cell Lung Cancer, Stage III",[4926],{"trials":4942,"activeCount":102},[],{"trials":4944,"activeCount":102},[],{"trials":4946,"activeCount":102},[],{"intervention":4948,"totalTrials":142,"cells":4949},"Nystatin",{"EARLY_PHASE1":4950,"PHASE1":4952,"PHASE2":4963,"PHASE3":4965,"PHASE4":4967,"NA":4969},{"trials":4951,"activeCount":102},[],{"trials":4953,"activeCount":102},[4954],{"nctId":4955,"briefTitle":4956,"status":114,"phases":4957,"primaryCompletion":4958,"completion":4958,"start":4959,"enrollment":20,"conditions":4960,"interventions":4962},"NCT04550546","Effects of Nystatin Suspension Oral Application on Oral Microbial Community",[90],"2022-02-28","2021-05-15",[4961],"Dental Caries",[4948],{"trials":4964,"activeCount":102},[],{"trials":4966,"activeCount":102},[],{"trials":4968,"activeCount":102},[],{"trials":4970,"activeCount":102},[],{"intervention":4972,"totalTrials":142,"cells":4973},"Temozolomide, Tamoxifen, Maprotiline",{"EARLY_PHASE1":4974,"PHASE1":4976,"PHASE2":4985,"PHASE3":4987,"PHASE4":4989,"NA":4991},{"trials":4975,"activeCount":102},[],{"trials":4977,"activeCount":102},[4978],{"nctId":4979,"briefTitle":4980,"status":2362,"phases":4981,"primaryCompletion":4982,"completion":2364,"start":42,"enrollment":102,"conditions":4983,"interventions":4984},"NCT04200066","A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma",[90],"2023-10-01",[1723,1464],[4972],{"trials":4986,"activeCount":102},[],{"trials":4988,"activeCount":102},[],{"trials":4990,"activeCount":102},[],{"trials":4992,"activeCount":102},[],{"intervention":4994,"totalTrials":142,"cells":4995},"Tetrathiomolybdate",{"EARLY_PHASE1":4996,"PHASE1":4998,"PHASE2":5009,"PHASE3":5011,"PHASE4":5013,"NA":5015},{"trials":4997,"activeCount":102},[],{"trials":4999,"activeCount":102},[5000],{"nctId":5001,"briefTitle":5002,"status":114,"phases":5003,"primaryCompletion":5004,"completion":5004,"start":2838,"enrollment":5005,"conditions":5006,"interventions":5008},"NCT01837329","Phase I Study of Tetrathiomolybdate in Combination With Carboplatin\u002FPemetrexed in Metastatic Non-small Cell Lung Cancer",[90],"2019-01-11",26,[5007],"Non-Small Cell Lung Cancer",[4994],{"trials":5010,"activeCount":102},[],{"trials":5012,"activeCount":102},[],{"trials":5014,"activeCount":102},[],{"trials":5016,"activeCount":102},[],{"intervention":5018,"totalTrials":142,"cells":5019},"Linoleic Acid\u002FOleic Acid",{"EARLY_PHASE1":5020,"PHASE1":5022,"PHASE2":5030,"PHASE3":5032,"PHASE4":5034,"NA":5036},{"trials":5021,"activeCount":102},[],{"trials":5023,"activeCount":102},[5024],{"nctId":5025,"briefTitle":5026,"status":329,"phases":5027,"primaryCompletion":2794,"completion":2794,"start":164,"enrollment":37,"conditions":5028,"interventions":5029},"NCT00638196","Placebo vs. Linoleic Acid Controlled Assessment of Treatment Efficacy in MS",[90],[1736],[5018],{"trials":5031,"activeCount":102},[],{"trials":5033,"activeCount":102},[],{"trials":5035,"activeCount":102},[],{"trials":5037,"activeCount":102},[],{"intervention":3714,"totalTrials":142,"cells":5039},{"EARLY_PHASE1":5040,"PHASE1":5042,"PHASE2":5048,"PHASE3":5050,"PHASE4":5052,"NA":5054},{"trials":5041,"activeCount":102},[],{"trials":5043,"activeCount":102},[5044],{"nctId":3706,"briefTitle":3707,"status":114,"phases":5045,"primaryCompletion":3166,"completion":3166,"start":3709,"enrollment":23,"conditions":5046,"interventions":5047},[90],[3711,3712],[291,3714],{"trials":5049,"activeCount":102},[],{"trials":5051,"activeCount":102},[],{"trials":5053,"activeCount":102},[],{"trials":5055,"activeCount":102},[],{"intervention":3742,"totalTrials":142,"cells":5057},{"EARLY_PHASE1":5058,"PHASE1":5060,"PHASE2":5066,"PHASE3":5068,"PHASE4":5070,"NA":5072},{"trials":5059,"activeCount":102},[],{"trials":5061,"activeCount":102},[5062],{"nctId":3735,"briefTitle":3736,"status":114,"phases":5063,"primaryCompletion":2794,"start":3738,"enrollment":26,"conditions":5064,"interventions":5065},[90],[3740],[3728,3742],{"trials":5067,"activeCount":102},[],{"trials":5069,"activeCount":102},[],{"trials":5071,"activeCount":102},[],{"trials":5073,"activeCount":102},[],{"intervention":1496,"totalTrials":142,"cells":5075},{"EARLY_PHASE1":5076,"PHASE1":5078,"PHASE2":5084,"PHASE3":5086,"PHASE4":5088,"NA":5090},{"trials":5077,"activeCount":102},[],{"trials":5079,"activeCount":102},[5080],{"nctId":1483,"briefTitle":1484,"status":114,"phases":5081,"primaryCompletion":1486,"completion":1487,"start":1488,"enrollment":1489,"conditions":5082,"interventions":5083},[90],[1491,1492,1493,1494,340,339],[363,1496,1497,362,364,1498,1499,1500],{"trials":5085,"activeCount":102},[],{"trials":5087,"activeCount":102},[],{"trials":5089,"activeCount":102},[],{"trials":5091,"activeCount":102},[],{"intervention":1497,"totalTrials":142,"cells":5093},{"EARLY_PHASE1":5094,"PHASE1":5096,"PHASE2":5102,"PHASE3":5104,"PHASE4":5106,"NA":5108},{"trials":5095,"activeCount":102},[],{"trials":5097,"activeCount":102},[5098],{"nctId":1483,"briefTitle":1484,"status":114,"phases":5099,"primaryCompletion":1486,"completion":1487,"start":1488,"enrollment":1489,"conditions":5100,"interventions":5101},[90],[1491,1492,1493,1494,340,339],[363,1496,1497,362,364,1498,1499,1500],{"trials":5103,"activeCount":102},[],{"trials":5105,"activeCount":102},[],{"trials":5107,"activeCount":102},[],{"trials":5109,"activeCount":102},[],{"intervention":1498,"totalTrials":142,"cells":5111},{"EARLY_PHASE1":5112,"PHASE1":5114,"PHASE2":5120,"PHASE3":5122,"PHASE4":5124,"NA":5126},{"trials":5113,"activeCount":102},[],{"trials":5115,"activeCount":102},[5116],{"nctId":1483,"briefTitle":1484,"status":114,"phases":5117,"primaryCompletion":1486,"completion":1487,"start":1488,"enrollment":1489,"conditions":5118,"interventions":5119},[90],[1491,1492,1493,1494,340,339],[363,1496,1497,362,364,1498,1499,1500],{"trials":5121,"activeCount":102},[],{"trials":5123,"activeCount":102},[],{"trials":5125,"activeCount":102},[],{"trials":5127,"activeCount":102},[],{"intervention":1499,"totalTrials":142,"cells":5129},{"EARLY_PHASE1":5130,"PHASE1":5132,"PHASE2":5138,"PHASE3":5140,"PHASE4":5142,"NA":5144},{"trials":5131,"activeCount":102},[],{"trials":5133,"activeCount":102},[5134],{"nctId":1483,"briefTitle":1484,"status":114,"phases":5135,"primaryCompletion":1486,"completion":1487,"start":1488,"enrollment":1489,"conditions":5136,"interventions":5137},[90],[1491,1492,1493,1494,340,339],[363,1496,1497,362,364,1498,1499,1500],{"trials":5139,"activeCount":102},[],{"trials":5141,"activeCount":102},[],{"trials":5143,"activeCount":102},[],{"trials":5145,"activeCount":102},[],{"intervention":1500,"totalTrials":142,"cells":5147},{"EARLY_PHASE1":5148,"PHASE1":5150,"PHASE2":5156,"PHASE3":5158,"PHASE4":5160,"NA":5162},{"trials":5149,"activeCount":102},[],{"trials":5151,"activeCount":102},[5152],{"nctId":1483,"briefTitle":1484,"status":114,"phases":5153,"primaryCompletion":1486,"completion":1487,"start":1488,"enrollment":1489,"conditions":5154,"interventions":5155},[90],[1491,1492,1493,1494,340,339],[363,1496,1497,362,364,1498,1499,1500],{"trials":5157,"activeCount":102},[],{"trials":5159,"activeCount":102},[],{"trials":5161,"activeCount":102},[],{"trials":5163,"activeCount":102},[],{"intervention":5165,"totalTrials":142,"cells":5166},"OPC 14117",{"EARLY_PHASE1":5167,"PHASE1":5169,"PHASE2":5179,"PHASE3":5181,"PHASE4":5183,"NA":5185},{"trials":5168,"activeCount":102},[],{"trials":5170,"activeCount":102},[5171],{"nctId":5172,"briefTitle":5173,"status":114,"phases":5174,"enrollment":351,"conditions":5175,"interventions":5178},"NCT00002148","Parallel Group, Placebo-Controlled, Tolerability, Safety, and Efficacy Study of OPC-14117 in HIV Dementia",[90],[5176,5177],"Cognitive Disorders","HIV Infections",[5165],{"trials":5180,"activeCount":102},[],{"trials":5182,"activeCount":102},[],{"trials":5184,"activeCount":102},[],{"trials":5186,"activeCount":102},[],{"intervention":5188,"totalTrials":142,"cells":5189},"Drug: Carfilzomib",{"EARLY_PHASE1":5190,"PHASE1":5192,"PHASE2":5201,"PHASE3":5203,"PHASE4":5205,"NA":5207},{"trials":5191,"activeCount":102},[],{"trials":5193,"activeCount":102},[5194],{"nctId":5195,"briefTitle":5196,"status":114,"phases":5197,"primaryCompletion":4676,"completion":3072,"start":3310,"enrollment":20,"conditions":5198,"interventions":5199},"NCT01276717","Study of Carfilzomib and Vorinostat for Relapsed or Refractory Lymphoma",[90],[339],[5188,5200],"Vorinostat",{"trials":5202,"activeCount":102},[],{"trials":5204,"activeCount":102},[],{"trials":5206,"activeCount":102},[],{"trials":5208,"activeCount":102},[],{"intervention":5200,"totalTrials":142,"cells":5210},{"EARLY_PHASE1":5211,"PHASE1":5213,"PHASE2":5219,"PHASE3":5221,"PHASE4":5223,"NA":5225},{"trials":5212,"activeCount":102},[],{"trials":5214,"activeCount":102},[5215],{"nctId":5195,"briefTitle":5196,"status":114,"phases":5216,"primaryCompletion":4676,"completion":3072,"start":3310,"enrollment":20,"conditions":5217,"interventions":5218},[90],[339],[5188,5200],{"trials":5220,"activeCount":102},[],{"trials":5222,"activeCount":102},[],{"trials":5224,"activeCount":102},[],{"trials":5226,"activeCount":102},[],{"intervention":5228,"totalTrials":142,"cells":5229},"Remune",{"EARLY_PHASE1":5230,"PHASE1":5232,"PHASE2":5244,"PHASE3":5246,"PHASE4":5248,"NA":5250},{"trials":5231,"activeCount":102},[],{"trials":5233,"activeCount":102},[5234],{"nctId":5235,"briefTitle":5236,"status":114,"phases":5237,"primaryCompletion":1630,"completion":3675,"start":5238,"enrollment":822,"conditions":5239,"interventions":5243},"NCT04131426","Evaluating the Combined Intervention of Nutritional Supplementation (Remune) and Exercise in Patients With Cancer Cachexia",[90],"2020-04-24",[5240,5241,3690,5242],"Cachexia; Cancer","Weight Loss","Gastrointestinal Cancer",[5228],{"trials":5245,"activeCount":102},[],{"trials":5247,"activeCount":102},[],{"trials":5249,"activeCount":102},[],{"trials":5251,"activeCount":102},[],{"intervention":3681,"totalTrials":142,"cells":5253},{"EARLY_PHASE1":5254,"PHASE1":5256,"PHASE2":5262,"PHASE3":5264,"PHASE4":5266,"NA":5268},{"trials":5255,"activeCount":102},[],{"trials":5257,"activeCount":102},[5258],{"nctId":3672,"briefTitle":3673,"status":114,"phases":5259,"primaryCompletion":3675,"completion":3676,"start":3677,"enrollment":20,"conditions":5260,"interventions":5261},[90],[341,3679],[3681,3665],{"trials":5263,"activeCount":102},[],{"trials":5265,"activeCount":102},[],{"trials":5267,"activeCount":102},[],{"trials":5269,"activeCount":102},[],{"intervention":5271,"totalTrials":142,"cells":5272},"Antithrombin III",{"EARLY_PHASE1":5273,"PHASE1":5275,"PHASE2":5285,"PHASE3":5287,"PHASE4":5289,"NA":5291},{"trials":5274,"activeCount":102},[],{"trials":5276,"activeCount":102},[5277],{"nctId":5278,"briefTitle":5279,"status":329,"phases":5280,"primaryCompletion":2168,"completion":2168,"start":5281,"enrollment":3900,"conditions":5282,"interventions":5284},"NCT01698567","Antithrombin III in Infants With Cardiopulmonary Bypass (CPB)",[90],"2012-07",[5283],"Congenital Heart Disease",[5271],{"trials":5286,"activeCount":102},[],{"trials":5288,"activeCount":102},[],{"trials":5290,"activeCount":102},[],{"trials":5292,"activeCount":102},[],{"intervention":5294,"totalTrials":142,"cells":5295},"Acetazolamide",{"EARLY_PHASE1":5296,"PHASE1":5298,"PHASE2":5307,"PHASE3":5309,"PHASE4":5311,"NA":5313},{"trials":5297,"activeCount":102},[],{"trials":5299,"activeCount":102},[5300],{"nctId":5301,"briefTitle":5302,"status":329,"phases":5303,"primaryCompletion":3310,"completion":3310,"start":3459,"enrollment":366,"conditions":5304,"interventions":5306},"NCT00839501","Effect of Potassium and Acetazolamide on People With Andersen-Tawil Syndrome",[90],[5305],"Andersen-Tawil Syndrome",[5294],{"trials":5308,"activeCount":102},[],{"trials":5310,"activeCount":102},[],{"trials":5312,"activeCount":102},[],{"trials":5314,"activeCount":102},[],{"intervention":5316,"totalTrials":142,"cells":5317},"Testosterone Enanthate",{"EARLY_PHASE1":5318,"PHASE1":5320,"PHASE2":5332,"PHASE3":5334,"PHASE4":5336,"NA":5338},{"trials":5319,"activeCount":102},[],{"trials":5321,"activeCount":102},[5322],{"nctId":5323,"briefTitle":5324,"status":114,"phases":5325,"primaryCompletion":5326,"completion":5326,"start":5327,"enrollment":20,"conditions":5328,"interventions":5330},"NCT03123913","Study of Testosterone and rHGH in FSHD",[90],"2022-03-28","2017-12-18",[5329],"Facioscapulohumeral Muscular Dystrophy",[5316,5331],"Somatropin",{"trials":5333,"activeCount":102},[],{"trials":5335,"activeCount":102},[],{"trials":5337,"activeCount":102},[],{"trials":5339,"activeCount":102},[],{"intervention":5331,"totalTrials":142,"cells":5341},{"EARLY_PHASE1":5342,"PHASE1":5344,"PHASE2":5350,"PHASE3":5352,"PHASE4":5354,"NA":5356},{"trials":5343,"activeCount":102},[],{"trials":5345,"activeCount":102},[5346],{"nctId":5323,"briefTitle":5324,"status":114,"phases":5347,"primaryCompletion":5326,"completion":5326,"start":5327,"enrollment":20,"conditions":5348,"interventions":5349},[90],[5329],[5316,5331],{"trials":5351,"activeCount":102},[],{"trials":5353,"activeCount":102},[],{"trials":5355,"activeCount":102},[],{"trials":5357,"activeCount":102},[],{"intervention":5359,"totalTrials":142,"cells":5360},"recombinant interferon gamma",{"EARLY_PHASE1":5361,"PHASE1":5363,"PHASE2":5373,"PHASE3":5375,"PHASE4":5377,"NA":5379},{"trials":5362,"activeCount":102},[],{"trials":5364,"activeCount":102},[5365],{"nctId":5366,"briefTitle":5367,"status":114,"phases":5368,"start":5369,"conditions":5370,"interventions":5372},"NCT00004016","Interferon Gamma in Treating Patients With Recurrent or Metastatic Melanoma or Other Solid Tumors",[90],"1999-04",[5371,3316],"Melanoma (Skin)",[5359],{"trials":5374,"activeCount":102},[],{"trials":5376,"activeCount":102},[],{"trials":5378,"activeCount":102},[],{"trials":5380,"activeCount":102},[],{"intervention":5382,"totalTrials":142,"cells":5383},"Ustekinumab",{"EARLY_PHASE1":5384,"PHASE1":5386,"PHASE2":5397,"PHASE3":5399,"PHASE4":5401,"NA":5403},{"trials":5385,"activeCount":102},[],{"trials":5387,"activeCount":102},[5388],{"nctId":5389,"briefTitle":5390,"status":114,"phases":5391,"primaryCompletion":5392,"completion":5392,"start":5393,"enrollment":29,"conditions":5394,"interventions":5396},"NCT04093531","Pilot Trial of Ustekinumab for Primary Sjögren's Syndrome",[90],"2022-05-11","2020-01-15",[5395],"Primary Sjögren Syndrome",[5382],{"trials":5398,"activeCount":102},[],{"trials":5400,"activeCount":102},[],{"trials":5402,"activeCount":102},[],{"trials":5404,"activeCount":102},[],{"intervention":416,"totalTrials":142,"cells":5406},{"EARLY_PHASE1":5407,"PHASE1":5409,"PHASE2":5415,"PHASE3":5417,"PHASE4":5419,"NA":5421},{"trials":5408,"activeCount":102},[],{"trials":5410,"activeCount":102},[5411],{"nctId":407,"briefTitle":408,"status":114,"phases":5412,"primaryCompletion":410,"completion":410,"start":411,"enrollment":412,"conditions":5413,"interventions":5414},[90],[414],[400,416],{"trials":5416,"activeCount":102},[],{"trials":5418,"activeCount":102},[],{"trials":5420,"activeCount":102},[],{"trials":5422,"activeCount":102},[],{"intervention":5424,"totalTrials":142,"cells":5425},"Benadryl versus Placebo",{"EARLY_PHASE1":5426,"PHASE1":5428,"PHASE2":5441,"PHASE3":5443,"PHASE4":5445,"NA":5447},{"trials":5427,"activeCount":102},[],{"trials":5429,"activeCount":102},[5430],{"nctId":5431,"briefTitle":5432,"status":2362,"phases":5433,"completion":285,"start":2865,"enrollment":102,"conditions":5434,"interventions":5440},"NCT00240123","Effect of Benadryl Sedation During ERCP or EUS",[90],[5435,5436,5437,5438,5439],"Gallbladder Disease","Gallstones","Pancreatitis","Abdominal Pain","Jaundice",[5424],{"trials":5442,"activeCount":102},[],{"trials":5444,"activeCount":102},[],{"trials":5446,"activeCount":102},[],{"trials":5448,"activeCount":102},[],{"intervention":5450,"totalTrials":142,"cells":5451},"High blood pressure treatment",{"EARLY_PHASE1":5452,"PHASE1":5454,"PHASE2":5463,"PHASE3":5465,"PHASE4":5467,"NA":5469},{"trials":5453,"activeCount":102},[],{"trials":5455,"activeCount":102},[5456],{"nctId":5457,"briefTitle":5458,"status":114,"phases":5459,"primaryCompletion":570,"completion":3738,"start":1800,"enrollment":5460,"conditions":5461,"interventions":5462},"NCT00178490","Effect of High Blood Pressure and Antihypertensive Treatment on Brain Functioning in Children",[90],100,[121],[5450],{"trials":5464,"activeCount":102},[],{"trials":5466,"activeCount":102},[],{"trials":5468,"activeCount":102},[],{"trials":5470,"activeCount":102},[],{"intervention":5472,"totalTrials":142,"cells":5473},"filgrastim",{"EARLY_PHASE1":5474,"PHASE1":5476,"PHASE2":5488,"PHASE3":5490,"PHASE4":5492,"NA":5494},{"trials":5475,"activeCount":102},[],{"trials":5477,"activeCount":102},[5478],{"nctId":5479,"briefTitle":5480,"status":114,"phases":5481,"primaryCompletion":5482,"completion":5482,"start":1770,"enrollment":23,"conditions":5483,"interventions":5484},"NCT00258271","Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia",[90],"2006-10",[338],[5472,5485,5486,5487],"cladribine","cytarabine","imatinib mesylate",{"trials":5489,"activeCount":102},[],{"trials":5491,"activeCount":102},[],{"trials":5493,"activeCount":102},[],{"trials":5495,"activeCount":102},[],{"intervention":5485,"totalTrials":142,"cells":5497},{"EARLY_PHASE1":5498,"PHASE1":5500,"PHASE2":5506,"PHASE3":5508,"PHASE4":5510,"NA":5512},{"trials":5499,"activeCount":102},[],{"trials":5501,"activeCount":102},[5502],{"nctId":5479,"briefTitle":5480,"status":114,"phases":5503,"primaryCompletion":5482,"completion":5482,"start":1770,"enrollment":23,"conditions":5504,"interventions":5505},[90],[338],[5472,5485,5486,5487],{"trials":5507,"activeCount":102},[],{"trials":5509,"activeCount":102},[],{"trials":5511,"activeCount":102},[],{"trials":5513,"activeCount":102},[],{"intervention":5486,"totalTrials":142,"cells":5515},{"EARLY_PHASE1":5516,"PHASE1":5518,"PHASE2":5524,"PHASE3":5526,"PHASE4":5528,"NA":5530},{"trials":5517,"activeCount":102},[],{"trials":5519,"activeCount":102},[5520],{"nctId":5479,"briefTitle":5480,"status":114,"phases":5521,"primaryCompletion":5482,"completion":5482,"start":1770,"enrollment":23,"conditions":5522,"interventions":5523},[90],[338],[5472,5485,5486,5487],{"trials":5525,"activeCount":102},[],{"trials":5527,"activeCount":102},[],{"trials":5529,"activeCount":102},[],{"trials":5531,"activeCount":102},[],{"intervention":5487,"totalTrials":142,"cells":5533},{"EARLY_PHASE1":5534,"PHASE1":5536,"PHASE2":5542,"PHASE3":5544,"PHASE4":5546,"NA":5548},{"trials":5535,"activeCount":102},[],{"trials":5537,"activeCount":102},[5538],{"nctId":5479,"briefTitle":5480,"status":114,"phases":5539,"primaryCompletion":5482,"completion":5482,"start":1770,"enrollment":23,"conditions":5540,"interventions":5541},[90],[338],[5472,5485,5486,5487],{"trials":5543,"activeCount":102},[],{"trials":5545,"activeCount":102},[],{"trials":5547,"activeCount":102},[],{"trials":5549,"activeCount":102},[],{"intervention":5551,"totalTrials":142,"cells":5552},"EDTA Eye Drops",{"EARLY_PHASE1":5553,"PHASE1":5564,"PHASE2":5566,"PHASE3":5568,"PHASE4":5570,"NA":5572},{"trials":5554,"activeCount":102},[5555],{"nctId":5556,"briefTitle":5557,"status":114,"phases":5558,"primaryCompletion":5559,"completion":5559,"start":5560,"enrollment":366,"conditions":5561,"interventions":5563},"NCT03985371","A Pilot Study to Assess the Preliminary Efficacy of EDTA Eye Drops on Band Keratopathy",[89],"2021-09-30","2020-06-29",[5562],"Corneal Dystrophy, Band-Shaped",[5551],{"trials":5565,"activeCount":102},[],{"trials":5567,"activeCount":102},[],{"trials":5569,"activeCount":102},[],{"trials":5571,"activeCount":102},[],{"trials":5573,"activeCount":102},[],{"intervention":5575,"totalTrials":142,"cells":5576},"B & L Soothe Lubricant Eye Drops",{"EARLY_PHASE1":5577,"PHASE1":5589,"PHASE2":5591,"PHASE3":5593,"PHASE4":5595,"NA":5597},{"trials":5578,"activeCount":102},[5579],{"nctId":5580,"briefTitle":5581,"status":114,"phases":5582,"primaryCompletion":5583,"completion":5583,"start":3458,"enrollment":20,"conditions":5584,"interventions":5586},"NCT01375582","Objective Evaluation of Ocular Surface Lubricants in Two Environments",[89],"2012-06",[5585],"Dry Eye",[5575,5587,5588],"Liposic EDO","OcuFresh Eye Wash",{"trials":5590,"activeCount":102},[],{"trials":5592,"activeCount":102},[],{"trials":5594,"activeCount":102},[],{"trials":5596,"activeCount":102},[],{"trials":5598,"activeCount":102},[],{"intervention":5587,"totalTrials":142,"cells":5600},{"EARLY_PHASE1":5601,"PHASE1":5607,"PHASE2":5609,"PHASE3":5611,"PHASE4":5613,"NA":5615},{"trials":5602,"activeCount":102},[5603],{"nctId":5580,"briefTitle":5581,"status":114,"phases":5604,"primaryCompletion":5583,"completion":5583,"start":3458,"enrollment":20,"conditions":5605,"interventions":5606},[89],[5585],[5575,5587,5588],{"trials":5608,"activeCount":102},[],{"trials":5610,"activeCount":102},[],{"trials":5612,"activeCount":102},[],{"trials":5614,"activeCount":102},[],{"trials":5616,"activeCount":102},[],{"intervention":5588,"totalTrials":142,"cells":5618},{"EARLY_PHASE1":5619,"PHASE1":5625,"PHASE2":5627,"PHASE3":5629,"PHASE4":5631,"NA":5633},{"trials":5620,"activeCount":102},[5621],{"nctId":5580,"briefTitle":5581,"status":114,"phases":5622,"primaryCompletion":5583,"completion":5583,"start":3458,"enrollment":20,"conditions":5623,"interventions":5624},[89],[5585],[5575,5587,5588],{"trials":5626,"activeCount":102},[],{"trials":5628,"activeCount":102},[],{"trials":5630,"activeCount":102},[],{"trials":5632,"activeCount":102},[],{"trials":5634,"activeCount":102},[],{"intervention":5636,"totalTrials":142,"cells":5637},"Mannitol",{"EARLY_PHASE1":5638,"PHASE1":5650,"PHASE2":5652,"PHASE3":5654,"PHASE4":5656,"NA":5658},{"trials":5639,"activeCount":102},[5640],{"nctId":5641,"briefTitle":5642,"status":114,"phases":5643,"primaryCompletion":5644,"completion":5644,"start":1488,"enrollment":5460,"conditions":5645,"interventions":5649},"NCT02306473","The Leaky Lung Test",[89],"2017-12-01",[22,5646,5647,5648],"Allergy","Reactive Airway Disease","Lung Diseases, Obstructive",[5636],{"trials":5651,"activeCount":102},[],{"trials":5653,"activeCount":102},[],{"trials":5655,"activeCount":102},[],{"trials":5657,"activeCount":102},[],{"trials":5659,"activeCount":102},[],{"intervention":5661,"totalTrials":142,"cells":5662},"Shingrix vaccine",{"EARLY_PHASE1":5663,"PHASE1":5675,"PHASE2":5677,"PHASE3":5679,"PHASE4":5681,"NA":5683},{"trials":5664,"activeCount":102},[5665],{"nctId":5666,"briefTitle":5667,"status":114,"phases":5668,"primaryCompletion":5669,"completion":5670,"start":5671,"enrollment":3123,"conditions":5672,"interventions":5674},"NCT03771157","Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors",[89],"2020-09-01","2022-08-03","2019-02-01",[586,5673],"Waldenstrom Macroglobulinemia (WM)",[5661],{"trials":5676,"activeCount":102},[],{"trials":5678,"activeCount":102},[],{"trials":5680,"activeCount":102},[],{"trials":5682,"activeCount":102},[],{"trials":5684,"activeCount":102},[],{"intervention":5686,"totalTrials":142,"cells":5687},"Temozolomide",{"EARLY_PHASE1":5688,"PHASE1":5699,"PHASE2":5701,"PHASE3":5703,"PHASE4":5705,"NA":5707},{"trials":5689,"activeCount":102},[5690],{"nctId":5691,"briefTitle":5692,"status":2362,"phases":5693,"primaryCompletion":5694,"completion":5694,"start":5695,"enrollment":102,"conditions":5696,"interventions":5698},"NCT03796507","Early Temozolomide in Patients With High-Grade Gliomas in Rehabilitation",[89],"2021-12-15","2021-09-01",[5697],"Glioma of Brain",[5686],{"trials":5700,"activeCount":102},[],{"trials":5702,"activeCount":102},[],{"trials":5704,"activeCount":102},[],{"trials":5706,"activeCount":102},[],{"trials":5708,"activeCount":102},[],{"intervention":5710,"totalTrials":142,"cells":5711},"Avatrombopag",{"EARLY_PHASE1":5712,"PHASE1":5724,"PHASE2":5726,"PHASE3":5728,"PHASE4":5730,"NA":5732},{"trials":5713,"activeCount":102},[5714],{"nctId":5715,"briefTitle":5716,"status":2362,"phases":5717,"primaryCompletion":5718,"completion":5719,"start":5720,"enrollment":102,"conditions":5721,"interventions":5723},"NCT04931849","Study of Avatrombopag for Temozolomide-induced Thrombocytopenia in Glioma (APATIT-G)",[89],"2023-10-11","2024-07-18","2022-05-06",[5722],"Thrombocytopenia",[5710],{"trials":5725,"activeCount":102},[],{"trials":5727,"activeCount":102},[],{"trials":5729,"activeCount":102},[],{"trials":5731,"activeCount":102},[],{"trials":5733,"activeCount":102},[],{"intervention":5735,"totalTrials":142,"cells":5736},"Ginger",{"EARLY_PHASE1":5737,"PHASE1":5750,"PHASE2":5752,"PHASE3":5754,"PHASE4":5756,"NA":5758},{"trials":5738,"activeCount":102},[5739],{"nctId":5740,"briefTitle":5741,"status":329,"phases":5742,"primaryCompletion":5743,"completion":5743,"start":3973,"enrollment":573,"conditions":5744,"interventions":5746},"NCT02670941","Aromatherapy for Chemotherapy-induced Symptoms",[89],"2018-09-12",[5745],"Chemotherapy Symptoms",[5735,5747,5748,5749],"Lavender","Orange","Jojoba",{"trials":5751,"activeCount":102},[],{"trials":5753,"activeCount":102},[],{"trials":5755,"activeCount":102},[],{"trials":5757,"activeCount":102},[],{"trials":5759,"activeCount":102},[],{"intervention":5747,"totalTrials":142,"cells":5761},{"EARLY_PHASE1":5762,"PHASE1":5768,"PHASE2":5770,"PHASE3":5772,"PHASE4":5774,"NA":5776},{"trials":5763,"activeCount":102},[5764],{"nctId":5740,"briefTitle":5741,"status":329,"phases":5765,"primaryCompletion":5743,"completion":5743,"start":3973,"enrollment":573,"conditions":5766,"interventions":5767},[89],[5745],[5735,5747,5748,5749],{"trials":5769,"activeCount":102},[],{"trials":5771,"activeCount":102},[],{"trials":5773,"activeCount":102},[],{"trials":5775,"activeCount":102},[],{"trials":5777,"activeCount":102},[],{"intervention":5748,"totalTrials":142,"cells":5779},{"EARLY_PHASE1":5780,"PHASE1":5786,"PHASE2":5788,"PHASE3":5790,"PHASE4":5792,"NA":5794},{"trials":5781,"activeCount":102},[5782],{"nctId":5740,"briefTitle":5741,"status":329,"phases":5783,"primaryCompletion":5743,"completion":5743,"start":3973,"enrollment":573,"conditions":5784,"interventions":5785},[89],[5745],[5735,5747,5748,5749],{"trials":5787,"activeCount":102},[],{"trials":5789,"activeCount":102},[],{"trials":5791,"activeCount":102},[],{"trials":5793,"activeCount":102},[],{"trials":5795,"activeCount":102},[],{"intervention":5749,"totalTrials":142,"cells":5797},{"EARLY_PHASE1":5798,"PHASE1":5804,"PHASE2":5806,"PHASE3":5808,"PHASE4":5810,"NA":5812},{"trials":5799,"activeCount":102},[5800],{"nctId":5740,"briefTitle":5741,"status":329,"phases":5801,"primaryCompletion":5743,"completion":5743,"start":3973,"enrollment":573,"conditions":5802,"interventions":5803},[89],[5745],[5735,5747,5748,5749],{"trials":5805,"activeCount":102},[],{"trials":5807,"activeCount":102},[],{"trials":5809,"activeCount":102},[],{"trials":5811,"activeCount":102},[],{"trials":5813,"activeCount":102},[],{"intervention":3465,"totalTrials":558,"cells":5815},{"EARLY_PHASE1":5816,"PHASE1":5818,"PHASE2":5820,"PHASE3":5842,"PHASE4":5844,"NA":5846},{"trials":5817,"activeCount":102},[],{"trials":5819,"activeCount":102},[],{"trials":5821,"activeCount":102},[5822,5831,5835],{"nctId":5823,"briefTitle":5824,"status":114,"phases":5825,"primaryCompletion":5826,"completion":5827,"start":1822,"enrollment":29,"conditions":5828,"interventions":5830},"NCT02347813","Preventing Squamous Cell Skin Cancer",[91],"2018-06-01","2019-06-01",[5829],"Squamous Cell Carcinoma of the Skin",[3465],{"nctId":3455,"briefTitle":3456,"status":114,"phases":5832,"primaryCompletion":2142,"completion":3458,"start":3459,"enrollment":302,"conditions":5833,"interventions":5834},[91],[3461,3462,3463],[3437,3465],{"nctId":5836,"briefTitle":5837,"status":114,"phases":5838,"primaryCompletion":2879,"completion":2879,"start":118,"enrollment":5839,"conditions":5840,"interventions":5841},"NCT01280123","Pioglitazone in Early Parkinson's Disease",[91],210,[2869],[3465],{"trials":5843,"activeCount":102},[],{"trials":5845,"activeCount":102},[],{"trials":5847,"activeCount":102},[5848],{"nctId":5849,"briefTitle":5850,"status":2362,"phases":5851,"primaryCompletion":4820,"completion":5852,"start":331,"enrollment":102,"conditions":5853,"interventions":5854},"NCT01695707","Assessing the Impact of Pioglitazone on Skin Barrier Function in Atopic Dermatitis Patients",[94],"2014-06",[2942],[3465],{"intervention":296,"totalTrials":366,"cells":5856},{"EARLY_PHASE1":5857,"PHASE1":5859,"PHASE2":5861,"PHASE3":5871,"PHASE4":5873,"NA":5875},{"trials":5858,"activeCount":102},[],{"trials":5860,"activeCount":102},[],{"trials":5862,"activeCount":102},[5863,5867],{"nctId":282,"briefTitle":283,"status":114,"phases":5864,"primaryCompletion":285,"start":286,"enrollment":287,"conditions":5865,"interventions":5866},[91],[289],[291,292,293,294,295,296,297],{"nctId":4858,"briefTitle":4859,"status":114,"phases":5868,"primaryCompletion":2714,"completion":2714,"start":4861,"enrollment":2522,"conditions":5869,"interventions":5870},[91],[4863],[4865,4849],{"trials":5872,"activeCount":102},[],{"trials":5874,"activeCount":102},[],{"trials":5876,"activeCount":102},[5877],{"nctId":327,"briefTitle":328,"status":329,"phases":5878,"primaryCompletion":331,"completion":332,"start":333,"enrollment":334,"conditions":5879,"interventions":5880},[94],[336,337,338,339,340,341,342],[292,294,344,295,296],{"intervention":5882,"totalTrials":98,"cells":5883},"Escitalopram",{"EARLY_PHASE1":5884,"PHASE1":5886,"PHASE2":5888,"PHASE3":5890,"PHASE4":5892,"NA":5904},{"trials":5885,"activeCount":102},[],{"trials":5887,"activeCount":102},[],{"trials":5889,"activeCount":102},[],{"trials":5891,"activeCount":102},[],{"trials":5893,"activeCount":102},[5894],{"nctId":5895,"briefTitle":5896,"status":114,"phases":5897,"primaryCompletion":5898,"completion":5898,"start":5899,"enrollment":20,"conditions":5900,"interventions":5903},"NCT00260624","Escitalopram Treatment of Patients With Agitated Dementia",[93],"2006-12","2003-02",[5901,5902],"Alzheimer's Disease","Psychomotor Agitation",[5882],{"trials":5905,"activeCount":102},[5906],{"nctId":5907,"briefTitle":5908,"status":114,"phases":5909,"primaryCompletion":5910,"completion":5910,"start":5911,"enrollment":20,"conditions":5912,"interventions":5914},"NCT00277108","Lexapro in the Treatment of Patients With Postpartum Depression",[94],"2007-04","2004-02",[5913],"Postpartum Depression",[5882],{"intervention":292,"totalTrials":98,"cells":5916},{"EARLY_PHASE1":5917,"PHASE1":5919,"PHASE2":5921,"PHASE3":5927,"PHASE4":5929,"NA":5931},{"trials":5918,"activeCount":102},[],{"trials":5920,"activeCount":102},[],{"trials":5922,"activeCount":102},[5923],{"nctId":282,"briefTitle":283,"status":114,"phases":5924,"primaryCompletion":285,"start":286,"enrollment":287,"conditions":5925,"interventions":5926},[91],[289],[291,292,293,294,295,296,297],{"trials":5928,"activeCount":102},[],{"trials":5930,"activeCount":102},[],{"trials":5932,"activeCount":102},[5933],{"nctId":327,"briefTitle":328,"status":329,"phases":5934,"primaryCompletion":331,"completion":332,"start":333,"enrollment":334,"conditions":5935,"interventions":5936},[94],[336,337,338,339,340,341,342],[292,294,344,295,296],{"intervention":344,"totalTrials":98,"cells":5938},{"EARLY_PHASE1":5939,"PHASE1":5941,"PHASE2":5943,"PHASE3":5952,"PHASE4":5954,"NA":5956},{"trials":5940,"activeCount":102},[],{"trials":5942,"activeCount":102},[],{"trials":5944,"activeCount":102},[5945],{"nctId":5946,"briefTitle":5947,"status":2362,"phases":5948,"primaryCompletion":1687,"completion":2878,"start":3408,"enrollment":102,"conditions":5949,"interventions":5950},"NCT00377325","The Effectiveness of Lower Cyclosporine Doses for Psoriasis",[91],[2146],[5951],"Cyclosporine",{"trials":5953,"activeCount":102},[],{"trials":5955,"activeCount":102},[],{"trials":5957,"activeCount":102},[5958],{"nctId":327,"briefTitle":328,"status":329,"phases":5959,"primaryCompletion":331,"completion":332,"start":333,"enrollment":334,"conditions":5960,"interventions":5961},[94],[336,337,338,339,340,341,342],[292,294,344,295,296],{"intervention":295,"totalTrials":98,"cells":5963},{"EARLY_PHASE1":5964,"PHASE1":5966,"PHASE2":5968,"PHASE3":5974,"PHASE4":5976,"NA":5978},{"trials":5965,"activeCount":102},[],{"trials":5967,"activeCount":102},[],{"trials":5969,"activeCount":102},[5970],{"nctId":282,"briefTitle":283,"status":114,"phases":5971,"primaryCompletion":285,"start":286,"enrollment":287,"conditions":5972,"interventions":5973},[91],[289],[291,292,293,294,295,296,297],{"trials":5975,"activeCount":102},[],{"trials":5977,"activeCount":102},[],{"trials":5979,"activeCount":102},[5980],{"nctId":327,"briefTitle":328,"status":329,"phases":5981,"primaryCompletion":331,"completion":332,"start":333,"enrollment":334,"conditions":5982,"interventions":5983},[94],[336,337,338,339,340,341,342],[292,294,344,295,296],{"intervention":2679,"totalTrials":98,"cells":5985},{"EARLY_PHASE1":5986,"PHASE1":5988,"PHASE2":5990,"PHASE3":5992,"PHASE4":5994,"NA":6000},{"trials":5987,"activeCount":102},[],{"trials":5989,"activeCount":102},[],{"trials":5991,"activeCount":102},[],{"trials":5993,"activeCount":102},[],{"trials":5995,"activeCount":102},[5996],{"nctId":2671,"briefTitle":2672,"status":114,"phases":5997,"primaryCompletion":2498,"completion":2498,"start":2674,"enrollment":2675,"conditions":5998,"interventions":5999},[93],[2677],[2679,2658],{"trials":6001,"activeCount":102},[6002],{"nctId":6003,"briefTitle":6004,"status":114,"phases":6005,"primaryCompletion":2564,"completion":2564,"start":5898,"enrollment":1009,"conditions":6006,"interventions":6008},"NCT01045122","Sedation in Patients at Risk for Upper Airway Collapse",[94],[6007],"Obstructive Sleep Apnea",[6009,2679],"Propofol",{"intervention":6011,"totalTrials":98,"cells":6012},"Ondansetron",{"EARLY_PHASE1":6013,"PHASE1":6015,"PHASE2":6017,"PHASE3":6019,"PHASE4":6021,"NA":6023},{"trials":6014,"activeCount":102},[],{"trials":6016,"activeCount":102},[],{"trials":6018,"activeCount":102},[],{"trials":6020,"activeCount":102},[],{"trials":6022,"activeCount":102},[],{"trials":6024,"activeCount":102},[6025,6035],{"nctId":6026,"briefTitle":6027,"status":114,"phases":6028,"primaryCompletion":6029,"completion":6029,"start":6030,"enrollment":6031,"conditions":6032,"interventions":6034},"NCT02456662","Scheduled Prophylactic Antiemetics for Reduction of Emesis With Doxycycline (SPARED) Trial",[94],"2019-04-03","2015-10-07",319,[6033],"Drug-induced Nausea and Vomiting",[6011],{"nctId":6036,"briefTitle":6037,"status":114,"phases":6038,"primaryCompletion":6039,"completion":6039,"start":6040,"conditions":6041,"interventions":6043},"NCT00005994","Patient Education in Preventing Nausea and Vomiting in Cancer Patients Receiving Chemotherapy",[94],"2001-07","2000-08",[6042,3316],"Nausea and Vomiting",[6044],"ondansetron",{"intervention":6046,"totalTrials":142,"cells":6047},"Methotrexate",{"EARLY_PHASE1":6048,"PHASE1":6050,"PHASE2":6052,"PHASE3":6054,"PHASE4":6056,"NA":6058},{"trials":6049,"activeCount":102},[],{"trials":6051,"activeCount":102},[],{"trials":6053,"activeCount":102},[],{"trials":6055,"activeCount":102},[],{"trials":6057,"activeCount":102},[],{"trials":6059,"activeCount":102},[6060],{"nctId":6061,"briefTitle":6062,"status":114,"phases":6063,"primaryCompletion":5852,"completion":5852,"start":2142,"enrollment":17,"conditions":6064,"interventions":6065},"NCT01123265","National Psoriasis Foundation - Dendritic Cell-Specific Transmembrane Protein (DC-Stamp) Biomarker Study",[],[2145],[6046,6066],"Anti-TNF",{"intervention":6066,"totalTrials":142,"cells":6068},{"EARLY_PHASE1":6069,"PHASE1":6071,"PHASE2":6073,"PHASE3":6075,"PHASE4":6077,"NA":6079},{"trials":6070,"activeCount":102},[],{"trials":6072,"activeCount":102},[],{"trials":6074,"activeCount":102},[],{"trials":6076,"activeCount":102},[],{"trials":6078,"activeCount":102},[],{"trials":6080,"activeCount":102},[6081],{"nctId":6061,"briefTitle":6062,"status":114,"phases":6082,"primaryCompletion":5852,"completion":5852,"start":2142,"enrollment":17,"conditions":6083,"interventions":6084},[],[2145],[6046,6066],{"intervention":6086,"totalTrials":142,"cells":6087},"Cytosine Arabinoside",{"EARLY_PHASE1":6088,"PHASE1":6090,"PHASE2":6092,"PHASE3":6094,"PHASE4":6096,"NA":6098},{"trials":6089,"activeCount":102},[],{"trials":6091,"activeCount":102},[],{"trials":6093,"activeCount":102},[],{"trials":6095,"activeCount":102},[],{"trials":6097,"activeCount":102},[],{"trials":6099,"activeCount":102},[6100],{"nctId":6101,"briefTitle":6102,"status":114,"phases":6103,"primaryCompletion":3338,"completion":6104,"start":2827,"enrollment":678,"conditions":6105,"interventions":6106},"NCT02101983","Pilot Study of Feasibility of Outpatient Daily High Dose Cytarabine as Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML)",[94],"2017-08",[3740],[6086],{"intervention":6108,"totalTrials":142,"cells":6109},"Prevacid Solutabs",{"EARLY_PHASE1":6110,"PHASE1":6112,"PHASE2":6114,"PHASE3":6116,"PHASE4":6118,"NA":6120},{"trials":6111,"activeCount":102},[],{"trials":6113,"activeCount":102},[],{"trials":6115,"activeCount":102},[],{"trials":6117,"activeCount":102},[],{"trials":6119,"activeCount":102},[],{"trials":6121,"activeCount":102},[6122],{"nctId":6123,"briefTitle":6124,"status":329,"phases":6125,"primaryCompletion":4820,"completion":4820,"start":3470,"enrollment":717,"conditions":6126,"interventions":6129},"NCT00624546","Effect of Antireflux Therapy on the Expression of Genes in Patients With GERD",[],[6127,6128],"GERD","Gastroesophageal Reflux",[6108],{"intervention":6131,"totalTrials":142,"cells":6132},"Instill Saline Drop",{"EARLY_PHASE1":6133,"PHASE1":6135,"PHASE2":6137,"PHASE3":6139,"PHASE4":6141,"NA":6143},{"trials":6134,"activeCount":102},[],{"trials":6136,"activeCount":102},[],{"trials":6138,"activeCount":102},[],{"trials":6140,"activeCount":102},[],{"trials":6142,"activeCount":102},[],{"trials":6144,"activeCount":102},[6145],{"nctId":6146,"briefTitle":6147,"status":114,"phases":6148,"primaryCompletion":3996,"completion":3996,"start":2142,"enrollment":1009,"conditions":6149,"interventions":6152},"NCT01128049","Non-invasive Tear Film Dynamic Measurements in Normal, MGD and ADDE Subjects After Saline Instillation",[94],[6150,6151],"Aqueous Deficient Dry Eye","Meibomium Gland Dysfunction",[6131],{"intervention":6154,"totalTrials":142,"cells":6155},"Botox",{"EARLY_PHASE1":6156,"PHASE1":6158,"PHASE2":6160,"PHASE3":6162,"PHASE4":6164,"NA":6166},{"trials":6157,"activeCount":102},[],{"trials":6159,"activeCount":102},[],{"trials":6161,"activeCount":102},[],{"trials":6163,"activeCount":102},[],{"trials":6165,"activeCount":102},[],{"trials":6167,"activeCount":102},[6168],{"nctId":6169,"briefTitle":6170,"status":114,"phases":6171,"primaryCompletion":2827,"completion":2827,"start":6172,"enrollment":573,"conditions":6173,"interventions":6175},"NCT00345332","A Multi-Center Trial of Botox for Severe Urge Urinary Incontinence",[94],"2005-10",[6174],"Urinary Incontinence",[6154],{"intervention":6177,"totalTrials":142,"cells":6178},"glycerin suppository",{"EARLY_PHASE1":6179,"PHASE1":6181,"PHASE2":6183,"PHASE3":6185,"PHASE4":6187,"NA":6189},{"trials":6180,"activeCount":102},[],{"trials":6182,"activeCount":102},[],{"trials":6184,"activeCount":102},[],{"trials":6186,"activeCount":102},[],{"trials":6188,"activeCount":102},[],{"trials":6190,"activeCount":102},[6191],{"nctId":6192,"briefTitle":6193,"status":114,"phases":6194,"primaryCompletion":2878,"completion":2878,"start":5281,"enrollment":6195,"conditions":6196,"interventions":6200},"NCT01746511","Glycerin Suppositories to Reduce Jaundice in Premature Infants",[94],79,[6197,6198,6199],"Idiopathic Hyperbilirubinemia","Neonatal Hyperbilirubinemia","Prematurity",[6177],{"intervention":6202,"totalTrials":142,"cells":6203},"Docusate",{"EARLY_PHASE1":6204,"PHASE1":6206,"PHASE2":6208,"PHASE3":6210,"PHASE4":6212,"NA":6214},{"trials":6205,"activeCount":102},[],{"trials":6207,"activeCount":102},[],{"trials":6209,"activeCount":102},[],{"trials":6211,"activeCount":102},[],{"trials":6213,"activeCount":102},[],{"trials":6215,"activeCount":102},[6216],{"nctId":6217,"briefTitle":6218,"status":114,"phases":6219,"primaryCompletion":3073,"completion":3073,"start":2451,"enrollment":6220,"conditions":6221,"interventions":6223},"NCT01044212","Bowel Function After Minimally Invasive Urogynecologic Surgery",[94],72,[6222],"Functional Disorder of Intestine",[6202,6224],"Bowel medications",{"intervention":6224,"totalTrials":142,"cells":6226},{"EARLY_PHASE1":6227,"PHASE1":6229,"PHASE2":6231,"PHASE3":6233,"PHASE4":6235,"NA":6237},{"trials":6228,"activeCount":102},[],{"trials":6230,"activeCount":102},[],{"trials":6232,"activeCount":102},[],{"trials":6234,"activeCount":102},[],{"trials":6236,"activeCount":102},[],{"trials":6238,"activeCount":102},[6239],{"nctId":6217,"briefTitle":6218,"status":114,"phases":6240,"primaryCompletion":3073,"completion":3073,"start":2451,"enrollment":6220,"conditions":6241,"interventions":6242},[94],[6222],[6202,6224],{"intervention":6244,"totalTrials":142,"cells":6245},"Voiding Trial",{"EARLY_PHASE1":6246,"PHASE1":6248,"PHASE2":6250,"PHASE3":6252,"PHASE4":6254,"NA":6256},{"trials":6247,"activeCount":102},[],{"trials":6249,"activeCount":102},[],{"trials":6251,"activeCount":102},[],{"trials":6253,"activeCount":102},[],{"trials":6255,"activeCount":102},[],{"trials":6257,"activeCount":102},[6258],{"nctId":6259,"briefTitle":6260,"status":114,"phases":6261,"primaryCompletion":571,"completion":571,"start":5482,"enrollment":6195,"conditions":6262,"interventions":6263},"NCT00392210","Assessment of Two Postoperative Techniques Used to Predict Voiding Efficiency After Gynecologic Surgery",[94],[6174],[6244],{"intervention":6265,"totalTrials":142,"cells":6266},"bleach bath",{"EARLY_PHASE1":6267,"PHASE1":6269,"PHASE2":6271,"PHASE3":6273,"PHASE4":6275,"NA":6277},{"trials":6268,"activeCount":102},[],{"trials":6270,"activeCount":102},[],{"trials":6272,"activeCount":102},[],{"trials":6274,"activeCount":102},[],{"trials":6276,"activeCount":102},[],{"trials":6278,"activeCount":102},[6279],{"nctId":6280,"briefTitle":6281,"status":114,"phases":6282,"primaryCompletion":6283,"completion":6283,"start":4820,"enrollment":596,"conditions":6284,"interventions":6285},"NCT01996150","Bleach Bath Treatment of Adults With Atopic Dermatitis",[94],"2017-06-01",[2942],[6265],{"intervention":6287,"totalTrials":142,"cells":6288},"Trivalent Inactivated Influenza Vaccine",{"EARLY_PHASE1":6289,"PHASE1":6291,"PHASE2":6293,"PHASE3":6295,"PHASE4":6297,"NA":6299},{"trials":6290,"activeCount":102},[],{"trials":6292,"activeCount":102},[],{"trials":6294,"activeCount":102},[],{"trials":6296,"activeCount":102},[],{"trials":6298,"activeCount":102},[],{"trials":6300,"activeCount":102},[6301],{"nctId":6302,"briefTitle":6303,"status":114,"phases":6304,"primaryCompletion":3500,"completion":3500,"start":572,"enrollment":6305,"conditions":6306,"interventions":6308},"NCT00455169","Influenza Vaccine in Premature Infants",[],66,[1691,6307],"Infant, Premature",[6287],{"intervention":6310,"totalTrials":142,"cells":6311},"Dose control for Arm B",{"EARLY_PHASE1":6312,"PHASE1":6314,"PHASE2":6316,"PHASE3":6318,"PHASE4":6320,"NA":6322},{"trials":6313,"activeCount":102},[],{"trials":6315,"activeCount":102},[],{"trials":6317,"activeCount":102},[],{"trials":6319,"activeCount":102},[],{"trials":6321,"activeCount":102},[],{"trials":6323,"activeCount":102},[6324],{"nctId":6325,"briefTitle":6326,"status":114,"phases":6327,"primaryCompletion":1734,"completion":1734,"start":6040,"enrollment":4509,"conditions":6328,"interventions":6329},"NCT00005922","Conditioning, the Placebo Effect, and Psoriasis",[94],[2146],[6310],{"intervention":6331,"totalTrials":142,"cells":6332},"Raltegravir",{"EARLY_PHASE1":6333,"PHASE1":6335,"PHASE2":6337,"PHASE3":6339,"PHASE4":6341,"NA":6343},{"trials":6334,"activeCount":102},[],{"trials":6336,"activeCount":102},[],{"trials":6338,"activeCount":102},[],{"trials":6340,"activeCount":102},[],{"trials":6342,"activeCount":102},[],{"trials":6344,"activeCount":102},[6345],{"nctId":6346,"briefTitle":6347,"status":114,"phases":6348,"primaryCompletion":3458,"completion":3458,"start":6349,"enrollment":533,"conditions":6350,"interventions":6351},"NCT00745368","Comparing Raltegravir Genital Tract Distribution in HIV-infected Men and Women",[94],"2008-09",[5177],[6331],{"intervention":6353,"totalTrials":142,"cells":6354},"Standard leukoreduced irradiated blood cell transfusion",{"EARLY_PHASE1":6355,"PHASE1":6357,"PHASE2":6359,"PHASE3":6361,"PHASE4":6363,"NA":6365},{"trials":6356,"activeCount":102},[],{"trials":6358,"activeCount":102},[],{"trials":6360,"activeCount":102},[],{"trials":6362,"activeCount":102},[],{"trials":6364,"activeCount":102},[],{"trials":6366,"activeCount":102},[6367],{"nctId":6368,"briefTitle":6369,"status":114,"phases":6370,"primaryCompletion":2451,"completion":2451,"start":6371,"enrollment":6372,"conditions":6373,"interventions":6374},"NCT00693498","Washed Versus Standard Blood Cell Transfusions in Pediatric Open Heart Surgery",[94],"2008-07",162,[5283],[6353,6375],"Washed leukoreduced irradiated blood cell transfusions",{"intervention":6375,"totalTrials":142,"cells":6377},{"EARLY_PHASE1":6378,"PHASE1":6380,"PHASE2":6382,"PHASE3":6384,"PHASE4":6386,"NA":6388},{"trials":6379,"activeCount":102},[],{"trials":6381,"activeCount":102},[],{"trials":6383,"activeCount":102},[],{"trials":6385,"activeCount":102},[],{"trials":6387,"activeCount":102},[],{"trials":6389,"activeCount":102},[6390],{"nctId":6368,"briefTitle":6369,"status":114,"phases":6391,"primaryCompletion":2451,"completion":2451,"start":6371,"enrollment":6372,"conditions":6392,"interventions":6393},[94],[5283],[6353,6375],{"intervention":6395,"totalTrials":142,"cells":6396},"Reslizumab",{"EARLY_PHASE1":6397,"PHASE1":6399,"PHASE2":6401,"PHASE3":6403,"PHASE4":6405,"NA":6407},{"trials":6398,"activeCount":102},[],{"trials":6400,"activeCount":102},[],{"trials":6402,"activeCount":102},[],{"trials":6404,"activeCount":102},[],{"trials":6406,"activeCount":102},[],{"trials":6408,"activeCount":102},[6409],{"nctId":6410,"briefTitle":6411,"status":2362,"phases":6412,"primaryCompletion":6413,"completion":6413,"start":6414,"enrollment":102,"conditions":6415,"interventions":6418},"NCT03369574","Study of Chronic Rhinosinusitis Symptoms in Asthma Patients Undergoing Treatment With Reslizumab",[],"2018-10-19","2017-11-14",[6416,22,6417],"Chronic Rhinosinusitis (Diagnosis)","Nasal Polyps",[6395],{"intervention":6420,"totalTrials":142,"cells":6421},"Tamsulosin",{"EARLY_PHASE1":6422,"PHASE1":6424,"PHASE2":6426,"PHASE3":6428,"PHASE4":6430,"NA":6432},{"trials":6423,"activeCount":102},[],{"trials":6425,"activeCount":102},[],{"trials":6427,"activeCount":102},[],{"trials":6429,"activeCount":102},[],{"trials":6431,"activeCount":102},[],{"trials":6433,"activeCount":102},[6434],{"nctId":6435,"briefTitle":6436,"status":329,"phases":6437,"primaryCompletion":6438,"completion":6438,"start":6439,"enrollment":273,"conditions":6440,"interventions":6442},"NCT02684344","Prophylactic Tamsulosin Use for Prevention of Post-Operative Urinary Retention",[94],"2017-12","2016-02",[6441],"Post-Operative Urinary Retention",[6420],{"intervention":6444,"totalTrials":142,"cells":6445},"Administration of Lotemax",{"EARLY_PHASE1":6446,"PHASE1":6448,"PHASE2":6450,"PHASE3":6452,"PHASE4":6454,"NA":6456},{"trials":6447,"activeCount":102},[],{"trials":6449,"activeCount":102},[],{"trials":6451,"activeCount":102},[],{"trials":6453,"activeCount":102},[],{"trials":6455,"activeCount":102},[],{"trials":6457,"activeCount":102},[6458],{"nctId":6459,"briefTitle":6460,"status":114,"phases":6461,"primaryCompletion":6462,"completion":6462,"start":1721,"enrollment":32,"conditions":6463,"interventions":6465},"NCT02322528","Evaluation of Ocular Surface Inflammatory Mediators Effected by Lotemax",[94],"2015-08",[6464],"Sjogren's Disease",[6444],{"intervention":6467,"totalTrials":142,"cells":6468},"DepoDur",{"EARLY_PHASE1":6469,"PHASE1":6471,"PHASE2":6473,"PHASE3":6475,"PHASE4":6477,"NA":6479},{"trials":6470,"activeCount":102},[],{"trials":6472,"activeCount":102},[],{"trials":6474,"activeCount":102},[],{"trials":6476,"activeCount":102},[],{"trials":6478,"activeCount":102},[],{"trials":6480,"activeCount":102},[6481],{"nctId":6482,"briefTitle":6483,"status":114,"phases":6484,"primaryCompletion":163,"completion":1617,"start":3531,"enrollment":176,"conditions":6485,"interventions":6487},"NCT00335517","Safety and Efficacy of DepoDur in Lumbar Spine Surgery Patients",[94],[6486],"Lumbar Spine Surgery",[6467],{"intervention":6489,"totalTrials":142,"cells":6490},"Certolizumab",{"EARLY_PHASE1":6491,"PHASE1":6493,"PHASE2":6495,"PHASE3":6497,"PHASE4":6499,"NA":6501},{"trials":6492,"activeCount":102},[],{"trials":6494,"activeCount":102},[],{"trials":6496,"activeCount":102},[],{"trials":6498,"activeCount":102},[],{"trials":6500,"activeCount":102},[],{"trials":6502,"activeCount":102},[6503],{"nctId":6504,"briefTitle":6505,"status":114,"phases":6506,"primaryCompletion":3337,"completion":3337,"start":1688,"enrollment":273,"conditions":6507,"interventions":6508},"NCT01098201","Certolizumab and Lower Extremity Lymph Flow in Rheumatoid Arthritis (RA)",[],[1245],[6489],{"intervention":6510,"totalTrials":142,"cells":6511},"Inactivated H1N1 vaccine",{"EARLY_PHASE1":6512,"PHASE1":6514,"PHASE2":6516,"PHASE3":6518,"PHASE4":6520,"NA":6522},{"trials":6513,"activeCount":102},[],{"trials":6515,"activeCount":102},[],{"trials":6517,"activeCount":102},[],{"trials":6519,"activeCount":102},[],{"trials":6521,"activeCount":102},[],{"trials":6523,"activeCount":102},[6524],{"nctId":6525,"briefTitle":6526,"status":114,"phases":6527,"primaryCompletion":1617,"completion":4861,"start":2451,"enrollment":6528,"conditions":6529,"interventions":6530},"NCT01023711","Immunologic Response to Inactivated Vaccine for Novel H1N1 Virus",[94],107,[1691],[6510,6510],{"intervention":6532,"totalTrials":142,"cells":6533},"topical lidocaine + oral desipramine, and\u002For placebo",{"EARLY_PHASE1":6534,"PHASE1":6536,"PHASE2":6538,"PHASE3":6540,"PHASE4":6542,"NA":6544},{"trials":6535,"activeCount":102},[],{"trials":6537,"activeCount":102},[],{"trials":6539,"activeCount":102},[],{"trials":6541,"activeCount":102},[],{"trials":6543,"activeCount":102},[],{"trials":6545,"activeCount":102},[6546],{"nctId":6547,"briefTitle":6548,"status":114,"phases":6549,"completion":4083,"start":2771,"enrollment":2565,"conditions":6550,"interventions":6552},"NCT00276068","Vulvar Vestibulitis Clinical Trial: Desipramine-Lidocaine",[94],[6551],"Vulvar Disease",[6532],{"intervention":6009,"totalTrials":142,"cells":6554},{"EARLY_PHASE1":6555,"PHASE1":6557,"PHASE2":6559,"PHASE3":6561,"PHASE4":6563,"NA":6565},{"trials":6556,"activeCount":102},[],{"trials":6558,"activeCount":102},[],{"trials":6560,"activeCount":102},[],{"trials":6562,"activeCount":102},[],{"trials":6564,"activeCount":102},[],{"trials":6566,"activeCount":102},[6567],{"nctId":6003,"briefTitle":6004,"status":114,"phases":6568,"primaryCompletion":2564,"completion":2564,"start":5898,"enrollment":1009,"conditions":6569,"interventions":6570},[94],[6007],[6009,2679],{"intervention":6572,"totalTrials":142,"cells":6573},"Bupivicaine 0.5%",{"EARLY_PHASE1":6574,"PHASE1":6576,"PHASE2":6578,"PHASE3":6580,"PHASE4":6582,"NA":6584},{"trials":6575,"activeCount":102},[],{"trials":6577,"activeCount":102},[],{"trials":6579,"activeCount":102},[],{"trials":6581,"activeCount":102},[],{"trials":6583,"activeCount":102},[],{"trials":6585,"activeCount":102},[6586],{"nctId":6587,"briefTitle":6588,"status":114,"phases":6589,"primaryCompletion":6590,"completion":6590,"start":1770,"enrollment":635,"conditions":6591,"interventions":6593},"NCT00178178","Arthroscopic Anterior Cruciate Ligament Reconstruction: A Comparison of Three Catheter Placement Positions",[94],"2007-11",[6592],"Pain, Postoperative",[6572],{"intervention":6595,"totalTrials":142,"cells":6596},"Hormone Replacement Therapy - HRT",{"EARLY_PHASE1":6597,"PHASE1":6599,"PHASE2":6601,"PHASE3":6603,"PHASE4":6605,"NA":6607},{"trials":6598,"activeCount":102},[],{"trials":6600,"activeCount":102},[],{"trials":6602,"activeCount":102},[],{"trials":6604,"activeCount":102},[],{"trials":6606,"activeCount":102},[],{"trials":6608,"activeCount":102},[6609],{"nctId":6610,"briefTitle":6611,"status":114,"phases":6612,"completion":6613,"start":6614,"enrollment":6615,"conditions":6616,"interventions":6622},"NCT00264407","Neural Changes in the Aging Auditory System",[],"2005-02","2001-01",126,[6617,6618,6619,6620,6621],"Progesterone","Estrogens","Hearing","Psychoacoustics","Auditory Perceptual Disorders",[6595],{"intervention":6624,"totalTrials":142,"cells":6625},"Flax oil",{"EARLY_PHASE1":6626,"PHASE1":6628,"PHASE2":6630,"PHASE3":6632,"PHASE4":6634,"NA":6636},{"trials":6627,"activeCount":102},[],{"trials":6629,"activeCount":102},[],{"trials":6631,"activeCount":102},[],{"trials":6633,"activeCount":102},[],{"trials":6635,"activeCount":102},[],{"trials":6637,"activeCount":102},[6638],{"nctId":6639,"briefTitle":6640,"status":114,"phases":6641,"primaryCompletion":3243,"completion":3243,"start":6642,"enrollment":6643,"conditions":6644,"interventions":6646},"NCT00252486","Omega-3 Fatty Acids in Children and Adolescents With Bipolar Disorder",[94],"2001-11",65,[6645],"Bipolar Disorder",[6624],{"intervention":6648,"totalTrials":142,"cells":6649},"Ciprofloxacin",{"EARLY_PHASE1":6650,"PHASE1":6652,"PHASE2":6654,"PHASE3":6656,"PHASE4":6658,"NA":6660},{"trials":6651,"activeCount":102},[],{"trials":6653,"activeCount":102},[],{"trials":6655,"activeCount":102},[],{"trials":6657,"activeCount":102},[],{"trials":6659,"activeCount":102},[],{"trials":6661,"activeCount":102},[6662],{"nctId":6663,"briefTitle":6664,"status":329,"phases":6665,"primaryCompletion":6666,"completion":6666,"start":3337,"enrollment":6667,"conditions":6668,"interventions":6671},"NCT02247960","Antibiotic Prophylaxis for Urinary Catheter Removal After Radical Prostatectomy",[94],"2016-05",175,[1398,6669,6670],"Urinary Tract Infection","Clostridium Difficile",[6648],{"intervention":6673,"totalTrials":142,"cells":6674},"Fosamax",{"EARLY_PHASE1":6675,"PHASE1":6677,"PHASE2":6679,"PHASE3":6681,"PHASE4":6683,"NA":6685},{"trials":6676,"activeCount":102},[],{"trials":6678,"activeCount":102},[],{"trials":6680,"activeCount":102},[],{"trials":6682,"activeCount":102},[],{"trials":6684,"activeCount":102},[],{"trials":6686,"activeCount":102},[6687],{"nctId":6688,"briefTitle":6689,"status":329,"phases":6690,"primaryCompletion":2170,"completion":2170,"start":2142,"enrollment":142,"conditions":6691,"interventions":6694},"NCT01131884","Pilot Study of Fosamax in Spinal Cord Injury",[94],[6692,6693],"Spinal Cord Injury","Osteoporosis",[6673],{"intervention":6696,"totalTrials":142,"cells":6697},"Vaginal progesterone gel",{"EARLY_PHASE1":6698,"PHASE1":6700,"PHASE2":6702,"PHASE3":6704,"PHASE4":6706,"NA":6708},{"trials":6699,"activeCount":102},[],{"trials":6701,"activeCount":102},[],{"trials":6703,"activeCount":102},[],{"trials":6705,"activeCount":102},[],{"trials":6707,"activeCount":102},[],{"trials":6709,"activeCount":102},[6710],{"nctId":6711,"briefTitle":6712,"status":2362,"phases":6713,"primaryCompletion":1701,"completion":1701,"start":2450,"enrollment":102,"conditions":6714,"interventions":6716},"NCT01206998","Vaginal Progesterone as a Treatment for Women Active Preterm Labor",[94],[6715],"Labor, Premature",[6696],{"intervention":6718,"totalTrials":142,"cells":6719},"Seasonal IIV 0.25 mL dose",{"EARLY_PHASE1":6720,"PHASE1":6722,"PHASE2":6724,"PHASE3":6726,"PHASE4":6728,"NA":6730},{"trials":6721,"activeCount":102},[],{"trials":6723,"activeCount":102},[],{"trials":6725,"activeCount":102},[],{"trials":6727,"activeCount":102},[],{"trials":6729,"activeCount":102},[],{"trials":6731,"activeCount":102},[6732],{"nctId":6733,"briefTitle":6734,"status":114,"phases":6735,"primaryCompletion":6736,"completion":6736,"start":1488,"enrollment":6737,"conditions":6738,"interventions":6739},"NCT02559505","Influenza Immunity in Children",[94],"2020-07-03",134,[1691],[6718,6740],"Seasonal IIV 0.5 mL dose",{"intervention":6740,"totalTrials":142,"cells":6742},{"EARLY_PHASE1":6743,"PHASE1":6745,"PHASE2":6747,"PHASE3":6749,"PHASE4":6751,"NA":6753},{"trials":6744,"activeCount":102},[],{"trials":6746,"activeCount":102},[],{"trials":6748,"activeCount":102},[],{"trials":6750,"activeCount":102},[],{"trials":6752,"activeCount":102},[],{"trials":6754,"activeCount":102},[6755],{"nctId":6733,"briefTitle":6734,"status":114,"phases":6756,"primaryCompletion":6736,"completion":6736,"start":1488,"enrollment":6737,"conditions":6757,"interventions":6758},[94],[1691],[6718,6740],{"intervention":6760,"totalTrials":142,"cells":6761},"Physostigmine",{"EARLY_PHASE1":6762,"PHASE1":6764,"PHASE2":6766,"PHASE3":6768,"PHASE4":6770,"NA":6772},{"trials":6763,"activeCount":102},[],{"trials":6765,"activeCount":102},[],{"trials":6767,"activeCount":102},[],{"trials":6769,"activeCount":102},[],{"trials":6771,"activeCount":102},[],{"trials":6773,"activeCount":102},[6774],{"nctId":6775,"briefTitle":6776,"status":114,"phases":6777,"primaryCompletion":1073,"completion":1073,"start":4631,"enrollment":32,"conditions":6778,"interventions":6780},"NCT01171118","Phamacological Reversal of Airway Instability During Sedation",[94],[6779],"Upper Airway Obstruction",[6760,6781],"Oxygen",{"intervention":6781,"totalTrials":142,"cells":6783},{"EARLY_PHASE1":6784,"PHASE1":6786,"PHASE2":6788,"PHASE3":6790,"PHASE4":6792,"NA":6794},{"trials":6785,"activeCount":102},[],{"trials":6787,"activeCount":102},[],{"trials":6789,"activeCount":102},[],{"trials":6791,"activeCount":102},[],{"trials":6793,"activeCount":102},[],{"trials":6795,"activeCount":102},[6796],{"nctId":6775,"briefTitle":6776,"status":114,"phases":6797,"primaryCompletion":1073,"completion":1073,"start":4631,"enrollment":32,"conditions":6798,"interventions":6799},[94],[6779],[6760,6781],{"intervention":6801,"totalTrials":142,"cells":6802},"Teriparatide",{"EARLY_PHASE1":6803,"PHASE1":6805,"PHASE2":6807,"PHASE3":6809,"PHASE4":6811,"NA":6813},{"trials":6804,"activeCount":102},[],{"trials":6806,"activeCount":102},[],{"trials":6808,"activeCount":102},[],{"trials":6810,"activeCount":102},[],{"trials":6812,"activeCount":102},[],{"trials":6814,"activeCount":102},[6815],{"nctId":6816,"briefTitle":6817,"status":329,"phases":6818,"primaryCompletion":5281,"completion":5281,"start":2758,"enrollment":32,"conditions":6819,"interventions":6821},"NCT00594906","Use of Teriparatide to Accelerate Fracture Healing",[94],[6820],"Pelvic Fracture",[6801],{"intervention":6823,"totalTrials":142,"cells":6824},"ceftriaxone",{"EARLY_PHASE1":6825,"PHASE1":6827,"PHASE2":6829,"PHASE3":6831,"PHASE4":6833,"NA":6835},{"trials":6826,"activeCount":102},[],{"trials":6828,"activeCount":102},[],{"trials":6830,"activeCount":102},[],{"trials":6832,"activeCount":102},[],{"trials":6834,"activeCount":102},[],{"trials":6836,"activeCount":102},[6837],{"nctId":6838,"briefTitle":6839,"status":114,"phases":6840,"primaryCompletion":6841,"completion":6841,"start":2168,"enrollment":3472,"conditions":6842,"interventions":6844},"NCT03133637","Ceftriaxone and Jaundice in Neonates",[],"2019-08-31",[6843],"Jaundice and Sepsis in Neonates",[6823]]